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Department: Chemistry and Biochemistry 
Mobile genetic elements (MGEs), including plasmids and bacteriophage, are a 
constant threat to the prokaryotes they invade. CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeats) – Cas (CRISPR-Associated) systems are one of the many 
systems prokaryotes use to defend against MGEs. CRISPR-Cas systems are incredibly 
diverse. There are two classes of CRISPR-Cas systems which are further divided into six 
types and over 33 subtypes. Each CRISPR-Cas subtype provides defense via a unique set 
of protein and RNA components. Type IV CRISPR-Cas systems are the least studied of 
the six CRISPR-Cas types. In fact, in some type IV systems, only the genetic architecture 
is known and their overall function is unclear. This dissertation contains many of the first 
structural and biochemical studies done on type IV systems. Reported here is the first 
structure of a type IV ribonucleoprotein complex, indicating that a certain subtype of type 
IV systems, IV-B, may have an exclusively non-defense function. Also reported is a 
biochemical characterization of a IV-A Cas endoribonuclease, the first evidence of 
defense against MGEs by a type IV system, and an initial exploration into potential 
iv 
 
mechanisms of defense. These studies indicate that another type IV subtype, IV-A, is a 
defense system, consistent with its classification as a CRISPR-Cas system. Beyond 
expanding the realm of prokaryotic defense systems, these studies answer many questions 
surrounding type IV systems and provide a clear direction to further our understanding of 
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Prokaryotic Defense Systems 
Hannah Nicole Taylor 
 
Bacteria are under constant threat of invasion by bacteriophage (viruses which 
infect bacteria). To prevent bacteriophage from entering and overtaking the bacteria, 
bacteria utilize defense systems to identify and destroy foreign elements. One method of 
defense is called CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic 
Repeats – CRISPR-Associated). Many different bacteria and most archaea use CRISPR-
Cas systems. There are many diverse types of CRISPR-Cas systems, each of which 
provides defense in a slightly different way. One such CRISPR-Cas type is called type 
IV. The type IV CRISPR-Cas system is poorly understood and there are very few studies 
published on type IV systems. This dissertation details some of the first studies done on 
type IV systems, showing that some type IV systems are indeed defense systems, while 
others may have evolved a non-defense function. Several biochemical studies were 
performed to better understand the underlying mechanisms of type IV systems. 
Historically, the study of CRISPR-Cas mechanisms has led to innovations in gene 
editing, cancer research, diagnostics, therapeutics, and much more. The work described 
here significantly furthers the CRISPR-Cas field and may lead to the discovery of new, 
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LIST OF ABBREVIATIONS 
Cas   “CRISPR-associated” 
Usually refers to a gene or protein associated with a CRISPR 
system or operon. 
CRISPR  “Clustered regularly interspaced short palindromic repeats” 
Describes the genomic locus that typifies CRISPR-Cas system and 
stores memories of past invasions. 
crRNA  “CRISPR-derived RNA” 
The RNA component of CRISPR-Cas RNP complexes. It is 
derived from transcripts of the CRISPR locus. 
Cryo-EM  “cryo-electron microscopy” 
Csf   “CRISPR-Cas subtype as in Acidithiobacillus ferrooxidans” 
The prefix for type IV CRISPR-Cas genes and proteins, e.g. csf1, 
Csf2, Csf RNP complex. 
CysH   “cysteine biosynthesis H” 
An enzyme involved in cysteine biosynthesis. CasCysH is a CysH-
like protein that is associated with type IV CRISR-Cas systems. 
dsDNA, ssDNA “double-stranded DNA”, “single-stranded DNA” 
DinG   “damage inducible gene G” 
An enzyme involved in DNA repair. CasDinG is a DinG-like 
protein that is associated with type IV CRISR-Cas systems. 
HD domain  “histidine (H) and aspartate (D) domain” 
Nuclease domain typified by histidine and aspartate residues and 
composed of several motifs. 
MGE   “mobile genetic element” 
Bits of nucleic acid which encode for its own movement around or 




PAM, rPAM  “protospacer adjacent motif”, “RNA protospacer adjacent motif” 
Describes a 2-5 nucleotide motif adjacent to protospacers 
(DNA/RNA complementary to crRNA) required for Cas RNP 
complexes to bind the protospacer. 
PFS   “protospacer flanking sequence” 
A PAM-like motif adjacent to protospacers in the type VI 
CRISPR-Cas system. 
RNP   “ribonucleoprotein” 






CRISPR-CAS SYSTEMS ARE A DIVERSE GROUP OF PROKARYOTIC 
DEFENSE SYSTEMS 
There is an intricate evolutionary relationship between mobile genetic elements 
(MGEs) (bacteriophage, plasmids, etc.) and their prokaryotic hosts. For example, 
bacteriophage (phage), viruses which infect bacteria and archaea, reproduce by hijacking 
the cellular machinery of the host and forcing replication of the phage genome and 
translation of phage proteins (Campbell, 2003; Frost et al., 2005). This hijacking is 
deleterious to the prokaryotic host, often resulting in cell death. Defense systems exist in 
bacteria and archaea to prevent the effects of infection by bacteriophage (Labrie et al., 
2010; Rostøl & Marraffini, 2019). In response to prokaryotic defense systems, 
bacteriophage encode anti-defense systems (Hampton et al., 2020). Most prokaryotes 
encode several types of defense systems, making it harder for a bacteriophage to bypass 
all defensive layers. Thus, the evolutionary history of prokaryotes and their parasitic 
bacteriophages is linked through an arms race (Gómez & Buckling, 2011; Hall et al., 
2011; Gurney et al., 2019). 
One type of prokaryotic defense system is the CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeats)-Cas (CRISPR-associated) system. CRISPR-Cas systems 
harbor nucleic acid memories of past MGE invaders by integrating short (~30bp) 
segments of invasive DNA into the bacterial/archaeal genome at the CRISPR locus 
(Barrangou et al., 2007; Nuñez et al., 2014; Rollie et al., 2015; Wang et al., 2015). The 




proteins to identify and eliminate successive invasions by complementary nucleic acids 
(Brouns et al., 2008; Carte et al., 2008; C. Hale et al., 2008; C. R. Hale et al., 2009; 
Garneau et al., 2010) (Figure 1-1).  
Like the prokaryotes they inhabit and the bacteriophage they defend against, 
CRISPR-Cas systems are incredibly diverse. There are two classes (class 1-2), six types 
(type I-VI), and over 33 subtypes (e.g. type I-A, I-B, I-C, etc.) of CRISPR-Cas systems 
(Makarova et al., 2015, 2020) (Figure 1-2). Class 1 CRISPR-Cas systems form a multi-
subunit ribonucleoprotein (RNP) complex with a CRISPR-derived RNA (crRNA) to 
surveil the cell and identify invasive nucleic acids, while the RNP complexes of class 2 
CRISPR-Cas systems are composed of a single protein subunit and crRNA (Figure 1-3). 
The CRISPR-Cas types are classified by the genes they encode and their operon 
architecture with each type encoding a type-specific, or signature, gene (Makarova et al., 
2018, 2020). Variants within each type are classified into subtypes with some encoding 
subtype-specific genes. The basic functions of the six CRISPR-Cas types have all been 
characterized, except the type IV system (Figure 1-2). To further our understanding of 
CRISPR-Cas systems, it is critical that we understand the function of type IV CRISPR-
Cas systems. 
 
TYPE IV SYSTEMS ARE MINIMAL, MOBILE CRISPR-CAS SYSTEMS 
Some functional aspects of type IV CRISPR-Cas systems can be inferred by 
comparing their operons to the operons of other CRISPR-Cas types. Firstly, type IV 
systems lack the cas1 gene (Makarova et al., 2015). This is especially striking as nearly 





Figure 1-1. The three stages of CRISPR-Cas defense. During adaptation Cas1 and 
Cas2 integrate small chucks of foreign DNA into the CRISPR. During biogenesis the 
CRISPR is transcribed and Cas6 endoribonucleases cleave the transcript to produce a 
library of crRNAs. The crRNAs are bound by Cas proteins to form Cas ribonucleoprotein 
(RNP) complexes. The RNP complex binds nucleic acids complementary to the crRNA, 






Figure 1-2. Classification of CRISPR-Cas systems into two classes, six types, and 
many subtypes. Diagrams depicting the Cas RNP complex for each type are shown, 
including descriptions of how nucleic acids are cleaved. RNP complex formation and 
possible nucleic acid binding and/or cleavage is unknown for type IV CRISPR-Cas 







Figure 1-3. Classification of CRISPR-Cas systems indicating binding and cleavage 
patterns. Binding and cleavage by Type IV systems is only hypothesized. Indicated 
protospacer adjacent motifs (PAMs) and protospacer flanking sequences (PFSs) are 
required for binding and/or activation of the system. See also Figure 1-2. Created with 




2009). Cas1 and its counterparts, Cas2 and Cas4, are referred to as adaptation or 
maintenance machinery, as they are responsible for integrating new nucleic acid 
sequences, called protospacers, into the CRISPR locus (Nuñez et al., 2014; Rollie et al.,  
2015; Wang et al., 2015; Kieper et al., 2018; Lee et al., 2018). The CRISPR locus is 
composed of short, repeated sequences, called repeats, interspaced with short, unique 
sequences derived from invasive nucleic acids, called spacers (Bolotin et al., 2005; 
Mojica et al., 2005; Pourcel et al., 2005) (Figure 1-1). At the 5’ end of the CRISPR is a 
leader sequence. Cas1 and Cas2 form an oligomeric complex which integrates 
protospacers into the CRISPR, always immediately after the leader sequence (Nuñez et 
al., 2014; Xiao et al., 2017). Despite their lack of a cas1 gene, many type IV systems do 
encode a CRISPR. It has been hypothesized that type IV system may borrow adaptation 
machinery from other CRISPR-Cas types, as has been seen with some type III CRISPR-
Cas systems (Staals et al., 2013, 2014; Elmore et al., 2015; Bernheim et al., 2020). 
Supporting this hypothesis, type IV systems are often present in organisms which encode 
two or more CRISPR-Cas systems of various types and some crosstalk between these 
systems has been implicated (Pinilla-Redondo et al., 2019). Type IV systems are 
considered minimal systems, as they lack components (Cas1/Cas2/Cas4) typically 
required for CRISPR-Cas immunity. 
Secondly, type IV systems encode several cas genes which are putative subunits 
of an RNP complex, thus indicating that type IV systems are class 1 CRISPR-Cas 
systems (Makarova et al., 2011, 2015). Recent work has shown that type IV systems form 
multi-subunit RNP complexes, confirming their identity as class 1 systems (Özcan et al., 




products that are, respectively, Cas7-like and Cas5-like. Multiple Cas7 proteins form the 
backbone of Cas RNP complexes and directly bind the crRNA (Jore et al., 2011; Lintner 
et al., 2011; Staals et al., 2013; Jackson et al., 2014; Mulepati et al., 2014; Osawa et al., 
2015) (Figure 1-4). The type IV Cas7 homolog, Csf2, has the same RNA binding 
capabilities (Zhou et al., 2021). Within multi-subunit Cas RNP complexes, a single Cas5 
subunit caps one end of the complex (Figure 1-4). Csf3 is the Cas5 homolog in type IV 
systems. Type IV systems also contain the csf1 gene. csf1 is unique to type IV and is a 
putative component of the RNP complex. Csf1 is most similar to the Cas8 and Cas10 
subunits of type I and type III Cas RNP complexes, respectively. Both Cas8 and Cas10 
bind adjacent to Cas5 at one end of the RNP complex (Staals et al., 2013; Jackson et al., 
2014). However, Csf1 has a much lower molecular weight than the type I and type III 
large subunits and a cross-linking experiment by Özcan et al. (2018) indicates that Csf1 
does not interact with Csf3, the type IV Cas5 homolog. Although the type IV Csf proteins 
form an RNP complex, like the type I and type III Cas proteins, the stoichiometry and 
arrangement of the protein subunits within the RNP complex are likely unique to type IV 
systems. 
Finally, in stark contrast to other CRISPR-Cas systems, type IV systems are 
almost always encoded on mobile genetic elements (MGEs) (plasmids, prophages, etc.) 
(Bernheim et al., 2020; Faure et al., 2019; Koonin & Makarova, 2017, 2019; Makarova et 
al., 2015; Pinilla-Redondo et al., 2019). This fact has spurred some tantalizing hypotheses 
for type IV system functions, including that type IV systems may be mobile defense 
systems, passed on plasmids between organisms as needed. CRISPR-Cas systems are 





Figure 1-4. Representative class 1 RNP complexes. (A) Type I-E RNP complex from 
E. coli. Colored by subunits. PDBid: 5H9F. (B) Type III-B RNP complex from 






phage genomes and as critical components of transposon systems. Phages utilize 
CRISPR-Cas systems to by-pass host defense systems and prevent super infection by 
competitor bacteriophages (Al-Shayeb et al., 2020; McKitterick et al., 2019; Naser et al., 
2017; Seed et al., 2013). Transposons use the RNA guided-DNA binding capabilities of 
the Cas RNP complex to identify genomic loci for transposition (Klompe et al., 2019; 
Peters et al., 2017). In the defense arms race between MGEs and prokaryotes, CRISPR 
systems are “guns for hire”, utilized by both prokaryotes and MGEs (Peters et al., 2017). 
As type IV CRISPR-Cas systems are almost always encoded by MGEs, they may have a 
functional mechanism that benefits MGEs over prokaryotes.  
 
TYPE IV CRISPR-CAS SYSTEMS CONTAIN DIVERSE SUBTYPES 
Type IV systems are further divided into three subtypes, A-C (Figure 1-5). Each 
of these subtypes encodes a subtype-specific gene and has a distinct subtype-specific 
genetic architecture (Makarova et al., 2020). Unlike the other five CRISPR-Cas types, 
subtypes within the type IV CRISPR-Cas system are distinct enough that they each are 
predicted to provide a unique function and utilize different enzymes and mechanisms. 
When I first started my graduate studies, only the type IV-A and type IV-B CRISPR-Cas 
subtypes had been classified, no biochemical studies and only minimal bioinformatic 
studies had been done on type IV systems, and the type IV structures and functions were 
completely unknown. The following paragraphs give a brief overview of the type IV 








Figure 1-5. Operons of the type IV subtypes. Dashed lines indicate a component that is 
only sometimes present. The yellow box represents an HD nuclease domain. dinG, cysH-






Type IV-A Systems are Minimal, Defense Systems 
Type IV-A systems encode a csf5/cas6 gene and a CRISPR (Makarova et al., 
2015, 2020) (Figure 1-5). In class 1 CRISPR-Cas systems, Cas6 enzymes are responsible 
for providing crRNAs to the Cas RNP complex (Brouns et al., 2008). The CRISPR locus 
is initially transcribed into a long pre-crRNA (Carte et al., 2008) (Figure 1-1). The 
repeats of the CRISPR often contain palindromic sequences which form RNA hairpins in 
the transcript. Cas6 binds and cleaves the repeat sequence, thus processing the pre-
crRNA into a library of crRNAs which are incorporated into Cas RNP complexes (one 
crRNA per RNP complex). Interestingly, type IV-A subtypes sometimes contain Cas6 
enzymes and sometimes contain Csf5 enzymes (Makarova et al., 2020). To determine 
whether the type IV-A Cas6 protein is a crRNA processing enzyme, a structure was 
determined for the IV-A Cas6 from Mahella australiensis and biochemical assays were 
used to characterize its endoribonuclease activity (Taylor et al., 2019). I show that the 
type IV-A Cas6 is a crRNA processing endonuclease (Chapter 3). Additional work has 
shown that type IV-A Csf5 enzymes are also crRNA processing endonucleases (Özcan et 
al., 2018) and that Csf5 and IV-A Cas6 have unique structures, active sites, and 
mechanisms of actions (Taylor et al., 2019; Taylor et al., 2021) (Chapter 3 and Chapter 
5), indicating that type IV progenitor systems may have acquired endoribonucleases 
multiple times along its evolutionary history. 
The subtype-specific gene of type IV-A systems is the putative helicase dinG 
(Makarova et al., 2020). Many bacteria encode dinG in their genomes and its gene 
product, DinG, has been associated with DNA damage repair (Lewis et al., 1992; 




et al., 2014). DinG is a helicase and some DinG variants have nuclease activity. To 
determine whether DinG associated with CRISPR-Cas systems (CasDinG) may have a 
similar enzymatic function, several amino-acid sequence alignments were performed. 
Results indicate that the CasDinG associated with type IV systems has likely evolved a 
Cas-specific function (Taylor et al., 2021) (Chapter 5). It is hypothesized that CasDinG 
may function as the ultimate destroyer of invasive nucleic acids in Type IV systems, 
similar to the function of Cas3 in Type I systems. In Type I systems a ribonucleoprotein 
complex identifies foreign dsDNA targets, then recruits Cas3 to the target dsDNA (Huo 
et al., 2014) (Figure 1-3). Cas3, a helicase and nuclease, translocates along the target 
dsDNA, cleaving it at certain intervals (Beloglazova et al., 2011; Mulepati & Bailey, 
2011; Sinkunas et al., 2011). The role of CasDinG within type IV-A systems is a major 
question within the field. To determine whether type IV-A systems are defense systems, a 
plasmid-curing assay was performed (Crowley et al., 2019). Indeed, the type IV-A 
system can defend against plasmid transformation and CasDinG is required for defense 
(Chapter 4). Further studies to elucidate the mechanisms of defense indicate that the type 
IV system utilizes a Csf RNP complex that preferentially binds single-stranded DNA and 
RNAs that are complementary to the crRNA guide (Chapter 6). CasDinG is also further 
implicated as a potential nuclease. 
 
Type IV-B Systems Likely Have a Non-Defense Function 
Type IV-B CRISPR-Cas systems encode csf1, csf2, csf3, and a cas11 subunit but, 
in addition to the absence of cas1, lack a cas6/csf5 and a CRISPR locus (Makarova et al., 




accessory nuclease, it is unlikely that the type IV-B system is a canonical CRISPR-Cas 
defense system. It is hypothesized that type IV-B systems may either be a gene regulation 
system, as the components of CRISPR-Cas systems, which recognize and bind nucleic 
acids, are still present, or that type IV-B systems may be a mobile CRISPR-Cas defense 
system, which borrows crRNAs from other CRISPR-Cas systems to perform its function 
(Makarova et al., 2011; Koonin & Makarova, 2017; Shmakov et al., 2018; Faure et al., 
2019). The latter hypothesis is consistent with the localization of Type IV-B systems on 
plasmids, therefore allowing the system to be passed between neighboring organisms as 
needed (Koonin & Makarova, 2019).  
Type IV-B systems also encode an accessory cysH gene (Shmakov et al., 2018; 
Makarova et al., 2020). cysH genes encode enzymes in the PAPS reductase family that 
are involved in sulfonucleotide reduction during L-cysteine biosynthesis (Carroll et al., 
2005). Bioinformatics studies were undertaken to determine whether CRISPR-Cas 
associated CysH proteins (CasCysH) could have a similar function to their non-CRISPR-
Cas associated counter parts. However, the CasCysH of type IV-B CRISPR-Cas systems 
has a devolved sulfonucleotide reduction active site, suggesting that the CasCysH 
function is specific to type IV-B systems (Taylor et al., 2021) (Chapter 5).  
The function of type IV-B systems has only been postulated. To determine 
whether the type IV-B system can form a Cas RNP complex and what its structure is, I 
purified and helped to determine the cryo-EM structure of a IV-B RNP complex, lending 






Type IV Systems are Diverse, with New Subtypes and Variants Still Being 
Discovered 
A hallmark of type IV systems is the diversity of its subtypes. For example, the 
genetic composition and predicted functions of type IV-A and type IV-B subtypes are 
incredibly different (Faure et al., 2019). Additionally, there are many identified variants 
of type IV systems which encode diverse genes, including recD (instead of dinG), a csf1-
csf3 fusion gene, and genes typically associated with type III systems (Kamruzzaman & 
Iredell, 2020; Pinilla-Redondo et al., 2019). Some variants entirely lack the type IV-
specific gene csf1 (Crowley et al., 2019; Pinilla-Redondo et al., 2019). The most notable 
variant, type IV-C, was only recently classified as a type IV subtype (Makarova et al., 
2020; Pinilla-Redondo et al., 2019). Type IV-C systems encode csf2, csf3, and the type 
IV cas11 genes (Figure 1-5). Intriguingly, type IV-C systems lack csf1 and instead 
encode a cas10-like gene with an HD nuclease domain. The presence of the type IV 
Cas11 in type IV-C systems indicates that an RNP complex similar to the IV-B RNP 
complex may form. However, the presence of an obvious nuclease domain indicates the 
IV-C system could perform a defense function. Overall, it seems that the type IV-C 
system will have a unique function from the other type IV subtypes, illustrating the rich 
functional diversity within type IV CRISPR-Cas systems. 
 
UNDERSTANDING TYPE IV SYSTEMS IS CRITICAL TO DEEPEN OUR 
KNOWLEDGE OF PROKARYOTIC BIOLOGY 
The study of CRISPR-Cas systems is greatly expanding our understanding of 
interactions between prokaryotes and bacteriophages, prokaryotic evolution, and basic 




uncharacterized enzymes, many of which have been repurposed as biotechnological tools 
that are revolutionizing basic research, data storage/transport, nucleic acid 
detection/diagnostics, medicine, and more (Shipman et al., 2017; Ma et al., 2017; 
Gaudelli et al., 2017; Kellner et al., 2019; Yan et al., 2019; Makarova et al., 2020). 
Despite the paradigm shifting work described in this dissertation, the function of type IV 
CRISPR-Cas systems remains a glaring gap in our understanding of prokaryotic defense 
systems. Additionally, type IV CRISPR-Cas systems are incredibly diverse and many 
type IV subtypes likely have evolved non-defense functions. Therefore, the study of type 
IV systems will uncover novel functions and enzymatic mechanisms. An increase in 
knowledge is assured and the potential for world-changing discoveries is high through the 
study of type IV CRISPR-Cas systems. 
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STRUCTURE OF A TYPE IV CRISPR-CAS RIBONUCLEOPROTEIN COMPLEX1 
 
ABSTRACT 
We reveal the cryo-electron microscopy structure of a type IV-B CRISPR 
ribonucleoprotein (RNP) complex (Csf) at 3.9-Å resolution. The complex best resembles 
the type III-A CRISPR Csm effector complex, consisting of a Cas7-like (Csf2) filament 
intertwined with a small subunit (Cas11) filament, but the complex lacks subunits for 
RNA processing and target DNA cleavage. Surprisingly, instead of assembling around a 
CRISPR-derived RNA (crRNA), the complex assembles upon heterogeneous RNA of a 
regular length arranged in a pseudo-A-form configuration. These findings provide a high-
resolution glimpse into the assembly and function of enigmatic type IV CRISPR systems, 
expanding our understanding of class I CRISPR-Cas system architecture, and suggesting 




Bacteria and archaea employ CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeat)-Cas (CRISPR-associated) systems for adaptive immunity against 
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phages, plasmids and other mobile-genetic elements (MGEs) (Makarova et al., 2020). In 
the multi-subunit class 1 systems, the CRISPR locus is transcribed and processed into 
small crRNA guides (CRISPR-derived RNA), around which several Cas proteins 
assemble to form large ribonucleoprotein (RNP) complexes that facilitate RNA-guided 
surveillance and degradation of complementary targets (Hille et al., 2018). While a 
myriad of structures have been determined for most types of CRISPR RNA-guided 
complexes (types I (Jackson et al., 2014; Mulepati, Héroux and Bailey, 2014; Chowdhury 
et al., 2017; Xiao et al., 2018; Rollins et al., 2019), II (Jinek et al., 2014; Jiang et al., 
2016; Zhu et al., 2019), III (Taylor et al., 2015; Jia et al., 2019; You et al., 2019; Sofos et 
al., 2020), V (Stella, Alcón and Montoya, 2017; Liu et al., 2019; Zhang et al., 2020; Li et 
al., 2021; Takeda et al., 2021) and IV (Yan et al., 2018; Slaymaker et al., 2019; Meeske 
et al., 2020)), the RNP complexes of the highly diverse type IV CRISPR systems have 
largely remained structurally uncharacterized (Crowley et al., 2019; Faure et al., 2019; 
Özcan et al., 2019; Taylor et al., 2019; Makarova et al., 2020). 
Type IV CRISPR systems primarily occur within plasmid-like elements, lack 
genes encoding adaptation modules (cas1, cas2 and cas4), and are classified into three 
distinct subtypes (IV-A, IV-B, IV-C) (Özcan et al., 2019; Pinilla-Redondo et al., 2019; 
Makarova et al., 2020). All type IV systems contain genes that encode for Csf2 (Cas7), 
Csf3 (Cas5), and Csf1 (large subunit) proteins, which assemble around an RNA to form a 
multi-subunit complex (Özcan et al., 2019; Pinilla-Redondo et al., 2019; Makarova et al., 
2020). However, subtype-specific signature genes suggest distinct subtype functions. 
Type IV-A systems encode a DinG helicase shown to be essential for type IV-A mediated 




cysH of the phosphoadenosine phosphosulfate reductase family, and type IV-C systems 
encode a large subunit that contains an HD-nuclease domain (Özcan et al., 2019; Pinilla-
Redondo et al., 2019; Makarova et al., 2020) (Figure 2-1). Additionally, type IV-A 
systems encode a CRISPR array and crRNA endonuclease, while type IV-B and type IV-
C systems generally do not. It has been proposed that systems lacking a CRISPR array 
form complexes on crRNAs generated from other CRISPR systems (e.g. type I or type 
III), but this hypothesis has yet to be explored experimentally. Interestingly, the two 
subtypes that do not contain a CRISPR array (type IV-B and type IV-C) encode a small 
α-helical protein (Cas11) predicted to form part of the multi-subunit complex. Thus, there 
are two distinct type IV multi-subunit complexes, one that contains the small Cas11 
subunit (types IV-B and IV-C), and another (type IV-A) that does not contain Cas11 but 
contains a crRNA derived from a type IV-A CRISPR array and processed by a type IV 
Cas6 endonuclease. To better understand the function of type IV CRISPR systems as well 
as their subtype-specific similarities and differences, we isolated a type IV-B complex, 
analyzed the sequence of the small RNAs bound within the complex, and determined a 
near-atomic resolution structure. 
 
RESULTS 
The Type IV-B RNP Assembles on Non-Specific RNAs 
The Mycobacterium sp. JS623 type IV-B CRISPR operon is encoded within a 
megaplasmid and lacks both a pre-crRNA maturase (Cas6/Csf5 (Taylor et al., 2019) and 
a CRISPR array, containing only csf1 (Cas8-like large subunit), cas11 (small subunit), 






Figure 2-1. Classification of type IV subytypes. Related to Figure 2-2. Schematic of 
the three distinct type IV subtypes defined in (Makarova et al., 2020).  Genetic features 
(genes and CRISPRs) found primarily in a single subtype are colored red. Gray 
rectangles indicate genes expected to encode proteins that form RNP complexes. The 
cas11 gene is colored white to highlight that it is found within the subtypes lacking a 
CRISPR (subtypes IV-B and IV-C). The HD nuclease domain of the cas8-like subunit of 






Figure 2-2. Structure of type IV-B CRISPR complex. See also Figures 2-1, 2-3, 2-4, 2-
5 and Table 2-1. (A) M. sp. JS623 plasmid-encoded CRISPR operons. Top: Type IV-B 
and I-E CRISPR loci present on pMCYCM02 megaplasmid. Bottom: Additional type IV-
B locus encoded by pMCYCM03 megaplasmid. Genes predicted to encode RNP complex 




of type IV-B CRISPR complex. Cas7 subunits are colored blue and white, and five Cas11 
subunits are colored as a yellow-orange-red gradient. Csf-bound RNA is green. (C) 
Refined model for the Csf effector complex derived from the cryo-EM maps shown in B. 
(D) Schematic of Cas7-Cas11 interactions. Five Csf2-Cas11 interactions occur in this 
complex (labelled i – v). (E) Positions of Cas11 contacts on Csf2 backbone, colored 
magenta as shown in panel D. Cas11 sits upon the Csf2-Csf2 interface. (F) Cas11 binds at 
the interface with buried surface area of 505 Å2 (150 Å2 and 355 Å2 with Csf2.3 and Csf2.4, 
respectively). Cas11 is completely occluded from bound RNA. Csf2 subunits are intimately 
connected (1021 Å2) and make a network of contacts with bound RNA (~1200 Å2 buried 




a type I-E system (with an associated CRISPR array) on the same megaplasmid, and 
another type IV-B operon encoded on a different megaplasmid (Figure 2-2A), suggesting 
that type IV-B complexes may assemble on crRNAs encoded and processed by other 
CRISPR systems. However, the structure and function of such hybrid complexes are 
unknown. 
To gain mechanistic insights into the type IV-B system, we transformed E. coli 
BL21 cells with an expression plasmid encoding the M. sp. JS623 type IV-B Cas 
proteins, and the M. sp. JS623 type I-E Cas6 and associated CRISPR array (Figure 2-
3A). Using strep-tag affinity, size exclusion chromatography, and subsequent negative 
stain we observed filamentous ribonucleoprotein (RNP) complexes that eluted close to 
the void volume and a smaller, discrete, RNA-containing species reminiscent of class 1 
multi-subunit crRNA-guided complexes (Figure 2-3) (Makarova, Zhang and Koonin, 
2017). While this latter fraction contained all four Csf subunits, Csf2 and Cas11 were the 








Figure 2-3. Purification of the M. sp JS623 RNP complex by affinity 
chromatography (N-Strep-MsCsf2) and size exclusion chromatography. Related to 
Figure 2-2. (A) Diagram of plasmid used to express the type IV-B complex in BL21 DE3 
cells. (B) SEC chromatogram highlighting peaks corresponding to Csf2:Cas11 filaments 
and the RNP complex. (C) SDS-PAGE, UREA-PAGE, and negative stain data indicating 
the presence of Csf2:Cas11 bound to long RNAs to create filamentous structures. (D) 
SDS-PAGE, UREA-PAGE, and negative stain data indicating the presence of Csf1, Csf2, 





nucleotides on denaturing PAGE (Figure 2-3D, 2-4A), RNAseq analysis revealed bound 
RNAs were heterogeneous in sequence identity. Few RNAs were derived from the 
plasmid-encoded CRISPR array, while the majority of Csf-bound RNAs originated from 
the expression plasmid (63%). (Figure 2-4B, C). To exclude the possibility that this was 
due to low expression of the CRISPR array and/or lack of crRNA processing by Cas6, we 
repeated this analysis and compared it to an RNA-seq analysis of the total cellular 
population of RNAs (total RNA) extracted from the same host (Figure 2-4D). These 
results showed that the CRISPR array was indeed expressed and processed by Cas6, 
resulting in mature crRNAs with a typical eight nucleotide 5’ handle (a characteristic for 
Cas6-mediated cleavages in the repeats). However, the mature crRNAs were not enriched 
in the RNAs isolated from type IV RNPs and were in low abundance (~0.12% of all 
reads). The apparent lack of sequence specific assembly of the Csf complex on mostly 





Figure 2-4. RNA sequencing on co-purifying nucleotides with type IV complex. 
Related to Figure 2-2. (A) UREA-PAGE gel showing nucleic acids co-purifying with the 
type IV-B complex. The triangle indicates the ~60nt band purified from isolated type IV-
B complexes that was used for RNA sequencing analysis. (B) Percentage of reads mapping 
to either to expression plasmid, chromosome, or of unknown origin. (C) Distribution of 
reads mapping on the expression plasmid.  (D) Comparison of repeat-containing RNAs 
from the total cellular RNA population (“total RNA”) and type IV RNP-associated (“type 
IV”) RNAs mapped on the CRISPR array of the expression plasmid (in blue). Reads 
indicated in green represent the 61-nt RNAs with a perfect repeat-derived 8-nt 5’ handle, 




Koonin, 2017), and might be indicative of a role of type IV CRISPR-Cas systems in 
functions other than antiviral defense. 
 
The Architecture of the Type IV-B RNP Resembles Type III Effector 
Complexes 
To compare the type IV-B RNP complex to the complexes of other class 1 
systems we next determined a cryo-EM structure of the IV-B Csf complex at 3.9 Å 
resolution (Figure 2-2B, Figure 2-5, Table 2-1), allowing us to build an atomic model of 
the complex de novo (Figure 2-2C). The type IV-B complex resembles a sea cucumber, 
with six Csf2 (Cas7-like) subunits forming a helical ‘backbone,’ and five Cas11 subunits 
comprising a helical ‘belly’. Each Cas11 subunit sits upon a Csf2-Csf2 interface (Figure 
2-2D, E & F). The "α-helix bundle” topology of Cas11 (Figure 2-6C) and presence of a 
contiguous positively-charged patch running along the length of the minor filament 
(Figure 2-7) are typical of Cas11 small subunits in class 1 CRISPR systems (Xiao et al., 
2017; Rollins et al., 2019), although the arrangement of helices within type IV Cas11 is 
distinct from type I and type III small subunits.  
Like other class 1 Cas7 proteins, Csf2 adopts a hand-shaped structure with 
fingers, a palm, and a thumb.  The palm makes extensive contacts with the bound RNA 
(buried surface area of ~1200 Å2 per Csf2 subunit) (Figure 2-8A), while the thumbs of 
neighbouring Csf2 subunits protrude into the center of the palm, inducing a kink in the 
RNA backbone and a ‘flipped’ base at six nucleotide intervals (typical of other class 1 
complexes (Jackson et al., 2014; Taylor et al., 2015)). Using our atomic model of Csf2 
we searched for structural homologues. Csf2 had significant similarity to the type III-A 








Figure 2-5. Cryo-EM analysis of Csf. Related to Figure 2-2. (A) Representative 
micrograph of Csf complex particles. (B) 2D class averages of discrete Csf oligomers used 
for 3D reconstruction. (C) Euler angular distribution of particles contributing to final 3D 
reconstruction. (D) Fourier shell correlation (FSC) of final 3D reconstruction, with a global 
resolution of 3.9 Å at the 0.143 threshold. (E) Map-to-model FSC, with a model resolution 
of 4.1 Å at the 0.5 threshold. (F) Map of Csf complex colored by local resolution. (G) – 
(I), Representative atomic models and corresponding cryo-EM densities for Csf2 (g), 
Cas11 (h) and RNA (i). (J) Low-pass filtered (8 Å) map of Csf complex at three different 
isosurface thresholds. At lower thresholds (0.0178 & 0.00396), additional density appears 
at the top of the complex. This density may correspond to Csf1 Csf3 subunits, however the 











Table 2-1. Cryo-EM data collection and processing parameters. Related to Figure 2-
2. 
  
Data collection and processing 
Magnification 22,500x 
Voltage (kV) 300 
Electron exposure (e-/Å) 40 
Defocus range (µM) -1.5 to -3.0 
Symmetry imposed C1 
Final particle images 296,319 
Map resolution (Å) 3.9 
FSC threshold 0.143 
Map resolution range (Å) 3.5 to > 8 
Refinement 
Model resolution (Å) (0.143 FSC) 4.1 
Map sharpening B factor (Å2) 130.2 
Model composition 
Nonhydrogen atoms 16636 
Residues (Protein/RNA) 2083/31 




Bond lengths (Å)/bond angle (º) 0.005/1.112 
Validation  
MolProbity score 1.9 
Clashscore 4.72 
Poor rotamers (%) 0 
Ramachandran plot 






Figure 2-6. Comparison to Cascade complexes. Related to Figure 2-8. (A) Comparison 
of Type IV-B Csf with other effector/Cascade complexes. crRNA within Type III-A (PDB 




(7kha) complexes were aligned to Csf RNA (RMSD 5.9 Å, 8.8 Å, and 12.7 Å respectively). 
Due to the highly curved nature of type I-E (4tvx) (Jackson et al., 2014) and I-F (5uz9) 
(Chowdhury et al., 2017) crRNA, it was not possible to perform such alignment to IV-B. 
Instead, individual backbone subunits were aligned to corresponding Csf2 subunits, thus 
aligning the top of I-E or I-F with the top of IV-B (RMSD ~24.4 Å and 25.8 Å, 
respectively). In all complexes, non-Cas7/Cas11 subunits are shown as transparent 
surfaces. All Cas7/Cas11 and RNA, crRNA and TS are colored as in Figures 2-2 & 2-8, 
with the addition of the TS in light red. (B) Alignment of Cas7 with Csf2. Csf2 is shown 
as grey, transparent cartoon. RMSD is typically ~20 Å – 25 Å, although they clearly align 
well by eye. The high RMSD is likely due to presence of additional residues not present in 
Csf2. (C) Cas11 subunits. All Cas11 subunits are helical bundles that resemble each other. 
However, due to diverse Cas11 sequences these subunits align poorly (RMSD 16 Å – 18 
Å). (D) Alignment of (cr)RNA from available CRISPR effector complexes. Type IV-B 
RNA aligns more closely to type III-A and -B crRNAs, consistent with the proposed 
evolutionary lineage of type IV CRISPR systems emerging from a type III-like ancestor. 
(E) Overlay of type IV-B and type III-A CRISPR complexes based on RNA alignment. 








Figure 2-7. Surface electrostatics of Csf complex. Related to Figure 2-8. (A) & (B) 
Cas11 and Csf2 filaments. Green dashed outlines denote complementary surfaces. (B) 
Surface electrostatics of the Csf complex. Cas11 subunits and RNA path are outlined. 
RNA is shown as green cartoon, but it is almost completely occluded by Cas7 subunits. 
The overall path of the RNA bound within the Cas7 filament is outlined by green dashed 
lines. (C) Csf2 filament with RNA contacts (green spheres) shown. Cas11 minor filament 
is removed for clarity. RNA is bound by a contiguous positively-charged surface. The 
high electrostatic contribution to RNA binding by Csf2 is typical of non-specific RNA-





Figure 2-8. RNA-binding by type IV-B Cas7. See also Figures 2-6, 2-7, and 2-9. (A) 
RNA (green) binding site runs across the palms of Csf2 subunits. Csf2.3 is colored 
according to conservation. The “thumb” of the n-1 Csf2 (i.e. Csf2.2) protrudes into the 
backbone of bound RNA (solid green), inducing a kink. (B) Alignment of type III-A 
backbone subunit Csm3 (PDB 607i, transparent) with Csf2 (solid blue). Csm3 and Csf2 
align with an r.m.s.d. of 2.9Å, with a Dali server Dali server Z-score 14.1. Csf2-bound 
RNA binds in the same conformation as crRNA (transparent green) to Csm3 (RMSD of 
1.5 Å). Catalytic residue Asp36Csm3 and putative catalytic residue Asp42Csf2 side chains are 
located near the target strand (TS - transparent red), bound to the type III crRNA 
(transparent green). (C) Residues flanking unstructured catalytic loop (27-35) and apical 
loop of Csm3 thumb also interact with the TS. Catalytic residue D36 is shown for clarity. 




(E) Putative interactions colored by conservation. The Csf2 thumb contains a flexible 20 
residue insertion, not visible in our cryo-EM map. (F) Path of TS bound by type III-A Csm 





only 16%. Csf2 and Csm3 superimpose with an r.m.s.d of 2.9 Å and use equivalent 
interfaces to bind RNA and induce near-identical RNA backbone conformations (r.m.s.d 
of 1.5 Å) (Figure 2-8A). This supports previous bioinformatics-based hypotheses that 
type IV systems originated from type III-like ancestors (Özcan et al., 2019; Pinilla-
Redondo et al., 2019; Makarova et al., 2020). 
The type III backbone protein Csm3 cleaves the phosphodiester backbone of 
crRNA-bound target strand (TS) RNA at 6-nt intervals (Staals et al., 2014; Steens et al.,  
2021). Given that the Csm crRNA aligns almost perfectly with Csf-bound RNA, we 
reasoned that Csf2 might also possess RNase activity. Within our aligned structures, both 
the catalytic Asp36Csm3 residue and the conserved Asp42Csf2 residue are similarly 
positioned within an unstructured “catalytic loop” (Figure 2-8C – E, Figure 2-9). 
However, despite this similarity, structural alignment with a target-bound type III 
complex reveals significant steric clashes between the path of the bound nucleic acid 
target and the Csf2 catalytic loop (Figure 2-8F & G), suggesting a significant 
conformational rearrangement of subunits would need to occur upon target binding to 






Figure 2-9. Weblogo of cleavage loop, with candidate catalytic residue (D42) denoted 
by arrow. Related to Figure 2-8. Multiple sequence alignment (MSA) generated using 
the top 100 result from a BLAST search against the Csf2 sequence from M. sp JS623. 
Output from the MSA was used to generate a sequence logo using the WebLogo server 







substrate bound structures and in vitro functional assays are needed to more fully explore 
the possibility of Csf2-mediated RNase activity. 
 
DISCUSSION 
Our structure of the Csf complex provides evidence that type IV-B evolved from 
type III CRISPR-Cas systems, but lost its CRISPR and Cas6-based crRNA processing 
activity due to functional re-specialization. Although the M. sp. JS623 type IV-B operon 
contains both Csf3 (Cas5) and the putative large subunit Csf1, we did not observe 
corresponding densities within the high-resolution cryo-EM structure. However, bands 
that correspond to Csf1 and Csf3 are observed in SDS-PAGE analysis of the sample 
(Figure 2-3D) and there is unmodeled ambiguous density on the top and bottom of the 
complex that could represent a flexible association with Csf1 and Csf3 or additional Csf2 
subunits.  In type I CRISPR systems, Cas5 binds the 5’ crRNA handle with high affinity 
and sequence specificity, nucleating complex assembly (Hochstrasser et al., 2016; 
Chowdhury et al., 2017; Jia et al., 2019). The lack of discernible density for the Cas5-like 
Csf3 subunit within our complex may explain the heterogeneous assembly of type IV-B 
Csf complexes around non-specific RNA (Figure 2-4). However, because the type IV-B 
system does not encode a CRISPR array, the identity of the RNA sequence that Csf3 
would specifically recognize is unknown. Indeed, it remains to be determined whether 
Csf3 truly serves a similar role to the Cas5 subunits in other systems, binding the 5’-
handle of processed crRNAs. We hypothesized that crRNAs generated from the adjacent 
type I-E CRISPR and Cas6 endonuclease would be bound by the type IV-B complex. 




any other RNAs available in the total sample. Interestingly, recent bioinformatic analysis 
indicated a negative co-occurrence of type IV-B systems with other CRISPR systems 
suggesting their function is not dependent on co-occurring CRISPR arrays (Pinilla-
Redondo et al., 2019). The ability of the Csf complex to assemble on non-specific RNAs 
of a uniform length suggests that type IV-B systems may have been functionally 
repurposed for a yet to be identified role. 
The lack of discernible density for the Csf3 and Csf1 subunits suggests our 
structure may not accurately reflect the functional type IV-B Csf effector complex. 
However, several lines of reasoning argue that even without obvious density for Csf1 and 
Csf3, this complex provides important insights into understanding type IV-B system 
function. Superposition of the helical Cas7 backbones from type III effector complexes 
with our structure show that they are nearly identical in arrangement (Figure 2-6A). 
Additionally, the crRNA from the type IV RNP can be overlaid on that of the type III 
effector with an r.m.s.d. of 1.5 Å (Figure 2-8A), indicating our complex presents RNA in 
a conformation amenable for base pairing with complementary nucleic acid. In fact, 
studies have shown that there are no structural differences between filaments assembled 
around non-specific RNAs and correctly processed crRNAs bound to the effector 
(Hochstrasser et al., 2016). Importantly, the structures of all CRISPR-Cas effector 
complexes involve non-sequence specific interactions between the crRNA and Cas7-like 
backbone proteins, suggesting that there would be no structural differences between a 
random RNA and a crRNA bound within the Cas7 backbone of an RNP complex. Thus, 
our structure likely accurately represents the structure of the Cas7-like core of the 




observed for Csf1 and Csf3. Completely novel information is gleaned from our cryo-EM 
reconstruction of the type IV-B RNP including (1) the first structure of a type IV Cas11 
protein, which adopts a novel small subunit fold, (2) the first structure of a Cas7-like 
Csf2 subunit, and (3) interactions between these subunits with each other and with bound 
RNA. 
Since all type IV systems identified lack adaptation subunits and almost all 
(97.8%) type IV-B operons identified lack a CRISPR array, it is likely they do not 
participate in selective pre-spacer acquisition or adaptive immunity (Özcan et al., 2019; 
Pinilla-Redondo et al., 2019; Makarova et al., 2020). Instead, they may have been co-
opted for an orthogonal function. While there is a precedent for the repurposing of 
CRISPR systems for non-defense functions (Klompe et al., 2019; Halpin-Healy et al., 
2020), the role of type IV-B systems remains a mystery. A particularly tantalizing 
hypothesis is that type IV-B Csf complexes assemble on small RNAs, acting as non-
specific RNA-sponges, and enabling IV-B-encoding megaplasmids to evade targeting by 
host cell RNA guided defenses (Pinilla-Redondo et al., 2019).  Future experiments are 
essential to reveal the biological functions of type IV systems. Recent classifications have 
indicated that although type IV-B systems are highly diverse, they are almost always 
associated with an adenosine 5’-phosphosulfate reductase-family gene cysH (Özcan et 
al., 2019; Pinilla-Redondo et al., 2019; Makarova et al., 2020) (Figure 2-1). Thus, 
understanding the interplay between cysH and the type IV-B Csf RNP complex may be 






LIMITATIONS OF THE STUDY 
The current structure lacks discernible density for Csf1 and Csf3 proteins. The 
equivalent subunits in Type I systems are responsible for specific functions. Without 
complementary functional in vitro and in vivo data, it is impossible to unambiguously 




Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the Lead Contact, David W. Taylor (dtaylor@utexas.edu). 
Materials Availability  
All unique/stable reagents generated in this study are available from the Lead Contact 
without restriction. 
Data and Code Availability 
The cryo-EM structure and associated atomic coordinates have been deposited in the 
Electron Microscopy Data Bank and the Protein Data Bank with accession codes EMD-
22340 and 7JHY, respectively. The raw sequencing data has been deposited in the 
Sequence Read Archive (SRA) database with submission number SUB8825456. 
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METHODS 
Expression and Purification of the M. sp. JS623 Csf Complex 
E.coli BL21 (DE3) cells containing the pCDF-Duet1-Csf1-Cas11-Strep-Csf2-
Csf3(MCS1)-Cas6 array (MCS2) expression vector were inoculated in 6 X 0.5 L 
lysogeny broth (LB) and grown at 37°C with 200 rpm shaking. Cells were grown to an 




Recombinant protein expression was induced with 0.8 mM IPTG (isopropyl β-D-1-
thiogalactopyranoside). After induction, cells were grown at 16°C for 18-24 hours and 
pelleted via centrifugation. Pelleted cells were resuspended in 20-30 mL Buffer W (100 
mM Tris, pH 8.0; 150 mM NaCl; 2 µM ZnSO4). Protease inhibitors were added to the 
following final concentrations: 10 µg/mL leupeptin, 2 µg/mL aprotinin, and 170 µg/mL 
phenylmethylsulfonyl fluoride (PMSF). Cells were lysed by sonication and lysate was 
clarified by centrifugation. Polyethylenimine was added to the soluble fraction at a final 
concentration of 0.1% to precipitate nucleic acids and again clarified by centrifugation. 
The supernatant was applied to a StrepTrap HP 5 mL column (GE Healthcare) and the 
bound protein was eluted with Buffer E (Buffer W + 5 mL desthiobiotin). The RNP 
complex was further purified with a Superose6 Increase 10/300 GL column (GE 
Healthcare), eluting into SEC Buffer (50 mM HEPES, pH 8.0; 150 mM NaCl; 2 µM 
ZnSO4). 
 
RNA Sequencing and Analysis 
Nucleic acids that co-purified with type IV-B complex were extracted with acid 
phenol:chloroform and subsequent ethanol precipitation. The resulting fraction was 
loaded on a 20% denaturing PAGE gel after which a band of approximately 55-60 nt 
(Figure 2-4A) was excised and purified from gel using the ZR small-RNA PAGE 
Recovery Kit (Zymo Research, USA). Small RNAs were prepared by GenXPro 
(GenXPro GmbH, Germany) using the TrueQuant smallRNA Seq kit according to the 
manufacturer’s instructions and were sequenced on a HiSeq2000 (Illumina, USA). After 




were mapped on the expression plasmid and the E.coli BL21 (DE3) genome (Genbank 
accession CP001509) with Geneious Prime 2020.10.2 (https://www.geneious.com). For 
comparing the abundance and processing of (mature) crRNAs of the total cellular RNA 
population versus those associated with the type IV complex (Figure 2-3D), the extracted 
total RNAs (NEB Monarch Total RNA Miniprep Kit) were first depleted for ribosomal 
RNAs (Invitrogen Ribominus Transcriptome Isolation Kit) before they were sequenced 
on an Illumina MiSeq (Center for Integrated Biosystems, Utah State University, USA). 
After quality control and adapter trimming, the resulting reads were mate-paired and 
merged using SeqPrep (https://github.com/jstjohn/SeqPrep), filtered for reads containing 
CRISPR-array repeat nucleotides, and mapped on the expression plasmid using Geneious 
(Langmead et al., 2009). Visualisation of the mapping results and further downstream 
analyses were performed using Geneious and Microsoft Excel. 
 
Cryo-EM Data Acquisition and Processing 
C-flat holy carbon grids (CF-4/2, Protochips Inc.) were glow-discharged for 30 
seconds using a Gatan Solarus plasma cleaner. 2.5 μl of Type IV complex (~0.3 mg/ml) 
was applied onto grids, blotted for 2.5 seconds with a blotting force of 1 and rapidly 
plunged into liquid ethane using a FEI Vitrobot MarkIV operated at 4 °C and 100% 
humidity. Data were acquired using a FEI Titan Krios transmission electron microscope 
(Sauer Structural Biology Laboratory, University of Texas at Austin) operating at 300 keV 
at a nominal magnification of ×22,500 (1.1 Å pixel size) with defocus ranging from -1.5 to 
-3.0 μm. The data were collected using a total exposure of 6 s fractionated into 20 frames 




dose of ~40 e–Å–2. Three datasets were automatically recorded on a Gatan K2 Summit 
direct electron detector operated in counting mode using the MSI-Template application 
within the automated macromolecular microscopy software LEGINON (Suloway et al., 
2005).  
All image pre-processing was performed in Appion (Lander et al., 2009). Individual 
movie frames were aligned and averaged using ‘MotionCor2’ drift-correction software 
(Zheng et al., 2017). The contrast transfer function (CTF) of each micrograph was 
estimated using CTFFIND4 (Rohou & Grigorieff, 2015). Particles were picked with a 
template-based particle picker using a reference-free 2D class average from a small subset 
of manually picked particles as templates. Selected particles were extracted from 
micrographs using particle extraction within Relion (Scheres, 2012) and the coordinates 
exported from Appion. After multiple rounds of 2D classification in Relion to remove junk 
particles, 824,421 particles were left and imported into cryoSPARC (Punjani et al., 2017) 
for further processing. After multiple rounds of 2D classification and heterogeneous 
refinement, a final reconstruction containing 296,319 particles was determined to a global 
resolution of 3.9 Å (based on the gold standard 0.143 FSC criterion using two independent 
half-maps) using local refinement (implementing non-uniform refinement) with a mask 
corresponding to the entire complex. 
 
Csf Model Building, Refinement and Structural Analysis 
An atomic model for the Csf complex was built de novo in Coot (Emsley et al, 
2004), and subjected to multiple iterative rounds of molecular dynamics - flexible fitting 




2018). The majority of the RNA was modelled as polyU, with occasional bases modelled 
as A depending on the size of the cryoEM density corresponding to the nucleobase (i.e. if 
the density was unambiguously a purine, (Bravo et al., 2021)).  The refined Csf complex 
model was validated using MolProbity (Chen et al., 2010) as implemented in Phenix. 
Protein sequence conservation analysis was performed using online ConSurf (Ashkenazy 
et al., 2016) server, with multiple sequence alignment (MSA) generated using the top 100 
result from a BLAST search against Csf sequences. Output from the MSA was used to 
generate a sequence logo using the WebLogo server (G. Crooks et al., 2004) 
Maps and models were visualized using ChimeraX (Goddard et al., 2018) and the 
electrostatic surfaces were determined using the APBS plugin (Baker et al., 2001) within 
PyMol. Root-mean-square deviation (r.m.s.d.) values between equivalent atoms in Csf2 
and type III-A Csm3, and between type IV-B RNA and III-A crRNA were calculated using 
ChimeraX and PyMol. 
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Prokaryotic CRISPR-Cas adaptive immune systems rely on small non-coding 
RNAs derived from CRISPR loci to recognize and destroy complementary nucleic acids. 
However, the mechanism of Type IV CRISPR RNA (crRNA) biogenesis is poorly 
understood. To dissect the mechanism of Type IV CRISPR RNA biogenesis, we 
determined the x-ray crystal structure of the putative Type IV CRISPR associated 
endoribonuclease Cas6 from Mahella australiensis (Ma Cas6-IV) and characterized its 
enzymatic activity with RNA cleavage assays. We show that Ma Cas6-IV specifically 
cleaves Type IV crRNA repeats at the 3’ side of a predicted stem loop, with a metal-
independent, single-turnover mechanism that relies on a histidine and a tyrosine located 
within the putative endonuclease active site. Structure and sequence alignments with 
Cas6 orthologs reveal that although Ma Cas6-IV shares little sequence homology with 
other Cas6 proteins, all share common structural features that bind distinct crRNA repeat 
sequences. This analysis of Type IV crRNA biogenesis provides a structural and 
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biochemical framework for understanding the similarities and differences of crRNA 
biogenesis across multi-subunit Class 1 CRISPR immune systems. 
 
INTRODUCTION 
Bacteria and archaea use small RNAs derived from CRISPR (Clustered Regularly 
Interspaced Short Palindromic Repeat) loci to guide CRISPR associated (Cas) proteins to 
complementary targets such as invasive phage and plasmid DNA [1–8]. Once bound, 
crRNA-guided ribonucleoprotein complexes undergo conformational rearrangements that 
activate trans- or cis-acting nucleases to degrade bound targets [9]. Thus, a critical step of 
prokaryotic crRNA-mediated immunity is crRNA biogenesis, where long, CRISPR-
derived transcripts are processed into small crRNA guides.  
Although crRNA biogenesis is a fundamental process of all known CRISPR 
adaptive immune systems, the proteins and mechanisms involved vary across the two 
CRISPR system classes (1 and 2), six types (I, II, III, IV, V and VI), and more than 
thirty-three distinct subtypes [10–13]. For example, some single-subunit Class 2 proteins 
rely on RNase III to cleave duplexed RNAs formed from the base pairing of crRNA 
repeats with a second trans-activating CRISPR RNA (e.g. Type II-A, and V-B) [14,15], 
while other Class 2 systems process crRNAs with endonuclease activities that reside 
within single subunit effector proteins (types V-A, and VI) [16,17].  
Most multi-subunit Class 1 systems process crRNAs with CRISPR associated 
endonucleases, called Cas6, which share conserved structural motifs that bind crRNAs 
[11]. In general, Cas6 enzymes use a metal-ion-independent mechanism to cleave 




[1,18]. Cleavage is generally catalyzed by stabilizing nucleophilic attack from the 2’ 
hydroxyl located upstream from the scissile phosphate [19–22]. In spite of these 
similarities, Cas6 amino acid sequences are remarkably diverse [23], and several 
structural and mechanistic differences have been observed [11]. For example, often a 
histidine is used to catalyze cleavage [20,23–27], but other residues, such as lysine, have 
been shown to catalyze the reaction when histidine is not present (e.g. subtype I-A) 
[28,29]. Additionally, distinct Cas6 proteins associate differently with processed crRNAs 
after cleavage. In subtypes I-B, I-E, I-D and I-F, Cas6 makes structural and base specific 
interactions with the stable stem-loop formed by the palindromic CRISPR repeat and 
typically stays bound after cleavage to form a component of the multi-subunit 
interference complex [19,21,22,24,25,30–33]. In contrast, the repeats of subtypes I-A, III-
A, and III-B are less stable, allowing Cas6 to dissociate from the processed crRNA and to 
perform multi-turnover crRNA cleavage [26,28,29,34]. 
Type IV CRISPR systems are categorized as Class 1 as they are predicted to form 
multi-subunit crRNA-guided complexes [6,10,13]. However, the enzymatic functions of 
Type IV systems remain largely unknown, including the mechanisms of crRNA 
biogenesis. All Type IV systems contain genes predicted to encode a multi-subunit 
complex consisting of a large-subunit (csf1, cas8-like), backbone (csf2, cas7-like), and 
tail (csf3, cas5-like) [10]. Type IV-A systems contain additional genes that encode for a 
putative helicase (dinG) and a cas6 endonuclease, while Type IV-B systems lack these 
accessory genes, and interestingly, often lack a CRISPR locus. Distinct Type IV-A 




cas6f (cas6 sequences observed in subtypes I-E and I-F), and a Type IV-specific cas6-
like gene called csf5 [13].  
The presence of cas6 homologs suggests that Type IV-A systems process their 
own crRNAs through a Cas6-mediated mechanism. Supporting this prediction, it was 
recently shown that in vivo assembly of a Type IV-A crRNA-protein complex required 
the Cas6-homolog Csf5 [35]. Independently purified Csf5 remained bound to a processed 
crRNA, suggesting Csf5 mediates single-turnover crRNA cleavage. However, Csf5 was 
unstable without a co-expressed crRNA, therefore, it could not be purified in its apo form 
and a mechanistic analysis of Csf5 catalytic activity was not assayed. Thus, a need 
remains for a mechanistic description of Type IV crRNA processing. 
To better understand the mechanism of crRNA biogenesis in Type IV CRISPR 
systems we recombinantly expressed and purified the apo Type IV Cas6 protein from the 
thermophilic anaerobe Mahella australiensis (Ma Cas6-IV) [36]. The genome of M. 
australiensis harbors putative Type I-B and Type IV-A CRISPR systems at two distinct 
loci (Figure 3-1A) each with distinct CRISPR repeat sequences which we have 
designated CRISPR I and CRISPR IV, respectively. We analyzed the Ma Cas6-IV-
mediated processing of Type IV crRNA repeats with cleavage assays and identified a 
putative nuclease active site by determining the structure of Ma Cas6-IV. Additionally 
we show that the crRNA is cleaved on the 3’ side of the predicted stem-loop structure, 
with nucleophilic attack on the scissile phosphate coming from the 2’ hydroxyl of base 
G22 of the repeat. These results provide a biochemical analysis of Type IV crRNA 
biogenesis and suggest that although various mechanisms exist, Cas6-mediated metal-





Figure 3-1. The Type IV Cas6 from M. australiensis (Ma Cas6-IV) cleaves the 
CRISPR repeat of the Type IV associated CRISPR. (A) M. australiensis contains a 
Type I CRISPR system and a Type IV CRISPR system, each with a distinct repeat 
sequence designated as Repeat I and Repeat IV. Nucleotides highlighted in blue indicate 
a purine-purine or pyrimidine-pyrimidine shift in sequence. Bases colored red indicate 
broader mutations. (B) Ma Cas6-IV-mediated processing of a pre-crRNA composed of 
four Repeat IV sequences interspersed with the first spacer sequence from the M. 
australiensis Type IV CRISPR. (C) SYBR Gold stained gel of the 30 nt long Repeat IV 
and the G22 2’-deoxy repeat incubated with Ma Cas6-IV. The G22 2’-deoxy repeat 




radiolabeled repeat by Ma Cas6-IV. Data for the Repeat IV cleavage were fit as described 
in (Niewoehner et al., 2014). Error bars denote standard deviation between two or more 
experiments. (E) Ma Cas6-IV-mediated cleavage trials of 5’-32P-end labeled Repeat IV, 
Repeat I, and their reverse complements (Repeat IV-RC, Repeat I-RC). Data were not fit 





Ma Cas6-IV Processes Pre-crRNAs 
To investigate the mechanism of Type IV crRNA biogenesis, we recombinantly 
expressed and purified N-terminally His-tagged Cas6 protein from the M. australiensis 
Type IV CRISPR system (Ma Cas6-IV) (Figure 3-1A and Figure 3-2). To determine if 
Ma Cas6-IV processes crRNAs, we performed an RNA cleavage assay with a pre-crRNA 
transcribed in vitro with the same directionality as the Type IV cas genes. The pre-
crRNA was designed to contain four Type IV repeat sequences, each 31 nucleotides in 
length, and three 36 nucleotide spacer sequences, each identical to the first spacer 
observed in the native CRISPR IV (Figure 3-3).  The first three of eight repeats observed 
in the Mahella CRISPR are identical, and this sequence was used in the pre-crRNA 
design (Figure 3-3). Switches in purine or pyrimidine identity occur within the repeat at 
positions along the 5’ and 3’ arms and stem of the repeat hairpin. We note that the base 
switches at the base of the stem would not disrupt base pairing if both Watson Crick and 
G-U wobble base pairs are acceptable for binding, suggesting the stem of the repeat may 






Figure 3-2. Ma Cas6-IV purifies as a monomer. (A) Size exclusion chromatogram of 
purified Ma Cas6-IV. Molecular weight standard elution peaks are indicated on top. His-
tagged Ma Cas6–IV elution peak suggests a 28 kDa monomer is purified. (B) SDS-PAGE 
representatives after each of the steps of purification (Ni affinity, Heparin ion exchange, 








Figure 3-3. CRISPR RNA repeat sequence degeneracy and spacer sequences. (A) 
Shown is the repeat spacer repeat sequence that was repeated three times in tandem to 
make the in vitro transcribed pre-crRNA. Nucleotides highlighted in blue indicate a 
purine-purine or pyrimidine-pyrimidine shift in sequence. Bases colored red indicate 
broader mutations. (B) The repeat and spacer sequences observed in the Mahella 
australiensis genome. Repeat nucleotides that differ from the first three repeats are 




1A and Figure 3-3). Other switches in the arms and loop of the hairpin likewise suggest 
that those positions are recognized through shape, or are not necessary at all for binding.  
Our initial nuclease assay showed that Ma Cas6-IV cleaves the pre-crRNA at 
regular intervals, producing several species of smaller RNAs with differences in length of 
~ 67 nucleotides (the length of the repeat + spacer) (Figure 3-1B). This result indicated 
that Ma Cas6-IV processes the pre-crRNA into smaller crRNAs with a mechanism 
similar to other Cas6 nucleases that bind and cleave conserved features of the 
palindromic CRISPR repeat [11]. To evaluate this activity in more detail, we showed that 
Ma Cas6-IV cleaves a radio- or fluorescein-labeled 30-nucleotide RNA identical in 
sequence to the first crRNA repeat of CRISPR IV (Figure 3-1C - E). As M. australiensis 
is a thermophile [36], we were not surprised to observe that optimal Ma Cas6-IV 
cleavage occurs at temperatures around 50°C, indicating the cleavage mechanism is 
thermostable (Figure 3-4). Additionally, Ma Cas6-IV was able to cleave crRNAs in the 
presence of high concentrations of the metal chelator EDTA (see Methods section), 
indicating that the cleavage mechanism is metal-ion-independent, consistent with other 
Class 1 crRNA processing mechanisms [1,18,21,28]. 
To determine where on the CRISPR repeat Ma Cas6-IV cuts, a small RNA 
marker was run alongside a cleaved repeat stained with SYBR gold (Figure 3-1C). We 
observed that the smaller of two distinct cleavage products ran next to the 8 nt band, 
while the larger ran next to a 20 nt band, indicating Ma Cas6-IV cleaves the repeat 
asymmetrically on the 3’-side of the repeat near position 22. To confirm the location of 
cleavage we incubated Ma Cas6-IV with a repeat containing a 2’-deoxy sugar at 





Figure 3-4. Cleavage of Repeat IV by WT Ma Cas6-IV at various temperatures. 
Cleavage of radiolabeled Type IV Repeat was monitored at different temperatures. 
Shown are data collected in triplicate and fit as in Figure 3-1. Cleavage occurred at all 




2’-deoxy repeat indicating the scissile phosphate resides on nucleotide 23 of the repeat, 
and cleavage is mediated through nucleophilic attack of the 2’ hydroxyl of position G22.   
Previous analysis of Cas6 endonucleases from the thermophile Thermus 
thermophilus (TtCas6A and TtCas6B) showed that some Cas6 endonucleases encoded in 
organisms with multiple CRISPR loci are capable of cleaving more than one CRISPR 
repeat sequence [24].  As M. australiensis contains two different CRISPR loci in its 
genome, each with a distinct CRISPR repeat sequence, Ma Cas6-IV could potentially 
cleave both Type IV and Type I repeats (Figure 3-1A). To measure the sequence 
specificity of Ma Cas6-IV, in addition to the Type IV repeat, we tested for nuclease 
activity against the Type I repeat, the Type I repeat-reverse complement, and the Type IV 




thermophilus that cleave multiple repeat sequences, Ma Cas6-IV cleaves only the Type 
IV crRNA, indicating Ma Cas6-IV is specific for the Type IV repeat sequence. 
 
Structure of Ma Cas6-IV 
Our initial analysis showed that Ma Cas6-IV specifically cleaves Type IV crRNA 
repeats, but mechanistic details, such as the turnover kinetics for this enzyme and the 
features important for binding and cleaving the crRNA, remained unknown. Sequence 
alignments of Ma Cas6-IV with Type I and Type III Cas6 orthologs, as well as the 
recently investigated Type IV-specific Csf5 protein revealed low sequence identity (~ 
16%) (Table 3-1), including in the region of the putative active site. Thus, the 
mechanistic details of Ma Cas6-IV could not be deduced through simple amino acid 
sequence alignments with previously characterized proteins.  
To better understand Ma Cas6-IV function, we determined the x-ray crystal 
structure of apo Ma Cas6-IV at 1.76 Å resolution (Figure 3-5 and Table 3-2). Crystals 
of N-terminally His-tagged Ma Cas6-IV were grown using sitting-drop vapor diffusion 
and formed in a hexagonal space group (P61) (Figure 3-6). Our initial attempts to solve 
the crystal structure using existing Cas6 structures as molecular replacement models 
failed. We hypothesized that this was due to structural differences between Ma Cas6-IV 
and the available Cas6 models, so we instead solved the structure using Single-
wavelength Anomalous Dispersion methods with crystals soaked overnight in Potassium 
Tetrachloroplatinate (See Methods and Table 3-2).  
The structure of Ma Cas6-IV reveals that two protein chains reside in the 




Table 3-1. Structural alignment data for Cas6 homologs from multiple subtypes of 
CRISPR-Cas systems. 
 















4ILR 2.8495 187/279 15.508 
Shao, Y. and Li, H. 
(2013) 
4ILL 2.8417 185/278 15.1351 
4ILM 3.2212 188/279 12.766 
Sso1437 3ZFV 
2.7694 165/259 16.9697 





3.4796 175/241 10.8571 
Lee, M.C. et al. 
(2018) 
I-B 
Thermus thermophilus TTHB231 
4C98 2.7742 172/242 17.4419 
Niewoehner, O. et 
al. (2014) 
4C9D 2.5348 189/262 16.9312 
Methanococcus maripaludis Mm Cas6b 4Z7K 
3.2812 167/218 16.1677 





4F3M 3.0815 67/213 8.9552 
Nam, K.H. et al. 





4.8526 43/184 13.9535 
Streptococcus pyogenes 3VZH 5.005 52/194 11.5385 





1WJ9 3.4209 134/188 10.4478 
Sashital, D.G. et al. 
(2011); Gesner, 
E.M. et al. (2011); 
Ebihara, A. et al. 
(2006) 
2Y8W 3.6472 150/215 11.3333 
3QRP 
3.609 151/214 10.596 
Escherichia coli CasE 4DZD 3.5718 147/193 9.5238   
I-F Pseudomonas aeruginosa Csy4 
2XLI 3.5108 85/167 3.5294 
Haurwitz, R.E. et 
al. (2010); 
Haurwitz, R.E. et 
al. (2012) 
4AL5 
3.4897 89/189 2.2472 
III-B 
Pyrococcus furiosus PfCas6 
3I4H 3.3531 180/232 13.3333 
Carte, J. et al. 
(2008); Wang, R. 
et al. (2011) 3PKM 3.4297 175/229 12 
3UFC 
3.5745 181/243 9.3923 
Park, H.M. et al. 
(2012) 
Marinomonas mediterranea Cas6 6DD5 
3.3147 188/652 14.3617 
Mohr, G. et al. 
(2018) 
IV-A Aromatoleum aromaticum Csf5 
6H9H 3.9062 108/250 8.3333 
Özcan, Ahsen, et 
al. (2019) 
6H9I 3.7411 156/250 8.3333 
Orphan Thermus thermophilus TTHB78 
4C97 2.338 173/233 16.763 
Niewoehner, O. et 
al. (2014) 
4C8Y 2.3557 180/238 16.6667 





Figure 3-5. Structure of apo Ma Cas6-IV and identification of the active site 
residues, His44 and Tyr31. (A) Ribbon model (left) and topology diagram (right) of the 
Ma Cas6-IV structure. The two RRM domains, C-terminal structural motifs involved in 
binding the crRNA, and putative active site are indicated. (B) Alignment of apo Ma 
Cas6-IV to RNA-bound TthCas6 (PDB:4C8Z) with a zoomed in view of the Ma Cas6-IV 
active site containing His44 and Tyr31 residues. RMSD of the alignment is 1.26 Å over 




aligned with the RNA of PDB 4C8Z.  Predicted positively charged surface is colored 
blue and negatively charged surface is colored red. (C) Cleavage assays of Repeat IV by 
predicted active site mutants of Ma Cas6-IV (left) with cleavage percentages fit to a 
pseudo-first order rate equation (right). Cleavage activity of H44A Ma Cas6-IV in the 








Table 3-2. Data collection and refinement statistics. 
 
  










Cell dimensions   
    a, b, c (Å) 85.5, 85.5, 142.6 85.9, 85.9, 144.5 
       (deg)  90.0, 90.0, 120.0 90.0, 90.0, 120.0 
Wavelength (Å) 1.55 1.0718 
Resolution (Å) 40-1.76 (1.82-1.76)* 40-2.95 (3.06-2.95) 
Rmerge(%) 5.3 (72.7) 6.5 (22.3) 
CC1/2 0.995 (0.736) 0.994 (0.941) 
I / σI  25.3 (2.2) 15.4 (3.5) 
Observations 350790 (23595) 95034 (5484) 
Unique reflections 58149 (5618) 24773 (2359) 
Multiplicity 6.0 (4.2) 3.8 (2.3) 
Completeness (%) 99.6 (96.3) 99.3 (94.9) 
 
Refinement 
Resolution† (Å) 40-1.76 (1.82-1.76)  
No. reflections 148794  
Rwork/Rfree (%) 17.1/19.6  
No. atoms 4202  
    Protein 
    Water 





B-factors   
    mean 43.84  
    Protein 42.84  
    Water 50.51  
    Ligands 78.20 
R.m.s. deviations   
   Bond lengths (Å) 0.008  
   Bond angles (deg) 
Ramachandran 
    Favored (%) 
    Allowed (%) 









   
*Values in parentheses are for highest-resolution shell. 





Figure 3-6.  Crystallographic symmetry and electron density of Ma Cas6. (A) Side 
and top views of the P61 symmetry of Cas6 dimers in the crystal. (B) Examples of 
electron density observed at the putative active site and within the C-terminal RRM 





amino acids of both proteins to be modeled along with 7 additional nucleotides of the 
histidine affinity tag (Figure 3-6).  The monomers are arranged with two-fold symmetry 
and are superimposable with an R.M.S.D. < 0.29 Å over 227 of 237 Cα carbons. 
Although the structure indicates Ma Cas6-IV is capable of forming a dimer, size 
exclusion profiles indicate it purifies as a monomer (Figure 3-2). Additionally, analysis 
with the PDBePISA server reveals the dimer interface is 1067 Å2 with a Complex 
Formation Significance Score (CSS) of 0.066 [37] (Figure 3-7). The low CSS score 
(scores range from 0 to 1) implies the interface is not significant for complex formation. 
These results, along with the observation that the dimer conformation is fundamentally 
different from other Cas6 dimers shown to be functionally relevant [24,29], suggest the 
observed dimer may solely be the result of crystal packing.   
Each monomer is composed of two modified RRM (RNA recognition motif) 
domains, also known as ferredoxin-like folds (Figure 3-5A).  Canonical RRM domains 
adopt β1 1, β2, β3 2, β4 fold, where the two helices pack against the concave face of an 
anti-parallel beta-sheet formed by the four beta-strands [38].  The two RRM domains of 
Ma Cas6-IV express this secondary structure, but in each domain the first alpha-helix has 
been modified into a helix-turn-helix. Additionally, the C-terminal RRM contains 
extended features between β1 and α1, β2 and β3, and α2 and β4.  To identify the function of 
these motifs we aligned our structure with the available Cas6 structures in the PDB using 
the secondary structure matching (SSM) tool in the molecular modeling program Coot 
(Figure 3-5, Table 3-1, and Figure 3-8) [39]. Our structural alignments reveal that the 
C-terminal RRM extensions align with conserved features important for binding the 





Figure 3-7. Structural analysis of the crystallographic dimer. (A) Ribbon views of the 
side and bottom of the crystallographic dimer. A yellow square line indicates the location 
of the active site on proximal side, and a dashed square line indicates the active site on 
the opposite side (B) Surface charge is shown on side and bottom views of dimer. Active 
sites are indicated as in A. (C) The dimers are shown as a surface. The interface is shown 
as cyan where the monomers of the dimer have been rotated 90 degrees. The calculated 






Figure 3-8. Alignment of Ma Cas6-IV with Cas6 orthologs. Ma Cas6-IV was aligned 
with Cas6 and Cas5d models available in the PDB using the SSM (Secondary Structure 
Matching) tool in Coot. The structure of Ma Cas6-IV is shown in the top left corner. PDB 




of each structure is shown. It is indicated in color where the topology of the aligned 




have been previously described as the groove-binding element (GBE), the β-hairpin, and 
the glycine-rich loop (G-loop) (Figure 3-5A) [11]. In Ma Cas6-IV the GBE forms a β-
hairpin. In RNA-bound structures of other Cas6 proteins, the GBE typically makes 
sequence and shape specific contacts within the major groove of the crRNA stem-loop 
[21,24,25,40]. An alignment of 184 Cα carbons with the RNA-bound TthCas6A protein 
from Thermus thermophilus (PDB 4C8Z, RMSD 2.45 Å) positions the GBE from Ma 
Cas6-IV into the major groove of the bound RNA, suggesting that the GBE of Ma Cas6-
IV binds the major groove of the crRNA stem-loop (Figure 3-5B and Figure 3-9). The β-
hairpin motif occurs in the majority of Cas6 enzymes, and typically contacts the base of 
the crRNA stem-loop and positions the scissile phosphate into the active site [21,25,28]. 
Our alignment with the RNA-bound TthCas6A shows the tip of the Ma Cas6-IV β-
hairpin pointing away from the scissile phosphate, suggesting this feature may undergo a 
conformational change upon binding the crRNA [25]. The G-loop, in the Ma Cas6-IV 
structure resides between α2 and β4 and forms a small loop-helix-loop structure. In other 
Cas6 enzymes, this motif is involved in binding the crRNA through ionic interactions 
along the phosphate backbone [23–25,41]. The G-loop in Ma Cas6-IV contains two 
lysine residues that help form a large positively charged patch on the surface of the 
protein (Figure 3-5B). In our alignment, the crRNA of the RNA-bound structure is 





Figure 3-9. Overlays of Ma Cas6 with Cas6 homologs bound to RNA. (A) Overlay of 
the RNA of PDB 4C8Z. Inset shows residues in putative active sites and distances to 2’-
3’ cyclic phosphate. (B) Second overlay with RNA from Type IV Cas-homolog Csf5. 






loop of Ma Cas6-IV may form ionic interactions with the negatively charged backbone of 
the CRISPR IV crRNA. Interestingly, this positive patch extends towards the back of the 
C-terminal RRM, suggesting a possible trajectory of the crRNA that wraps around the 
protein as seen in Type III-A Cas6 enzymes (Figure 3-5B bottom and Figure 3-9) 
[26,28,34]. 
 
His44 and Tyr31 are Catalytic Residues of the Ma Cas6-IV Active Site 
Cas6 nuclease active sites are typically located in the cleft between the two RRM 
folds [11] but, without a substrate bound, our structure of apo Ma Cas6-IV was not 
sufficient to determine the location of the Ma Cas6-IV active site. In our alignment with 
TthCas6A bound to RNA, Ma Cas6-IV residues His44 and Tyr31 are located within 4 Å 
of the aligned scissile phosphate, suggesting they could be involved in catalysis. Indeed, 
in the TthCas6A protein, a histidine in this region was shown to catalyze cleavage [24], 
and histidine residues in this region have been shown to have a role in catalysis of several 
other Cas6 enzymes [20,23,25–27]. To determine if the Ma Cas6-IV residues His44 and 
Tyr31 are responsible for catalysis of RNA cleavage, we created alanine mutants of each 
residue, alone and in tandem, and assayed their ability to cleave Repeat IV. Mutation of 
either residue to alanine severely reduced cleavage (Figure 3-5C and 3-5D). Previous 
analyses of Cas6 catalytic activity showed that, in some cases, nuclease activity lost upon 
histidine mutation could be restored with the addition of imidazole [24]. To better 
understand how the histidine catalyzes cleavage, we added 500 mM imidazole to our 
H44A Ma Cas6-IV mutant cleavage reaction. Under these conditions, H44A Ma Cas6-IV 




ring compensates for the histidine mutant, consistent with a model where the active site 
histidine plays a role in catalysis [20,42]. 
 
Ma Cas6-IV is a Single-Turnover Enzyme to the CRISPR Repeat RNA 
Substrate 
Many Cas6 enzymes exhibit single-turnover characteristics, remaining bound to 
their cleaved crRNA products, while others dissociate from cleaved crRNAs allowing for 
multi-turnover activity [11]. To determine the turnover number of the Ma Cas6-IV 
enzyme, we performed nuclease assays with constant concentrations of Repeat IV and 
varying concentrations of Ma Cas6-IV corresponding to the following ratios of Cas6 to 
RNA substrate; 2:1, 1:1, 1:2, 1:4, and 1:8. In both the 2:1 and 1:1 conditions nearly all of 
the RNA substrate was cleaved. In each successive condition, a cleavage amplitude was 
reached where less total RNA was cleaved than in the previous condition (Figure 3-10). 
When excess substrate is present, cleavage does not go to completion, but rather 
corresponds to the cleavage of one RNA molecule per Cas6 active site. Thus, we 
conclude that Ma Cas6-IV is a single-turnover enzyme. 
 
Structural Comparison of Ma Cas6-IV to Csf5 
Although Type IV systems are similar in gene arrangement and identity, Type IV 
Cas6 proteins are unexpectedly diverse in sequence (Figure 3-11 and Table 3-1). Type 
IV systems contain several Cas6 variants, including sequences that resemble Cas6e and 
Cas6f, and others that encode a Type IV-specific Cas6 homolog called Csf5 [13]. 
Structural comparisons of Ma Cas6-IV with Csf5 from Aromatoleum aromaticum reveal 





Figure 3-10. Ma Cas6-IV exhibits single-turnover characteristics for Repeat IV. (A) 
Cleavage of Repeat 4 by Ma Cas6-IV with a Cas6:Repeat IV ratio of 2:1. (B) Isotherms 
and electrophoresis gels of additional ratios of Cas6:Repeat are shown. The data were fit 








Figure 3-11. Structure and sequence alignments of Ma Cas6-IV with other Type IV 
RNA endonucleases. (A) A structural comparison of Ma Cas6-IV with the Cas6-
homolog Csf5 from Aromatoleum aromaticum (PDB 6H9I). Features involved in binding 
crRNAs are indicated. The Csf5 protein contains a large insert called the alpha-helical 
finger domain (light green) that is not observed in Ma Cas6-IV. Residues predicted to 
activate cleavage of the crRNA are indicated in the inset below. (B) Sequence alignment 
of Ma Cas6-IV with other RNA endonucleases observed in Type IV systems. The N- and 




bind crRNA, including the groove-binding element (GBE), beta-hairpin, and glycine-rich 
loop (G-loop). The alpha-helical finger domain (-HFD) insert of Csf5 is also indicated. 
Active site residues of Ma Cas6-IV and Csf5 are bolded in red. Cas6e and Cas6f 






(Figure 3-11A). The C-terminal RRM domains of both enzymes contain the motifs that 
bind crRNA (GBE, β-hairpin, and G-loop), but the C-terminal domain of Csf5 differs 
from Ma Cas6-IV in that the second alpha helix (α2) of the canonical RRM fold is absent 
(Figure 3-8). In both Csf5 and Ma Cas6-IV the α1 helices of the N-terminal RRM 
domains have been replaced with helix-turn-helix motifs that house putative active-site 
residues (Figure 3-11B). However, instead of the small loop sequence observed in Ma 
Cas6-IV that connects the helix-loop-helix to β2, Csf5 has an insertion of ~40 amino 
acids called the α-helical finger domain that contains two additional helices. One of these 
helices interacts with the minor groove of the crRNA stem-loop, providing additional 
contacts for binding the crRNA that may provide additional specificity toward Type IV 
crRNA repeats.  
Interestingly, despite structural similarity the mechanisms of cleavage utilized by 
these protein homologs are diverse. Both Csf5 and Ma Cas6-IV contain a histidine in the 
N-terminal RRM at the same sequence position (H44). In Ma Cas6-IV the histidine 
resides in the helix-turn-helix and is within H-bonding distance of the scissile phosphate 
(Figure 3-9). However, in Csf5 this histidine resides within the 40 amino acid insert 
several Ångstroms away from the scissile phosphate, suggesting it does not participate in 
nuclease activity. In support of this hypothesis, an H44A mutant of Csf5 did not impair 
cleavage [35]. Rather, mutation of arginine residues located on the helix-turn-helix and 
the G-loop (R23A, R38A, R242A) impaired cleavage (Figure 3-11A). Notably several of 
these arginines are located in similar positions to the active site residues of Ma Cas6-IV 




crRNA processing enzymes are diverse in sequence, they rely on similar structural 
themes to bind and cleave crRNA substrates. 
 
DISCUSSION 
Because Type IV CRISPR systems have just recently been discovered, the 
biological function of these systems remains largely unknown. We hypothesized that pre-
crRNA transcripts from adjacent CRISPR loci would be processed into small crRNA-
guides to direct a biological function. To understand the feasibility and mechanism of 
Type IV crRNA biogenesis, we characterized the structure and activity of a Type IV-A 
Cas6 crRNA endonuclease from the microbe Mahella australiensis (Ma Cas6-IV). We 
observed that Ma Cas6-IV processes pre-crRNAs in vitro by cleaving within the CRISPR 
repeat sequence, through a mechanism that is metal-independent and facilitated by 
residues His44 and Tyr31. Analysis of repeat cleavage products suggests that the repeat is 
cleaved asymmetrically on the 3’ side of the predicted stem loop with the 5’-phosphate of 
the 23rd nucleotide as the scissile phosphate. We show that Ma Cas6-IV cleaves crRNAs 
with single-turnover kinetics, suggesting the enzyme stays bound after cleavage to one 
side of the repeat. Binding assays and crystal structures show that in several Type I 
systems Cas6 remains bound to its crRNA product, forming part of the interference 
complex that uses the crRNA as a guide to bind complementary targets [30–32,43]. We 
hypothesize that the single-turnover kinetics we observe are due to Ma Cas6-IV 
remaining bound to the 5’ side of its cleaved crRNA product, suggesting Ma Cas6-IV 
may be a component of a multi-subunit complex that assembles on the processed crRNA. 




sides of the crRNA that does not allow for additional repeats to be cleaved. Further work 
is needed to determine how Ma Cas6-IV interacts with the repeat cleavage products and 
whether it forms a part of the predicted multi-subunit complex.  
Phylogenetic work previously predicted that multi-subunit complexes would form 
in Type IV-A systems and would be composed of Csf2 (Cas7-like backbone protein), 
Csf3 (Cas5-like tail protein) and the Type IV signature protein Csf1 [6,10,13]. 
Supporting this prediction, Özcan and colleagues recombinantly expressed and isolated a 
Type IV-A complex containing these exact subunits and the Cas6-homolog Csf5 [35]. 
This recent work, coupled with our observations, suggest that in Type IV-A systems Cas6 
mediates cleavage of the pre-crRNA, creating small crRNA guides that are then bound by 
Csf1, Csf2, and Csf3 to form a multi-subunit crRNA-guided complex. It appears that in 
some cases Cas6 forms a part of the multi-subunit complex, but it remains unknown if 
this is a conserved feature of all Type IV-A systems.  
The function of Type IV systems also remains unknown. A recent phylogenetic 
analysis reported that many Type IV system spacers are complementary to known phage 
sequences [6], suggesting the system acts as an immune system. However, analysis of the 
spacers of Mahella australiensis using the CRISPRTarget tool [44] reported no plausible 
matches, with only three spacer sequences retaining some complementarity to phage 
sequences, but with multiple mismatches (Figure 3-12). Even if it were clear that Type 
IV systems target phage or plasmid sequences the function of such targeting would 
remain unknown, as no nuclease domains have yet been clearly identified in any of the 
Type IV systems. Thus, a more detailed analysis of the structure and function of these 





Figure 3-12. CRISPRTarget results with Mahella australiensis spacer sequences as 





In contrast to Type IV-A systems, Type IV-B systems do not encode Cas6 
enzymes and are not associated with CRISPR loci. However, Type IV-B systems do 
encode the Csf1, Csf2, and Csf3 proteins, suggesting they may be capable of forming a 
complex on processed crRNA guides. It has been proposed that Type IV-B systems may 
utilize crRNAs generated from other CRISPR systems to form complexes and may have 
a non-defense function [45]. However, it has yet to be shown that Type IV-B proteins can 
form a complex on a crRNA.  
Cas6-like RNA endonucleases associated with Type IV-A systems are quite 
diverse in amino acid sequence. A small group of systems encode for the Type IV-
specific Csf5 protein, but others encode variants of Cas6 that are dissimilar in sequence 
but retain the dual RRM architecture observed in Cas6 proteins (Figure 3-11B). The 
wide range of Cas6 sequences across Type IV-A systems suggests that perhaps Cas6 
enzymes were acquired by Type IV-B systems at different times in evolutionary history. 
We postulate that such fusions also included a CRISPR locus, providing a crRNA-guide 
upon which the Csf1, Csf2, and Csf3 proteins could assemble. Interestingly, the protein 
for which Ma Cas6-IV is most similar in structure and sequence is an orphaned Cas6-
homolog from Thermus thermophilus (TthCas6A) (Figure 3-5, Figure 3-3, and Table 3-
1). TthCas6A is not found within a CRISPR system but is adjacent to a CRISPR locus, 
suggesting it could combine with other systems in tandem with its CRISPR locus.  We 
speculate that perhaps a similar orphaned Cas6 sequence combined with a Type IV-B 
system to produce the Type IV-A system of Mahella australiensis.   
This work and a recent study on the Type IV system from A. aromaticum [35] 




mechanism. Additionally it has been shown that multi-protein complexes assemble onto 
these crRNAs [35]. However, the biological function of both Type IV-A and Type IV-B 




Expression and Purification of Ma Cas6-IV 
The full-length M. australiensis Cas6 gene sequence (Uniprot AEE97687.1) was 
obtained from IDT (Integrated DNA Technologies) as a gBlock. The sequence was PCR 
amplified with primers containing LIC (Ligation Independent Cloning) overhangs, and 
was subcloned, using ligation independent cloning, into the 2B-T transfer vector. Ma 
Cas6-IV mutants were created using the Q5 Site-Directed Mutagenesis kit (New England 
BioLabs (NEB)). 
Recombinant protein expression was induced in BL21 DE3 cells with 0.1 mM of 
IPTG (isopropyl β-D-1-thiogalactopyranoside) at an optical cell density (O. D. 600 nM) 
of ~0.3-0.4. After induction, cells were grown at 16°C for 24 hours and then pelleted via 
centrifugation. Pelleted cells were added at a ratio of 1:8 (g of cells : mL of buffer) to 
25mM NaPO4 (pH 7.5), 500mM NaCl, 25mM imidazole, 5% glycerol, 0.01% Triton X-
100, 1 mM Tris [2-carboxyethyl] phosphine hydrochloride (TCEP), 0.5 mM 
phenylmethylsulphonyl fluoride (PMSF), and 0.1 mM lysozyme. Cells were lysed by 
sonication. Sonicated lysate was clarified via centrifugation. Clarified lysate was placed 
over a HisTrap FF column (GE Healthcare) and the bound protein was eluted with a high 




glycerol, 1 mM TCEP) then desalted into 25 mM NaPO4 (pH 7.5), 150 mM NaCl, 1mM 
TCEP, 5% glycerol with a HiPrep 26/10 desalting column (GE healthcare). Desalted 
protein was placed over a HiTrap SP FF column (GE healthcare) and eluted with a NaCl 
gradient. The protein was further purified with a Superdex 200 pg 26/600 column (GE 
Healthcare) and eluted in 100 mM HEPES (pH 7.5), 150 KCl, 5% glycerol, 1 mM TCEP. 
The protein was then concentrated to 6-8 mg/ml using Vivaspin centrifugation 
concentrators. Wild type and mutant protein constructs were expressed and purified with 
the same protocol. 
 
Generation of RNA Substrates 
The Ma pre-crRNA was generated using in vitro transcription with the HiScribe 
T7 Quick kit (NEB) and a plasmid linearized immediately after the encoded Ma CRISPR 
under control of a T7 promoter. All small RNA oligonucleotides were synthesized by 
IDT with or without a 3’ fluorescein label. Radiolabeled substrates were 5’-end labeled 
with (γ-32P)-ATP (Perkin Elmer) and T4 polynucleotide kinase (NEB). Labeled RNAs 
were separated from excess ATP with a MicroSpin G-25 column (GE Healthcare), then 
gel purified on a 12% denaturing (7M urea) polyacrylamide gel, ethanol precipitated, and 
recovered in water. 
 
Pre-crRNA Cleavage Assay 
15 µM Cas6 and 0.25 µM Ma pre-crRNA were incubated at 50°C in 20 mM 
HEPES (pH 7.5), 100 mM KCl, 1 mM β-Mercaptoethanol, and 50 mM EDTA. 10 µl 




chloroform and briefly centrifuged. Eight µl of the aqueous layer was mixed with 
formamide RNA loading buffer and resolved on a 12% denaturing (7M urea) 
polyacrylamide gel with a Low Range ssRNA ladder (NEB). The gel was stained with 
SYBR Gold Nucleic Acid Gel stain (Invitrogen) and imaged with a ChemiDoc MP 
Imaging system (Bio-Rad). 
 
Repeat Cleavage and Turnover Assays 
2.5 µM Cas6 and 5 nM 5’-end 32P or 1 µM 3’-end fluorescein labeled RNA 
substrate were incubated at 50°C in 20 mM HEPES (pH 7.5), 100 mM KCl, 1 mM β-
Mercaptoethanol, and 50 mM EDTA. Time points were collected and resolved on a gel as 
described for the pre-crRNA cleavage assay. Fluorescein labeled substrates were imaged 
and quantified with a ChemiDoc MP Imaging system (Bio-Rad). Gels containing 32P 
labeled substrates were dried, exposed to a phosphor storage screen, and scanned with a 
Typhoon (GE Healthcare) phosphorimager. Cleaved and uncleaved fractions were 
quantified using ImageQuant (GE Healthcare) software. All data were fit as described by 
Niewoehner and colleagues [24]. Briefly, using Kaleidagraph (Synergy Software), the 
cleavage assay data were fit to the equation: 
𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑐𝑙𝑒𝑎𝑣𝑒𝑑 = 𝑐𝑢𝑟𝑣𝑒 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 × (1 − exp(−𝑟𝑎𝑡𝑒 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 × 𝑡𝑖𝑚𝑒)) 
Reported data is the average of three experiments and error bars represent 
standard deviations. To recover the cleavage activity of the Ma Cas6-IV H63A mutant, 




The turnover kinetics of Ma Cas6-IV were tested by performing cleavage assays 
as described above, except with 1000 nM substrate (5 nM of which was radiolabeled) and 
varying concentrations of Ma Cas6-IV (2000, 1000, 500, 250, and 125 nM). 
 
Crystal Growth and Structure Determination 
Ma Cas6-IV was crystallized at 22°C using the sitting drop vapor diffusion 
method. Drops were made by mixing equal volumes of protein (6-8 mg/ml in 100 mM 
HEPES (pH 7.5), 150 KCl, 5% glycerol, 1 mM TCEP) and reservoir solution (0.1 M 
sodium acetate trihydrate (pH 4.8-5.1) and 1.60 - 1.75 M ammonium sulphate). Most 
crystals grew to a size large enough for data collection in about a week.   
As initial attempts at solving the crystal structure using molecular replacement 
with existing models failed, and because we were unable to grow crystals of appreciable 
size with selenomethionine derivatized protein, we solved the structure by soaking in 
heavy metals. Crystals were soaked in tetrachloroplatinate overnight and then back 
soaked into cryo-protectant containing the mother liquor solution and 30% dextrose 
followed by flash freezing.  Native and anomalous diffraction data were collected 
remotely at SSRL beamline 12-2 with high redundancy and completeness (Table 3-1). 
The Phenix tool autosol was used to identify an initial substructure, phase the data, 
density modify initial maps, and autobuild an initial model [46–50]. Although 
incomplete, the initial autobuild model was sufficient for molecular replacement for 
phasing the native data [51]. Iterative rounds of model building and refinement using 





Structure and Sequence Alignments 
Ma Cas6-IV was aligned with Cas6, and Cas5d models available in the PDB 
using the SSM (Secondary Structure Matching) tool in Coot [39]. After alignment Coot 
spits out statistics that list the number of Cα carbons aligned, the R.M.S.D. of the 
alignment, and the percentage of residues aligned that are identical (see Table B1). 
Alignment of diverse Type IV Cas6 sequences that had structures available (Ma Cas6-IV 
and Aa Csf5) was done in Coot using SSM. However the Cas6e and Cas6f sequences 
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The model coordinates and structure factors for the apo Ma Cas6-IV structure 
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A TYPE IV-A CRISPR-CAS SYSTEM IN PSEUDOMONAS AERUGINOSA STRAIN 
PA83 MEDIATES RNA-GUIDED INTERFERENCE IN VIVO3 
 
ABSTRACT 
Bacteria and archaea use CRISPR-Cas adaptive immune systems to destroy 
complementary nucleic acids using RNAs derived from CRISPR loci.  Here we provide 
the first functional evidence for Type IV CRISPR-Cas, demonstrating that the system 
from Pseudomonas aeruginosa strain PA83 mediates RNA-guided interference against a 
plasmid in vivo, both clearing the plasmid and inhibiting its uptake. This interference 
depends on the putative NTP-dependent helicase activity of Csf4/DinG. 
 
INTRODUCTION 
Prokaryotes use small non-coding RNAs derived from CRISPR (Clustered 
Regularly Interspaced Short Palindromic Repeat) arrays to guide CRISPR associated 
(Cas) proteins to invasive complementary nucleic acids such as phage and plasmid DNA 
for destruction1–5.  
Computational analyses have grouped CRISPR-Cas systems into two classes, 6 
types and at least 33 subtypes6.  The function of Class 1, Type IV systems, remains 
largely unknown, in part because this system is comparatively rare and considered a 
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minimal CRISPR-Cas variant6. All Type IV systems contain genes predicted to encode a 
multi-subunit complex composed of large (csf1, cas8-like), backbone (csf2, cas7-like) 
and tail subunits (csf3, cas5-like). To date, Type IV systems have been subdivided into 
IV-A and IV-B subtypes. Type IV-A systems contain genes that encode for a putative 
helicase (dinG) and a cas6-like endonuclease, whereas Type IV-B system lack these 
genes and are often missing a CRISPR locus6.  It has been shown that the Type IV-A 
Cas6 from Mahella australiensis and a Cas6-like homolog, Csf5 from Aromatoleum 
aromaticum, are involved in biogenesis of CRISPR derived RNAs (crRNA)7,8.  
Additionally, the Type IV-A proteins from A. aromaticum (AaCsf1, AaCsf2, AaCsf3 and 
AaCsf5) were shown to form a complex that assembles on a crRNA8.  It has been 
hypothesized that the Type IV-A ribonucleoprotein complex enables RNA-guided target 
detection, the function of which remains unknown8. Here we investigate the Type IV 
CRISPR-Cas systems in Pseudomonas aeruginosa and demonstrate that a Type IV-A 
system mediates interference against plasmids in vivo. 
 
MATERIALS AND METHODS 
Bioinformatic Analysis 
A Psi-Blast was performed on January 8, 2018 on the NCBI protein database with 
the seed WP_018940624.1 (Csf1), WP_013006553.1 (Csf2), and WP_018940624.1 
(Csf3) of Thioalkalivibrio sp. K90Mix. Csf1, Csf2, and Csf3 returned 389, 1134, and 737 
hits, of which 38, 48, and 41 hits were from P. aeruginosa, respectively. We proceeded 
by downloading amino acid sequences solely from P. aeruginosa for later bioinformatic 




addition, genes upstream and downstream of these hits were downloaded and compared 
by amino acid identity. Position relative to Csf2 hits was used to compare genes, 
revealing 4 conserved architectures. Each system, including intergenic regions and 7 
genes in each direction of Csf2, in a given architecture was saved for further analysis. In 
some of these systems the downstream region of Csf3 contained putative CRISPR arrays 
already annotated, while the rest did not have annotation. An in-house script was written 
to search for non-identical repeats, with a search seed of the palindromic region 
CCCCGC or GCCGCC. By accounting for a hamming distance up to 3 between nearby 
putative repeats, unannotated regions were found to have CRISPR arrays. This was 
assisted with the inference of direction, using the rate of divergence from the consensus 
sequence over the array to find the conserved orientation between systems. Spacers 
between repeats were declared to have originated from a Pseudomonas plasmid if they 
appeared at least once on an annotated plasmid. Spacers were used to search for 
protospacers that originated from phages/prophages or plasmids. This was done using 
BLASTn to find matches in prokaryotes, which were then determined to be either located 
on a plasmid or a prophage (using the online tool PHASTER9). To rule out that BLASTn 
hits were spacer sequences in CRISPR arrays, the protospacer was confirmed to be within 










NZ_CP017294 – P. aeruginosa PA83 plasmid unnamed1 
 
CRISPR Array Used in Plasmid Transformation Efficiency and Maintenance 
Assays 
We used the direct repeat found on the PA83 plasmid upstream of spacers that 
had hits to phage (5’-GTGTTCCCCGCATACGCGGGGGTGAACGG-3’). The CRISPR 
arrays used in our experiments contain a single spacer flanked by two of the same direct 
repeats. We evaluated two targeting spacers (TS1, TS2) and one non-targeting spacer 
(NTS). The spacer sequences we used in our experiments were TS1: 5’-
TGGAGCAACACCTGAAGGAAGGCTTGATGAGC -3’, TS2: 5-
CTCAACCGAGGGTGGTTTTGTCTA-3’ and NTS 5’-
CTGAGTGTGATCGATGCCATCAGCGAAGGGCC-3’. The targeting spacers TS1 and 
TS2 target a sequence specific to the CAO1 gene from Oryza sativa (rice). These target 
sequences were picked for future experiments unrelated to this manuscript.  
 
Plasmids 
All P. aeruginosa genes and CRISPRs were synthesized by Twist Bioscience 
(San Francisco). PaCsf1was codon optimized for synthesis (see DNA sequence in 
Supplementary Table 1). Primers are listed in Supplementary Table 1. csf1, csf2 and 
Annotation Feature GenPept Genomic position 
Putative ATP-dependent DNA helicase DinG Csf4/DinG PSA83_06667 299162..301341 
Hypothetical protein Csf5/Cas6 PSA83_06666 298385..299113 (complement) 
CRISPR type AFERR-associated protein 
Csf1 
Csf1 PSA83_06665  297670..298401 (complement) 
CRISPR type AFERR-associated protein 
Csf2 
Csf2 PSA83_06664 296619..297665 (complement) 
CRISPR type AFERR-associated protein 
Csf3 





csf5/cas6 were placed on the same plasmid, with ribosome binding sites in between each 
gene, and was initially obtained in the pTWIST CMV expression vector. The CMV 
enhancer was removed and a T7 promoter was inserted upstream of the three gene 
polycistronic block, via two separate mutagenesis reactions.  The cassette was PCR 
amplified and subcloned into pCDF using NcoI and PacI sites for origin of replication 
compatibility with other plasmids expressing the system. The CRISPR array with TS1, 
csf3 and csf4/dinG were synthesized and inserted into the pTWIST Amp High Copy 
expression vector. The CRISPR was PCR amplified and subcloned into multiple cloning 
site 1 of pACYC via EcoRI and SacI.  csf3 and csf4/dinG were PCR amplified and 
subcloned into multiple cloning site 2  of pACYC containing the CRISPR via NdeI and 
EcoRV sites. CRISPR arrays with TS2 and NTS were subcloned into pACYC plasmids 
containing csf3 and csf4/dinG via EcoRI and SacI. To test each targeting spacer 
independently, TS1 and TS2 were tested with distinct vectors. 
 
Plasmid Transformation Efficiency Assay 
Plasmid transformation efficiency assays were adapted from work previously 
described10. In brief, E. coli BL21-AI cells were co-transformed with pCDF-csf1-csf2-
csf5/cas6 and pACYC-Pa83CRTS1-csf3-csf4/dinG to reconstitute the components of the 
PA83 Type IV-A1 operon. The Type IV system genes and CRISPR were placed on two 
different plasmids as has been previously done to express multi-subunit class 1 
systems1,11,12. This strategy makes it easier to clone, and later mutate systems containing 
multiple genes and a CRISPR locus and reduces the overall size of expression plasmids. 




transformed with 25ng of target or non-target plasmid. The target and non-target plasmid 
are in pET27b(+), and the non-target differs from the target in that it is truncated and 
does not contain the protospacer sequence. After transformation with the target or non-
target plasmid, the cells were grown overnight at 37°C in 5mL of LB-media 
supplemented with 1 mM IPTG, 0.2% L-arabinose, 50, 25 and 50 g/ml of kanamycin, 
chloramphenicol and streptomycin respectively, shaking at 200 rpm. Serially diluted cells 
were plated on LB-agar plates supplemented with 1 mM IPTG, 0.2% L-arabinose, 50, 25 
and 50 g/ml of kanamycin, chloramphenicol and streptomycin respectively. The next 
day, colony forming units were counted for analysis. The error bars represent standard 
error of the mean calculated from three independent transformations. The experiment was 
performed with three biological replicates that produced the same results. 
 
Plasmid Maintenance Assay 
Plasmid maintenance assays were adapted from work previously described10,13. 
We transformed BL21-AI cells to generate individual cell lines expressing either the full 
or partial Type IV-A operons. We transformed these cells lines with an equimolar 
mixture of target and non-target plasmid.  After transformation the cells were grown for 1 
hour at 37°C in 500L of LB-media supplemented with 1 mM IPTG and 0.2% L-
arabinose for induction, shaking at 200 rpm. Each experiment contained an uninduced 
control for comparison, where cells were grown solely in LB.  Induced cells were plated 
on LB-agar supplemented with 1 mM IPTG, 0.2% L-arabinose, 50, 25 and 50 g/ml of 
kanamycin, chloramphenicol and streptomycin respectively and uninduced cells were 




colonies were randomly screened for the presence of target or non-target plasmid by 
colony PCR using forward (5’-GAGTTCTGGCTGGCTAGCC-3’) and reverse (5’-
GGAATTGTGAGCGGATAACAA-3’) primers that amplify a 679 bp region of the 
target or 384 bp of the non-target plasmid. PCR reactions were separated by agarose gel 
electrophoresis and stained with ethidium bromide. The number of PCR products 
corresponding to the target and non-target were counted and the data is expressed as a 
ratio of target to non-target bands.  The error bars represent standard error of the mean 
calculated from three independent experiments.  Values significantly below one indicate 
CRISPR interference. csf4/dinG mutants were made by site-directed mutagenesis using 
the pACYC-Pa83CRTS1-csf3-csf4/dinG plasmid as a template. All individual 
components of the Type IV operon were removed from either pCDF-csf1-csf2-csf5/cas6 
or pACYC-Pa83CRTS1-csf3-csf4/dinG plasmids via site-directed mutagenesis. All site-
directed mutagenesis reactions were performed with the Q5® Site-Directed Mutagenesis 
Kit (New England BioLabs Inc.).  Primers are listed in Supplementary Table 1. 
 
RESULTS 
Using the Type IV CRISPR-Cas system from Thioalkalivibrio sp. K90Mix11 as a 
seed, we searched P. aeruginosa genomes for putative Type IV-A CRISPR-Cas systems 
using PSI-BLAST12. We observed 4 variants of Type IV-A systems based on amino acid 
sequence identity, gene arrangement, and CRISPR repeat sequence (Figure 4-1A, 
Supplementary Figure 1, Supplementary Table 2). Variant systems were grouped based 
on the shared sequence identity between conserved genes (csf2, csf3, csf4, csf5/cas6, 





Figure 4-1. Type IV-A CRISPR-Cas systems found in P. aeruginosa. (A) 
Classification of Type IV-A CRISPR-Cas systems found in P. aeruginosa. Conserved 
architectures of these four variants is observed. All four variants include csf2, csf3, 
csf4/dinG, and csf5/cas6. Despite the similar architecture between Type IV-A1 and Type-
IV-A2, they represent two separate groups based on differences in direct repeat 
sequences and amino acid divergence (Supplementary Figure 1). (B) Consensus 
sequences for direct repeats found in Type IV-A CRISPR arrays in P. aeruginosa. 
Palindromic regions are in the center of the repeat. (C) Table of spacers found in each 
system. Systems are grouped by variant, with group 2 consolidated, as all their CRISPR 
arrays are identical. Spacers are coloured based on mapping results according to the 
legend. A dendrogram was generated based on representative csf2 sequences to illustrate 







conserved within each variant (Figure 4-1A). Some variants had annotated CRISPR 
arrays, however, visual inspection of the region downstream of csf3 found unannotated  
palindromic repeats. An in-house script was written to take mutant repeats into account 
so that CRISPRs containing repeats that differ slightly in sequence from one another 
were found. Using hamming distance of 3 mismatches between a system’s repeats a total 
of 335 repeats were found, with their respective consensus sequences shown in Figure 4-
1B. From identifying these repeats a total of 195 spacers were found, of which 142 were 
unique (Figure 4-1C). While redundant spacers were removed from consideration, all 
repeats were used to create consensus motifs (Figure 4-1B). Out of the 142 spacers, 52 
are complementary to putative protospacers. 25 of these protospacers are found in 
prokaryotes without prophage or plasmid match, while 27 of the protospacers match 
either plasmids (8), prophages (5), or elements with signatures of both prophages and 
plasmids (14) (Figure 4-1C, Supplementary Tables 3 and 4). 
Given that Type IV systems are often found on plasmids, we selected a plasmid-
encoded system from P. aeruginosa strain PA83 as a model. This strain has a CRISPR 
array with a spacer matching a phage, suggesting it may be active. Owing to the large 
number of anti-CRISPR proteins found in P. aeruginosa13, we investigated the 
interference function heterologously in E. coli using distinct plasmid transformation 
efficiency and maintenance assays. 
In the plasmid transformation efficiency assay, we compared the number of 
colonies generated when the cells harboring the full P. aeruginosa PA83 Type IV-A1 
operon were transformed with a target or non-target plasmid (Figure 4-2A). Successful 





Figure 4-2. The Type IV-A1 CRISPR-Cas variant from Pseudomonas aeruginosa 
PA83 mediates RNA-guided interference in vivo. (A) Plasmid transformation 
efficiency assay described in the methods section. Small arrows on plasmids indicate a 
T7 promoter. (B) A reduction in plasmid transformation efficiency was observed when 
cells harboring a CRISPR array with TS1, csf1, csf2, csf5/cas6, csf3, csf4/dinG were 
transformed with the target compared to those transformed with the non-target plasmid. 
(C) Plasmid maintenance assay described in the methods section. Small arrows on 
plasmids indicate a T7 promoter. (D) An interference defect is observed when any 
component is removed and when the Csf4/DinG DEAH-box is mutated (D336A/E337A). 
TS1 was used in each deletion line and the Csf4/DinG mutant. As each condition 
represents a different competent cell line, an uninduced control was always included 




target plasmid, leading to an ~4 order of magnitude decrease in transformation efficiency 
(Figure 4-2B).  
We next evaluated the interference requirements of the Type IV-A1 operon from 
P. aeruginosa PA83 by systematically deleting each component and evaluating 
interference with plasmid maintenance assays (Figure 4-2C). As each deletion required 
comparing different competent cell lines, we switched to plasmid maintenance assays to 
evaluate interference differences by PCR to reduce variation that could be attributed to 
differences between the competencies of prepared cell lines.  In this experiment 
equimolar amounts of plasmids with target or non-target sequences were mixed and 
transformed into cells expressing the Type IV-A1 system. The ratio of colonies 
containing target vs non-target plasmid was assessed with colony PCR. A ratio less than 
1 of target / non-target indicates interference (Figure 4-2). An interference deficiency 
was observed when any component of the Type IV-A1 operon was removed, including a 
point mutation in the genes encoding the putative DEAH-box helicase, Csf4/DinG 
(Figure 4-2D). DEAH-box helicases are proteins that unwind double-stranded nucleic 
acids using the energy released by NTP hydrolysis14. The putative activity of the DEAH-
box of the Csf4/DinG helicase was inactivated by mutating the first two residues of the 
DEAH-box (D336A/E337A), and indeed, we found that these mutations resulted in an 
interference defect (Figure 4-2D). The target and non-target plasmids both contain a T7 
promoter upstream of a 5’-CTTTC-3’ sequence that lies adjacent to the protospacer. In 
the case of the target plasmid, this sequence is directly upstream of the protospacer. It is 
unclear at this time whether this is a protospacer adjacent motif (PAM) utilized by the 




is also uncertain whether DNA or RNA is targeted, however the crRNA is not expected 
to base pair with the RNA transcribed from the target.  
 
DISCUSSION 
Here we provide the first functional evidence that a Type IV CRISPR-Cas system 
mediates RNA-guided interference against plasmids in vivo and that this activity requires 
the putative NTP-dependent helicase activity of Csf4/DinG. 
Although we show Type IV CRISPR system interference requires the putative 
DinG helicase, the function of CRISPR associated DinG proteins remains unclear. 
However, studies on DinG proteins that are not associated with CRISPR systems show 
that related DinG helicases are involved in recombinational DNA repair and the re-
initiation of replication after DNA damage15. Also it has been shown that non-CRISPR 
associated DinG unwinds R-and D-loops, forked substrates and 5’ single-stranded 
overhangs with 5’ to 3’ polarity15,17 allowing other proteins to access nucleic acid or 
modify nucleic acid structure. Additionally there is evidence that non-CRISPR associated 
DinG is recruited to disturbances in duplex DNA via changes in redox potential, and that 
in turn DinG recruits a nuclease to the disturbance site20.  The Type IV associated and 
non-CRISPR associated DinG proteins are somewhat similar in sequence suggesting the 
CRISPR associated DinG protein may express similar functions. However such activities 
remain to be confirmed in CRISPR associated DinG proteins. 
Unlike Type I systems, which encode for the helicase-nuclease Cas3, the protein 
sequences of the Type IV system appear to not contain any obvious nuclease domains. 




the plasmid targets are cleaved. We speculate that similar to Type I and Type III systems, 
multi-subunit complexes composed of Csf proteins and a crRNA use the crRNA as a 
guide to bind complementary nucleic acid forming R-loops. We expect DinG, is recruited 
to the R-loops and then that DinG either acts directly to destroy the plasmid through an 
unknown mechanism or recruits an endogenous nuclease to mediate RNA-guided 
interference. However, these hypotheses remain to be tested. As Type IV-A systems lack 
a predicted effector nuclease and often lack a Cas1-Cas2 adaptation module, it has been 
reasoned that this CRISPR-Cas system cannot function as an independent adaptive 
immune system18. Here we show that a Type IV-A system from P. aeruginosa is capable 
of interference. However, it remains unknown if Type IV-A systems are capable of 
acquiring their own spacer sequences and whether DinG or the putative Csf crRNA 
complex are involved.  
Here we provide the first evidence that a Type IV-A CRISPR-Cas system from P. 
aeruginosa mediates RNA-guided interference of plasmid DNA, and that such activity 
requires a putative multi-subunit crRNA-guided complex and a putative NTP-dependent 
helicase Csf4/DinG. However, many outstanding questions remain for this area of 
CRISPR-Cas biology: Do Type IV-A systems act alone as distinct RNA-guided adaptive 
immune systems21,22 or does interference require additional host factors? Do Type IV-A 
systems associate with the acquisition machinery of other CRISPR-Cas systems to 
acquire immunity21,22,8? Do Type IV-A systems have roles apart from immunity 







We conclude that the Type IV-A1 system from P. aeruginosa strain PA83 
mediates RNA-guided interference against plasmids in vivo. This activity requires all 
components of the Type IV-A1 operon, including the accessory protein Csf4/DinG and 
its putative NTP-dependent helicase activity. 
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POSITIONING DIVERSE TYPE IV STRUCTURES AND FUNCTIONS WITHIN 
CLASS 1 CRISPR-CAS SYSTEMS4 
 
ABSTRACT 
Type IV CRISPR systems encode CRISPR associated (Cas) -like proteins that 
combine with small RNAs to form multi-subunit ribonucleoprotein complexes. However, 
the lack of Cas nucleases, integrases, and other genetic features commonly observed in 
most CRISPR systems has made it difficult to predict type IV mechanisms of action and 
biological function. Here we summarize recent bioinformatic and experimental 
advancements that collectively provide the first glimpses into the function of specific 
type IV subtypes. We also provide a bioinformatic and structural analysis of type IV-
specific proteins within the context of multi-subunit (class 1) CRISPR systems, informing 
future studies aimed at elucidating the function of these cryptic systems. 
 
INTRODUCTION 
CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-
CRISPR associated) prokaryotic defense systems utilize Cas1 and Cas2 proteins, along 
with system-specific proteins such as Cas4, IHF, Csn2, and Cas9, to integrate foreign 
genetic material into the CRISPR locus, immunizing the cell against viruses and plasmids 
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(Datsenko et al., 2012; Heler et al., 2015; S. A. Jackson et al., 2017; Kieper et al., 2018; 
Lee et al., 2018; Nuñez et al., 2014, 2016; Rollie et al., 2015; Sternberg et al., 2016; J. 
Wang et al., 2015; Wei et al., 2015; Yosef et al., 2012). To provide immunity, the 
CRISPR locus is transcribed and processed by RNA nucleases into CRISPR derived 
RNAs (crRNAs) (Brouns et al., 2008b; Deltcheva et al., 2011; Haurwitz et al., 2010; 
Marraffini & Sontheimer, 2008). The crRNAs combine with Cas proteins to form 
ribonucleoprotein (RNP) complexes, which recognize and bind complementary nucleic 
acids. Binding induces cleavage of the foreign nucleic acid, protecting the cell (Brouns et 
al., 2008b; Carte et al., 2008; Garneau et al., 2010; C. Hale et al., 2008; C. R. Hale et al., 
2009; Hille et al., 2018; R. N. Jackson et al., 2017; Marraffini & Sontheimer, 2008).  
Although all CRISPR systems use these general mechanisms to achieve 
immunity, the systems themselves are remarkably diverse, comprising two classes (1-2), 
six types (I-VI), and at least 33 subtypes (Makarova et al., 2020; Yan et al., 2019). In 
class 2 systems (types II, V, VI) a single Cas protein binds the crRNA to form the RNP 
complex, while class 1 RNP complexes (types I, III, IV) bind the crRNA with several 
proteins. Of the six CRISPR-Cas types, the least understood is type IV. Recent 
bioinformatic, biochemical, and structural studies of type IV CRISPR-Cas systems have 
provided valuable insights into type IV system function. Here we compile known data on 
type IV systems, highlight recent advances in type IV system biology and biochemistry, 
and indicate questions concerning type IV systems that need to be addressed. 
Additionally, we provide phylogenetic analyses that suggest ancillary proteins associated 





TYPE IV SYSTEMS ARE MINIMAL, MOBILE CRISPR-Cas SYSTEMS 
Distinguishable from other CRISPR-Cas systems, Type IV systems encode a 
distinct cas7-like gene (csf2), lack adaptation genes, rarely encode an obvious nuclease, 
and are primarily found on plasmids (Koonin & Makarova, 2017, 2019; Pinilla-Redondo 
et al., 2019). These unique features of type IV systems have made it difficult to predict 
the function of type IV systems. 
All type IV systems encode homologs of proteins known to form multi-subunit 
RNP complexes, explaining their class 1 designation. However, the presence of specific 
genes, gene arrangements, and differences in gene sequences have been used to further 
classify type IV systems into three distinct subtypes (IV-A, IV-B, and IV-C) (Makarova 
et al., 2011, 2015; Makarova et al., 2020). Types IV-A, IV-B, and IV-C each contain a 
subtype-specific gene (dinG, cysH-like, and cas10-like, respectively) and subtype-
specific features (Figure 5-1A). Type IV-A operons encode the three core type IV genes 
(csf1, csf2, and csf3), an endoribonuclease (cas6/csf5), a CRISPR array, and a putative 
helicase (dinG). Type IV-B operons encode the three core type IV genes and a cas11-like 
gene but lack a CRISPR locus. Additionally, type IV-B operons encode an ancillary 
cysH-like gene, labeled such because its predicted secondary structure resembles the cysH 
gene (Faure et al., 2019; Shmakov et al., 2018). Type IV-C systems encode csf2 and csf3, 
but in place of the csf1 gene they encode a cas10-like gene with a putative HD-nuclease 
domain. They also encode the cas11-like gene observed in IV-B systems, and sometimes 
a cas6 RNA endonuclease and CRISPR array (Makarova et al., 2020; Pinilla-Redondo et 






Figure 5-1. The type IV Cas accessory proteins have evolved a Cas specific function. 
(A) Classification schematic of type IV CRISPR-Cas systems. A typical locus is 
represented for each type IV subtype. Dashed lines indicate components that are 
sometimes not encoded by the subtype. Shaded backgrounds highlight which gene 
products form the ribonucleoprotein (RNP) complex. The yellow square in the IV-C 
cas10-like large subunit represents an HD nuclease domain. (B) Phylogenetic tree of Cas- 
and non-CasDinG sequences. Posterior probabilities are shown. (C) Cartoons of Cas- and 
non-CasDinG sequences indicating positions of certain helicase motifs and domain 
architecture. Weblogos (Crooks, 2004) of the FeS cluster region in non-CasDinG (below, 
blue outline) and CasDinG (top, red outline) are shown. (D) Phylogenetic tree of Cas- 




non-CasCysH sequences. CasCysH is predicted to adopt the Rossman −− fold 
observed in non-CasCysH structures. Positions and sequences of P- and PP-loops are 
indicated. Weblogos of the catalytic cysteine in non-CasCysH (bottom, teal outline) and 




It is curious that the type IV systems that encode CRISPR loci do so in the 
absence of adaptation genes. It has been hypothesized that these type IV systems 
commandeer adaptation machinery from other CRISPR-Cas types to maintain their 
CRISPRs, similar to some type III systems (Staals et al., 2013, 2014; J. Elmore et al., 
2015; Bernheim et al., 2020). Supporting this hypothesis, recent bioinformatic work 
showed that some type IV-A subtypes co-localize with certain type I systems (e.g. I-F, I-
E), and that spacers found within co-localized type IV CRISPR loci appeared to be 
selected with the same criteria utilized by the type I system adaptation machinery (e.g. 
both I-E and IV-A protospacers are flanked with an 5’-AAG-3’ protospacer adjacent 
motif (PAM)) suggesting there may be functional cross-talk between these systems 
(Pinilla-Redondo et al., 2019).  In vivo and in vitro experimental work that examines 
adaptation in type IV systems with adaptation proteins from co-localized systems is 
needed to confirm this proposed cooperation. 
 
THE cas7-LIKE GENE, csf2, DISTINGUISHES TYPE IV FROM OTHER CLASS 
1 CRISPR-Cas SYSTEMS 
Initial bioinformatic analyses proposed csf1 as the type IV cas signature gene 




identified, necessitating that the type IV cas7 homolog, csf2, be used to classify type IV 
systems (Pinilla-Redondo et al., 2019). In type I and type III systems, Cas7-like proteins 
bind the crRNA guide within a helical backbone of a multi-subunit RNP complex and 
make direct interactions with other protein subunits (Jore et al., 2011; Lintner et al., 2011; 
Staals et al., 2013; R. N. Jackson, Golden, Erp, et al., 2014; Mulepati et al., 2014; Osawa 
et al., 2015b). Similarly, a recent cryo-EM structure of the type IV-B RNP complex 
revealed that Csf2 proteins bind RNA within a helical backbone, indicating a conserved 
function for Cas7-like proteins in all class 1 systems (Y. Zhou et al., 2021). Despite this 
conservation, the sequence and structure of Csf2 is distinguishable from other Cas7 
proteins (Makarova et al., 2011) (Figure 5-2). For example, when representative Cas7 
sequences from all class 1 subtypes were aligned and a phylogenetic tree created, Csf2 
sequences clustered on a separate branch from type I and type III Cas7 sequences (Figure 
5-3A and Methods). Csf2 is distinct from other Cas7 homologs but appears to be most 
closely related to type III, supporting evolutionary hypotheses that type IV systems 
diverged from type III systems (Koonin & Makarova, 2019; Makarova et al., 2020; 
Pinilla-Redondo et al., 2019). Interestingly, an alignment of only Csf2 sequences shows 
clustering of Csf2 from each type IV subtype on its own branch, illustrating the intrinsic 
diversity of type IV subtypes and suggesting subtype-specific functional distinctions 
(Figure 5-3B). It is worth noting that the type IV-B Csf2 subunit structure is most similar 
to the structure of the Cas7 homolog in type III-A systems, Csm3 (Y. Zhou et al., 2021). 
Csm3 contains a catalytic aspartate that cleaves RNA targets (Tamulaitis et al., 2014). 
Alignment of target-bound Csm3 with Csf2 indicates that, although Csf2 also contains a 





Figure 5-2. Csf2 is a unique Cas7-like backbone subunit. (A) Structure of IV-B Csf2 
(PDBid 7JHY) and protein topology map highlighting the hand-like domains typical of 
Cas7-like proteins. Dashed lines for the thumb indicate that secondary structure is not 
obvious in the model. (B) Structures of III-A Csm3 (PDBid 6O7I) and III-B Cmr4 
(PDBid 3X1L) depicted as in (A). (C) Structures of Cas7 from I-C (PDBid 7KHA), I-E 






Figure 5-3. Csf2 is unique from other Cas7-like subunits and distinct within the type 
IV subtypes. (A) A phylogenetic tree of Csf2 sequences from all three type IV subtypes 
and a selection of Cas7 sequences from each of the several type I and type III subtypes. 
(B) A phylogenetic tree of Csf2 sequences from all three type IV subtypes. Csf2 
sequences from Mycobacterium JS623 (Zhou et al., 2021), Mahella australiensis (Taylor 
et al., 2019), Pseudomonas aeruginosa (Crowley et al., 2019), and Aromatoleum 
aromaticum (Özcan et al., 2018) are indicated. Sequences for both trees were selected 




cleavage (Y. Zhou et al., 2021). Additional structural studies of type IV complexes bound 
to nucleic acid targets and complementary biochemical assays are needed to determine 
whether Csf2 is capable of RNA nuclease activity. 
 
TYPE IV-A SYSTEMS ARE DEFENSE SYSTEMS WITH AN UNKNOWN 
MECHANIM OF ACTION INVOLVING A DinG HELICASE 
Recently, a type IV-A system from Pseudomonas aeruginosa was shown to 
exhibit crRNA-guided defense against plasmids (Crowley et al., 2019), consistent with an 
analysis of type IV CRISPR spacers that suggested type IV-A systems disproportionately 
target plasmids (Pinilla-Redondo et al., 2019). Notably, earlier bioinformatic work 
indicated that many type IV-A spacers target viruses and prophage sequences encoding 
putative anti-CRISPRs, suggesting type IV-A systems also actively target viruses 
(Nobrega et al., 2020; Shmakov et al., 2017; Yin et al., 2019). However, direct data, such 
as viral plaque assays, are needed to confirm that type IV-A systems protect against viral 
attack.  
Structural and biochemical work on a type IV-A complex from Aromatoleum 
aromaticum and IV-A Cas6 from Mahella australiensis demonstrated that the RNA 
endonuclease Csf5/Cas6 processes a crRNA upon which Csf1, Csf2, Csf3, and Csf5 form 
an RNP complex (Özcan et al., 2018; Taylor et al., 2019). At least three distinct crRNA 
processing endoribonucleases are encoded by Type IV-A systems (Cas6, Csf5, and 
Cas6e) (Makarova et al., 2020) (Figure 5-4A). Sequence alignments between 
biochemically characterized and putative type IV Csf5/Cas6 enzymes revealed Csf5 
enzymes cleave RNA with arginine active site residues, while type IV Cas6 and Cas6e 





Figure 5-4. Type IV Cas6/Csf5 subunits are distinct from Cas6 homologs of other 
CRISPR systems. (A) A phylogenetic tree of type IV Cas6/Csf5 sequences and select 
type I and type III Cas6 sequences. Sequences were selected from (Makarova et al., 
2020). (B) A Clustal Omega (Madeira et al., 2019) amino acid sequence alignment of 
type IV-A and IV-B Cas6e and type I-E Cas6e, highlighting the active site residues. The 
Cas6e active site is not highly conserved among type IV Cas6e sequences. Bolded 







Figure 5-5. Type IV Cas6/Csf5 structures and active sites. (A) Structural comparisons 
of apo IV-A Cas6 from Mahella australiensis (PDBid 6NJY) and substrate-bound IV-B 
Csf5 from Aromatoleum aromaticum (PDBid 6H9I). Both structures are composed of 
two RRM folds with the active site positioned in the cleft between the folds. (B) A 
Clustal Omega (Madeira et al., 2019) alignment of Csf5 sequences from subtype IV-A 




architectures (Tyr/His or Arg) are indicated. All aligned sequences share the conserved 
G-loop motif. The bolded sequences have experimentally confirmed active sites: IV-A 
Cas6 from M. australiensis (Taylor et al., 2019) and IV-A Csf5 from A. aromaticum 




these obvious differences in endoribonucleases, we hypothesize that in all type IV-A 
systems the Csf1, Csf2, Csf3, and Csf5/Cas6 proteins bind to the processed crRNA to 
form a multi-subunit complex that binds complementary nucleic acid.  
It remains unclear if type IV RNP complexes bind single stranded RNA (like the 
type III Csm and Cmr complexes (C. R. Hale et al., 2009; Samai et al., 2015)) or double 
stranded DNA (like the type I Cascade complexes (Brouns et al., 2008b)) and how type 
IV complexes distinguish self from non-self in its binding targets. RNPs that target 
dsDNA usually rely on a protein-mediated binding event with a specific non-self 
sequence adjacent to the complementary target, called a PAM (protospacer adjacent 
motif) (Mojica et al., 2009; Westra et al., 2012, 2013). PAM binding provides the energy 
for target duplex unwinding and interrogation of the DNA by the crRNA-guide. Work by 
Pinilla-Redondo et al. (2019) identified a consensus PAM (5’-AAG-3’) flanking 
protospacers targeted by a subset of type IV-A systems, suggesting type IV-A systems 
rely on PAM recognition to license binding. However, the consensus PAM may only 
reflect a preference of the acquisition machinery, which may explain why consensus 
PAM sequences have not been identified in all IV-A systems. Reliance on a specific 




but it should be noted that a promiscuous PAM recognition mechanism may indicate that 
the type IV complexes have evolved to accommodate the preferences of diverse Cas1 and 
Cas2 proteins that use different PAM sequences in spacer acquisition.  
Additionally, the structural similarities of the type IV-B complex to the type III 
Csm complex suggest that type IV complexes may target RNA (Y. Zhou et al., 2021). 
Instead of recognizing a “non-self” PAM to license base pairing with a double-stranded 
DNA target, RNPs that bind RNA generally use a “self recognition” mechanism to 
distinguish self from non-self sequences (Marraffini & Sontheimer, 2010). Self-sequence 
located in the flanking regions of a bound RNA can base pair with the direct repeat of the 
crRNA disrupting downstream activation of effector nucleases (L. You et al., 2019). Self-
sequences are inhibitory to overall immune function (J. R. Elmore et al., 2016; Estrella et 
al., 2016; Han et al., 2017; Kazlauskiene et al., 2016; Liu et al., 2017; Marraffini & 
Sontheimer, 2010; Zhang et al., 2016), but in some systems only a subset of non-self 
protospacer flanking sequences (called RNA-PAMs (rPAM) in type III systems or 
protospacer flanking sites (PFS) in type VI systems) are activating (Abudayyeh et al., 
2016; J. R. Elmore et al., 2016; Marraffini & Sontheimer, 2010). We suspect that one or 
more Csf subunits may be responsible for PAM recognition to license DNA binding or 
rPAM recognition to activate immunity. We anticipate that in vivo PAM screens and 
biochemical binding assays with purified type IV-A RNPs will reveal the type IV-A self 
vs. non-self recognition mechanism. 
Type IV-mediated plasmid clearance required all type IV-A system genes (csf1, 
csf2, csf3, csf5, and dinG/csf4) and a CRISPR containing a spacer complementary to a 




deleting the dinG gene or mutating the ATPase active site residues (DEAH-box) fully 
disrupted plasmid clearance, we hypothesize that RNP complex binding recruits the type 
IV-associated DinG (CasDinG) helicase to the bound target and CasDinG-mediated ATP 
binding and hydrolysis performs work, such as duplex unwinding, that is essential for 
plasmid clearance. Such a mechanism is similar to the more extensively studied type I 
Cas3 helicase-nuclease that unwinds and degrades dsDNA targets bound by the type I 
Cascade RNP complex (Beloglazova et al., 2011; Mulepati & Bailey, 2011; Sinkunas et 
al., 2011).  
Both DinG and Cas3 classify as superfamily 2 helicases but, unlike Cas3, 
CasDinG proteins have no identifiable nuclease domains and have yet to be 
biochemically or structurally characterized (Fairman-Williams et al., 2010; Makarova et 
al., 2020). DinG helicases are generally involved in DNA recombination and repair, and 
are classified by amino acid sequence motifs involved in ATP binding and hydrolysis and 
nucleic acid binding and translocation (Cheng & Wigley, 2018; Lewis et al., 1992; 
McRobbie et al., 2012; Thakur et al., 2014; Voloshin et al., 2003b; Voloshin & Camerini-
Otero, 2007b; Wu & Brosh, 2012). The motifs are located across two RecA helicase 
domains (Figure 5-6). The first helicase domain also harbors two insertions, an iron 
sulfur cluster domain, and an arch domain, which are both important for duplex strand 
splitting (Peissert et al., 2020; Ren et al., 2009).  
Since non-CasDinG helicases and their homologs have been extensively studied 
biochemically and structurally, we hypothesized that an in-depth comparison of CasDinG 
with non-CasDinG sequences would provide insight to CasDinG function. To investigate 





Figure 5-6. The conserved helicase motifs of CasDinG and non-CasDinG. (A) 
Cartoon depiction of a Cas- and non-CasDinG primary amino acid sequence indicating 
the positions of the helicase motifs. (B) Weblogos (Crooks, 2004) of the helicase motifs 
of Cas- and non-CasDinG helicases. CasDinG motifs are outlined in red boxes and non-





CasDinG sequences from organisms containing a type IV-A system and generated a 
phylogenetic tree (Figure 5-1B and Methods). Interestingly, CasDinG and non-CasDinG 
sequences clustered separately even when the sequences were retrieved from the same 
organism, suggesting CasDinG is functionally distinct from non-CasDinG. Notably, 
CasDinG helicases contain insertions within the first RecA domain of the same lengths as 
the iron-sulfur and arch insertions, but they lack homology with non-CasDinG sequences, 
including the residues important for coordinating the iron-sulfur cluster (Figure 5-1C). 
Sequence differences in these regions suggest these inserts may be a source of functional 
distinctions important for defense activities. Many functions for CasDinG have been 
hypothesized, including a role in displacing bound RNP complexes, cleaving bound 
targets with an unidentified nuclease activity (perhaps housed within an insert), or 
recruitment of endogenous nucleases to bound targets (Grodick et al., 2014b). Notably, 
DinG helicases have been observed in a few type I and III systems (Dwarakanath et al., 
2015; Makarova et al., 2020), indicating an evolutionary link and suggesting that some 
CasDinG activities essential for type IV immunity may have been co-opted by other class 
1 systems. 
In summary, recent bioinformatic and in vivo studies have indicated type IV-A 
systems protect prokaryotes from plasmids and viruses, but the mechanisms that underpin 







TYPE IV-B SYSTEMS FORM AN RNP COMPLEX OF UNKNOWN FUNCTION 
AND A SPECIALIZED CysH-LIKE PROTEIN WITH PUTATIVE ATP α-
HYDROLASE ACTIVITY 
Unlike type IV-A and IV-C subtypes, type IV-B systems lack a CRISPR locus 
and a crRNA processing enzyme, and are associated with an ancillary gene identified as 
cysH-like by the HHpred secondary structure prediction and alignment tool (Makarova et 
al., 2020; Zimmermann et al., 2018) (Figure 5-1A). A recent structural study 
recombinantly expressed and purified a Mycobacterium sp. JS623 IV-B Csf RNP 
complex containing four type IV-B proteins (Csf1, Csf2, Csf3, and Cas11) (Y. Zhou et 
al., 2021). Interestingly, RNA sequencing revealed the type IV-B Csf complex bound 
small heterogeneous RNAs, instead of co-expressed type I-E crRNAs from the 
Mycobacterium sp. JS623 plasmid, suggesting a possible function other than CRISPR-
mediated defense. A high resolution cryo-EM structure of the complex revealed several 
Csf2 subunits bind an RNA within a helical filament, while Cas11 subunits form a minor 
filament that contacts the larger filament at Csf2 dimer interfaces (Y. Zhou et al., 2021). 
This structure of intertwined large and small protein filaments is similar to other class 1 
RNP complexes, suggesting similar function as an RNA-guided complex that binds 
complementary targets  (Jore et al., 2011; Lintner et al., 2011; Staals et al., 2013; R. N. 
Jackson, Golden, Erp, et al., 2014; Mulepati et al., 2014; Osawa et al., 2015b) (Figure 5-
7).  
Several observations are currently confounding an understanding of the type IV-B 
complex function. First, electron density for Csf1 and Csf3 subunits was not clearly 
observed within the structure, although SDS-PAGE indicated their presence in the 





Figure 5-7. Structural comparison of class 1 RNP complexes from type IV-B (PDBid 
7JHY) (Zhou et al., 2021), type III-A (PDBid 6O7I) (Jia et al., 2019), type III-B (PDBid 
3X1L) (Osawa et al., 2015), type I-C (PDBid 7KHA) (O’Brien et al., 2020), type I-E 
(PDBid 5H9F) (Hayes et al., 2016), and type I-F (PDBid 6B44) (Guo et al., 2017). 






unknown. Second, because the IV-B Csf complex bound heterogenous RNA, it remains 
unknown whether the Csf complex lacks sequence-specific preference for small RNAs or 
if the RNA(s) that the complex would normally bind were not available in the 
recombinant expression conditions. Finally, the role of the strictly conserved ancillary 
CysH-like protein and how it may interact with the complex is unknown.   
The key to understanding the function of type IV-B systems likely lies with the 
uncharacterized, but ubiquitous, type IV-B accessory cysH-like gene (Faure et al., 2019; 
Shmakov et al., 2018). Typical CysH proteins are phosphoadenosine phosphosulfate 
(PAPS) reductases involved in sulfate assimilation. Structures reveal CysH proteins fit 
within a family of enzymes that adopt a Rossman-like −− sandwich fold that binds 
the nucleotides (InterPro IPR014729) (Blum et al., 2020). CysH proteins also contain a P-
loop motif (GXXGXGKT/S consensus sequence) that binds nucleotide phosphates, and a 
conserved C-terminal cysteine that performs nucleophilic attack on the PAPS −sulfate, 
hydrolyzing PAPS at the -phosphate and forming a covalent thiosulfanate intermediate 
during sulfur reduction (Carroll et al., 2005; Chartron et al., 2007; Savage et al., 1997). 
Interestingly, the DndC protein from the recently discovered DND bacterial immune 
system also belongs to the PAPS reductase family, and uses a similar mechanism to 
incorporate sulfur into the backbone of chromosomal DNA through a disulfide cysteine 
(Faure et al., 2019; L. Wang et al., 2018; D. You et al., 2007). These phosphorothioate 
modifications serve as an epigenetic signature that allows the DND system to distinguish 
self from non-self DNA (Wang et al., 2019). The predicted structural homology between 
the type IV-B CysH (CasCysH) and DndC proteins justifies speculation that CasCysH 




sequences suggests that if CasCysH does epigenetically modify DNA, it will not be 
through the formation of phosphorothioates. Although HHPred predicts CasCysH adopts 
a Rossman-like −− sandwich fold, the catalytic cysteine important for sulfonate 
reduction in non-CasCysH and phosphothiolation of DNA by DndC is absent. 
Interestingly, the P-loop sequence of CasCysH is more similar to the PP-motif 
(pyrophospohatase motif) (SGGXDS/T consensus sequence) observed in ATP PPases 
(Bork & Koonin, 1994) (Figure 5-1E).  
To better understand CasCysH activity and to explore the relationship between 
non-CasCysH and CasCysH proteins, sequences from organisms encoding both Cas- and 
non-CasCysH were aligned and phylogenetic trees determined. As was seen with Cas- 
and non-CasDinG, CasCysH sequences cluster separately from non-CasCysH sequences 
even when the sequences were retrieved from the same organisms (Figure 5-1D). 
Together these differences suggest CasCysH evolved to preserve nucleotide binding 
without sulfonucleotide reduction.  
Non-CasCysH enzymes fall within the larger classification of ATP α-hydrolases, 
which include N-type ATP PPases (Savage et al., 1997). However, unlike non-CasCysH 
and DndC, N-type ATP PPases catalyze sequential reactions involving substrate 
AMPylation, instead of the formation of covalent enzyme substrate intermediates 
requiring nucleophilic attack from a catalytic cysteine (Wang et al., 2019; Chartron et al., 
2007). The absence of a catalytic cysteine suggests that the role of CasCysH is to 
stabilize the AMPylation of specific substrates through catalysis of ATP −hydrolase 
activity. We hypothesize that such an activity could be used to modify nucleic acids 




formation of secondary messengers.  Future biochemical studies aimed at defining the 
function of CasCysH and its interactions with the IV-B Csf RNP complex will be critical 
for understanding type IV-B systems. 
Several hypotheses exist concerning the function of type IV-B CRISPR-Cas 
systems. As they lack both a CRISPR array and an obvious nuclease it seems unlikely 
that type IV-B systems function as independent CRISPR-Cas defense systems (Faure et 
al., 2019; Makarova et al., 2011; Y. Zhou et al., 2021). It has been suggested that type 
IV-B systems could bind crRNAs derived from other CRISPR systems, forming IV-B 
RNP complexes that perform RNA-guided defense (Makarova et al., 2011, 2015; Koonin 
& Makarova, 2019). As type IV systems are generally encoded on plasmids, such a 
crRNA scavenging system could be passed between organisms, acting as a mobile 
defense system. Interestingly, it was recently shown that sometimes type IV-B systems 
colocalize with specific class 1 systems, suggesting a cooperative function (Pinilla-
Redondo et al., 2019). However, the same study showed that type IV-B systems are most 
often observed without other CRISPR systems, supporting an alternative hypothesis that 
proposes IV-B systems may protect plasmids from RNA-guided defense mechanisms by 
sponging up and inactivating small guide RNAs, including crRNAs (Faure et al., 2019; 
Koonin & Makarova, 2017; Pinilla-Redondo et al., 2019). Such an anti-guide-RNA 
activity could give plasmids containing a type IV-B system a selective advantage 
(Shmakov et al., 2018; Koonin & Makarova, 2019). Although intriguing, neither of these 
hypotheses explain the role of the highly conserved ancillary protein CasCysH, 





THE NEWLY CLASSIFIED TYPE IV-C SYSTEM HIGHLIGHTS THE DIVERSE 
NATURE OF TYPE IV CRISPR-Cas SYSTEMS 
Only recently did bioinformatics studies classify the subtype IV-C CRISPR-Cas 
system (Makarova et al., 2020; Pinilla-Redondo et al., 2019). Type IV-C systems lack a 
Csf1 subunit, instead encoding a Cas10-like subunit with an HD nuclease domain 
(Figure 5-1A). Type III CRISPR-Cas systems also encode Cas10, which is the large 
subunit of the RNP complex. In type III systems Cas10 has nuclease activity and 
synthesizes cyclic oligoadenylate second messengers (Jung et al., 2015; Kazlauskiene et 
al., 2017; Niewoehner et al., 2017). The type IV Cas10 contains an HD nuclease domain 
but not a nucleotide cyclase motif ‘GGDD’, suggesting it has nuclease but not cyclic 
adenylate synthetase activity (Pinilla-Redondo et al., 2019). Interestingly, the HD domain 
motifs of type IV Cas10 are more similar to the HD domain of Cas3 than the type III 
Cas10 (Aravind & Koonin, 1998; Makarova et al., 2020). The presence of a cas10-like 
gene in type IV-C systems and the similarity between the type III-A and type IV-B RNP 
complexes support proposals that type IV and type III CRISPR-Cas systems share a 
common ancestor (Pinilla-Redondo et al., 2019; Makarova et al., 2020; Y. Zhou et al., 
2021). Experimental work is needed to better understand the function of these fascinating 
systems. 
Several variants of type IV systems have been identified in bioinformatics studies 
and clinical samples which include type IV systems; without a csf1, with a csf1-csf3 
fusion, with a recD helicase instead of dinG, and in association with IncH1b plasmids 
(Crowley et al., 2019; Pinilla-Redondo et al., 2019; Kamruzzaman & Iredell, 2020; 




reveal unique mechanisms and functions that may expand the CRISPR-based genome 
editing toolbox. 
 
UNANSWERED QUESTIONS CONCERNING TYPE IV BIOCHEMISTRY AND 
BIOLOGICAL FUNCTION 
Throughout this perspective we have highlighted pressing questions concerning 
type IV CRISPR-Cas system structures and functions. Here we suggest models for the 
function of each type IV subtype and indicate areas which require further understanding. 
Type IV-A systems have been shown to form RNP complexes and prevent targeted 
plasmid transformation, but they have not been shown to target viruses nor is the 
mechanism of crRNA-guided defense clear (Figure 5-8A). Understanding the targets of 
the type IV-A system is critical to understanding the full scope of its defense activity. The 
presence of a helicase within the system suggests the need to unwind a duplex substrate. 
We suspect that the type IV-A system targets dsDNA, as it does defend against invasive 
plasmids (Crowley et al., 2019). However, CasDinG could also be important for 
unwinding duplex secondary structure within ssRNA targets or for targeting dsRNA 
phages (Poranen & Tuma, 2004). Remaining questions include the targeting parameters 
of the complex (DNA vs RNA, seed sequence, mismatch tolerance), how the complex 
distinguishes self from non-self, the role of CasDinG in immunity, and how targets are 
cleared without an identifiable nuclease domain within the system. We speculate that the 
IV-A RNP complex will bind to a dsDNA target and recruit CasDinG to the resulting R-
loop, allowing CasDinG to unwind the target. To clear the target from the cell, we 
hypothesize that either an endogenous nuclease will degrade the unwound nucleic acid, 





Figure 5-8. Models of type IV system functions highlighting questions that remain to 
be answered. (A) IV-A RNP complexes likely bind DNA targets and recruit CasDinG 
for target unwinding and degradation. (B) IV-B RNP complexes likely interact with 
CasCysH to perform an unknown function. (C) The putative IV-C RNP complex likely 







The ultimate function of type IV-B Csf RNP complexes is still unknown (Figure 
5-8B). Many questions of type IV-B system function will be answered as the source of 
the RNA component of the IV-B RNP complex is discovered and the function of the 
accessory protein CasCysH is understood. We propose that the Csf RNP complex will 
bind a nucleic acid target and recruit CasCysH to modify the nucleic acid. 
No biochemical studies have been done on type IV-C systems, to date. We 
hypothesize that the IV-C Csf proteins will form an RNP complex with a crRNA and the 
Cas10-like subunit (Figure 5-8C). The IV-C Csf RNP complex will bind a nucleic acid 
target complementary to the crRNA and the HD nuclease domain of the Cas10-like 
subunit will cleave the target. Some IV-C systems have a CRISPR and a crRNA 
processing endonuclease and others do not, suggesting some IV-C systems may serve a 
crRNA-guided defense function while others may employ Cas proteins to perform an 
entirely different, non-defense function. Future studies should seek to understand the role 
of Cas10 within the type IV Csf RNP complex and the overall function of type IV-C 
CRISPR-Cas systems. 
To understand the function of type IV CRISPR-Cas systems, it is critical that we 
determine the structures and biochemical functions of the type IV subtype specific 
proteins: CasDinG, CasCysH, and Cas10-like. Phylogenetic trees suggest that the IV-A 
DinG and IV-B CysH have evolved to support a putative Cas specific function. The IV-C 
Cas10 also has a unique domain composition that likely supports a distinct function. We 
propose that, due to the different accessory proteins and subtype specific proteins 




action and possibly distinct function. We highly anticipate future work detailing the 
mechanisms and functions of type IV RNP complexes and their accessory proteins. 
 
METHODS 
Sequence Alignment and Phylogenetic Tree Generation for DinG and CysH 
DinG sequences were identified by searching all bacterial genomes from NCBI 
(downloaded on 12/03/2020) for homologs of a list of manually curated non-Cas 
associated dinGs using BLAST (S. F. Altschul et al., 1990), as well as matches to HMM 
profiles for cas-associated dinGs (csf4) using hmmsearch3 (hmmer.org). DinG homologs 
were classified as cas-associated if they were within 10 genes of a Type IV-A CRISPR-
Cas locus. Type IV-A CRISPR-Cas loci were identified by searching for loci which 
contained matches to HMM profiles for csf2, csf3, csf4, and csf5 within 10 genes of each 
other. All HMM profiles were obtained from TIGRFAM and Makarova et al., 2020 and 
searching was performed using hmmsearch3 with an evalue cutoff of 0.001. All BLAST 
searches were performed with an evalue cutoff of 0.001.  
CysH sequences were identified in the same way as dinG sequences. Type IV-B 
CRISPR-Cas loci were identified by searching for loci which contained homologs of 
csf2, csf3, and cysH. CysH sequences were considered cas-associated if they were within 
15 genes of a Type IV-B CRISPR-Cas locus. 
All dinG and cysH sequences were then clustered using MMseqs2 (Steinegger & 
Söding, 2017) with a minimum sequence identity of 0.80 within a cluster. It was 
confirmed that no clusters contained both cas and non-cas associated sequences and one 




then aligned with MAFFT (L-INS-i option) and phylogenies were reconstructed using 
MrBayes (Katoh & Standley, 2013; Ronquist et al., 2012). MrBayes was run until the 
standard deviation of split frequencies remained below 0.02 for 100000 generations.  
 
Sequence Alignment and Phylogenetic Tree Generation for Cas7 and Cas6 
Homologs 
Alignments were performed and phylogenetic trees generated as described for 
DinG and CysH. Only sequences identified in Makarova et al., 2020 were included. 
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The type IV-A CRISPR-Cas system from Pseudomonas aeruginosa has been 
shown to provide defense against invasive plasmids. However, the mechanisms of defense 
are unknown. To determine possible defense mechanisms, the P. aeruginosa type IV-A 
system was expressed and purified from E. coli and shown to form an RNP complex with 
a crRNA. EMSAs were used to show that the IV-A RNP complex preferentially binds 
nucleic acids complementary to the crRNA. Surprisingly, the IV-A RNP complex did not 
bind dsDNA. Preliminary data suggests that CasDinG may be a nuclease. We propose that 
the type IV-A CRISPR-Cas system provides plasmid defense through RNP binding to 
transcribed plasmid RNA which recruits CasDinG to degrade nearby nucleic acids, 
including the plasmid. 
INTRODUCTION 
Bacteria and archaea use CRISPR-Cas systems to defend themselves from 
invasion by mobile genetic elements (MGEs) such as bacteriophage and plasmids 
(Barrangou et al., 2007). The CRISPR locus within prokaryotic genomes contains 
sequences (called spacers) comprised of MGE DNA co-opted during a previous infection 
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by the MGE (Bolotin et al., 2005; Mojica et al., 2005; Pourcel et al., 2005). Transcription 
and processing of the CRISPR locus generates CRISPR-derived RNAs (crRNAs) which 
are complementary to the MGE (Brouns et al., 2008; Carte et al., 2008; C. Hale et al., 
2008). Cas proteins form a ribonucleoprotein (RNP) complex with the crRNA to surveil 
the cell for invasive nucleic acids and induce cleavage of the MGE upon binding (Brouns 
et al., 2008; C. R. Hale et al., 2009; Garneau et al., 2010). Two classes, six types, and 
over 33 subtypes of CRISPR-Cas systems have been classified, with each CRISPR-Cas 
type performing its defense function via unique Cas proteins and mechanisms (Makarova 
et al., 2015, 2020). The type IV-A CRISPR-Cas subtype defends against invasive 
plasmids (Crowley et al., 2019). However, the mechanisms used by the type IV-A system 
are unclear.  
Type IV-A systems encode csf1 (cas8-like), csf2 (cas7-like), csf3 (cas5-like), csf5 
(cas6-like), dinG/csf4, and a CRISPR locus (Makarova et al., 2015, 2020) (Figure 6-1A). 
In Aromatoleum aromaticum the IV-A Csf proteins (Csf1, Csf2, Csf3, and Csf5) form a 
Csf RNP complex with a crRNA that is processed by Csf5 (Özcan et al., 2018). The 
stoichiometry of this complex has not been determined, although it appears that Csf2 is 
present in excess to the other subunits (Özcan et al., 2018). Additionally, the type IV-A 
encoded DinG (CasDinG) has not been biochemically characterized nor studied in 
tandem with the IV-A Csf RNP complex. Non-CasDinG enzymes are helicases which 
have been implicated in damage inducible DNA repair (Lewis et al., 1992; Voloshin & 
Camerini-Otero, 2007; Thakur et al., 2014). Some non-CasDinG helicases also have 
nuclease activity (McRobbie et al., 2012). CasDinG contains helicase motifs but does not 





Figure 6-1. The IV-A Csf proteins form an RNP complex with a crRNA guide. (A) 
Type IV-A operon in P. aeruginosa. (B) SDS-PAGE analysis of the purified Csf RNP 
complex. (C) UREA-PAGE analysis of nucleic acids extracted from the purified Csf 
RNP complex. (D) Gel filtration chromatogram of the Csf RNP complex. (E) Sequenced 
miRNAs extracted from the purified Csf RNP complex. Red arrows indicate cleavage 





activity or may have evolved a novel nuclease domain (Taylor et al., 2021). A recent 
study showed that the type IV-A CRISPR-Cas system from Pseudomonas aeruginosa 
was able to protect BL21 cells expressing the IV-A system from transformation by 
plasmids containing a sequence complementary to crRNAs derived from the CRISPR 
spacer (Crowley et al., 2019). The IV-A system genes csf1, csf2, csf3, csf5, and the 
CRISPR locus are all required for plasmid defense, indicating that a Csf RNP complex 
could be essential for defense activity (Crowley et al., 2019). dinG/csf4 is also required 
for defense, and mutation of the CasDinG DEAD-box motif, which is required for 
helicase activity, abolishes defense activity (Crowley et al., 2019). This data indicates 
that CasDinG is likely a functional helicase and its helicase activity is crucial for the 
ultimate degradation of invasive nucleic acids.  
To better understand the type IV-A CRISPR-Cas mechanisms of action, we 
expressed and purified the type IV-A csf genes from P. aeruginosa. We determined that a 
P. aeruginosa IV-A Csf RNP complex forms around a crRNA and binds complementary 
nucleic acid substrates. Mass spectrometry and negative stain experiments confirm the 
stoichiometry and shape of the Csf RNP complex. Preliminary data from the expression 
and purification of CasDinG from P. aeruginosa suggests that CasDinG may possess 
nuclease activity, though further replications and controls are required to confirm this 
activity. Altogether, the data presented here provide a more in-depth view of the 
mechanisms of defense against MGEs by the type IV-A CRISPR-Cas system and 







The Type IV-A Csf Proteins from Pseudomonas Aeruginosa Form an RNP 
Complex with a crRNA 
To determine whether a Csf RNP complex forms in the P. aeruginosa type IV-A 
CRISPR-Cas system, the csf genes were co-expressed and purified from pCDF-Duet and 
pACYC-Duet vectors (Figure 6-2). The encoded CRISPR consists of a repeat-spacer-
repeat sequence. Based on the composition of a type IV-A Csf RNP complex in 
Aromatoleum aromaticum (Özcan et al., 2018), casdinG was not included in the co-
expression. An N-terminal Strep-tag present on Csf2 was sufficient to pull-down a Csf 
RNP complex through affinity chromatography (Figure 6-1). All Csf proteins and an 
approximagely 50 bp RNA are present in the Csf RNP complex, as seen via SDS-PAGE 
and nucleic acid extractions. Negative stain cryo-electron microscopy (cryoEM) was 
performed to determine the shape of the complex (Figure 6-1F). The P. aeruginosa Csf 
RNP complex forms a curved filament of a distinct length, typical of muti-subunit Cas 
RNP complexes and reminiscent of the A. aromaticum Csf RNP complex (Jore et al., 
2011; Staals et al., 2013; Jackson et al., 2014; Özcan et al., 2018). Native mass 
spectrometry (native-MS) confirms the stoichiometry of the complex 1:2:1:1 for 
Csf1:Csf2:Csf3:Csf5 (Figure 6-3). However, multiple complexes with molecular masses 
larger and smaller than the 1:2:1:1 complex were present in the native mass spectra. 
Negative stain and native-MS data combined indicate that the major RNP complex 
species has the 1:2:1:1 stoichiometry, though other stoichiometries may be possible. 
Some subunits of the Csf RNP complex may have flexible interactions with the complex, 





Figure 6-2. Expression vectors used to co-express the components of the IV-A Csf 
RNP complex. Tags included were the N-Strep on Csf2 alone or in combination with 





Figure 6-3. Native mass spectra of the Csf RNP complex. The spectra indicates that 








To confirm that the RNA component of the Csf RNP complex is a processed 
crRNA, miRNAs were extracted from the Csf RNP complex and sequenced. The RNA 
sequencing data indicates the presence of a processed crRNA containing a spacer 
sequence flanked by repeat sequences which have been cleaved at the base of the repeat 
hairpin (Figure 6-1E and Figure 6-4).  
 
The Type IV-A Csf RNP Complex Exhibits crRNA Guided Binding of 
Nucleic Acid Substrates 
To determine whether the IV-A Csf RNP complex binds nucleic acid substrates, 
we performed electromobility shift assays (EMSAs) with the Csf RNP complex and 
several nucleic acid substrates both complementary to and non-complementary to the 
crRNA spacer (Figure 6-5 and Table 6-1). To prevent contamination of the Csf RNP 
complex with excess Csf2 subunits, a dual affinity tag purification was performed, in 
which a secondary N-His affinity tag on Csf5 was used to purify the RNP complex after 
purification with the N-Strep affinity tag on Csf2. ssDNA, dsDNA, and RNA 
oligonucleotide substrates were designed to contain the same sequence, including the 
putative protospacer binding motif (PAM), used to demonstrate plasmid defense with the 
P. aeruginosa IV-A system (Crowley et al., 2019). A bubble DNA oligo, which is double 
stranded except at the target sequence, was also designed (Figure 6-5A). The Csf RNP 
complex bound the ssDNA target, bubble DNA target, and RNA target oligos with an 
apparent KD of 20.1 nM ± 3.2, 48.4 nM ± 17.4, and 14.9 nM ± 3.8, respectively (Figure 
6-5B).  
At least two bands corresponding to bound oligos are present for all three of these 





Figure 6-4. crRNA processing of the CRISPR transcript used during the expression 
of the Csf RNP complex. Hairpins form within the repeat sequence (orange). Red arrows 
indicate cleavage sites at the base of the hairpin. The 61 nucleotide fully processed 
crRNA contains one repeat hairpin and the spacer sequence (blue). The processed crRNA 






Figure 6-5. The Csf RNP complex binds single ssDNA, bubble DNA, and RNA, but 
not dsDNA. (A) Cartoons of oligos used to test Csf RNP complex binding. Red stars 
indicate 5’-32P – radiolabels. (B) EMSAs and binding curves with the Csf RNP complex 
up to 1000 nM and oligos in (A). Data was collected in triplicate for each data point. 









to the length of the oligonucleotide (73 nucleotides for DNA substrates, 53 nucleotides 
for RNA substrates) (Table 6-1). As the concentration of RNP complex increases, the 
RNP complex may be binding the oligo in a non-sequence specific manner, thus shifting 
the bound substrate higher on the gel. However, even at the highest concentrations of 
RNP complex used, very little non-sequence specific binding occurred with substrates 
lacking complementarity to the crRNA, indicating that non-sequence specific binding is  
rare. The super-shift seen may be due to non-sequence specific binding by additional 
RNP complexes only if this secondary binding event is stabilized by the RNP complex 
bound to the substrate through crRNA sequence specific binding. A more tantalizing 
hypothesis suggests that the super-shift may be due to a dynamic RNP complex. After the 
RNP complex binds the substrate, additional Csf subunits may attach to the RNP 
complex, thus increasing its size. This hypothesis is supported by native mass 
spectrometry data, which shows that complexes of multiple sizes are present in the 
sample (Figure 6-3). Native mass spectrometry data collected on a RNP complex bound 
to a substrate would lend insight into the composition of the RNP complex after binding 
occurs. 
Interestingly, the Csf RNP complex did not bind the dsDNA target oligo to an 
appreciable degree within the concentrations of Csf RNP tested (Figure 6-5B). For each 
nucleic acid oligo tested the Csf RNP complex did not bind the oligo containing the non-
target sequence within the range of concentrations that were tested, indicating that 






CasDinG May Possess Nuclease Activity 
As it is known that CasDinG is required for the P. aeruginosa IV-A defense 
activity, we next performed EMSAs with P. aeruginosa CasDinG (purified with a N-
Strep tag) and the nucleic acid oligos described in the previous section (Figure 6-6). 
CasDinG EMSAs were performed with both the target and non-target versions of each 
oligo. However, since CasDinG was expressed without a CRISPR present and it has not 
been shown that CasDinG binds crRNAs, we expect that the presence of the target or 
non-target sequence within the nucleic acid oligo will not affect CasDinG binding. Bands 
corresponding to oligos bound by CasDinG are present only on the ssDNA target and 
non-target oligos, bubble DNA target oligo, and RNA target and non-target oligos 
(Figure 6-6B). Unexpectedly, CasDinG displayed cleavage activity with all oligos tested. 
This nuclease activity is visualized either as the appearance of a cleavage band or 
disappearance of the oligo altogether (Figure 6-6B). This ubiquitous cleavage activity  
was not expected, and gels were trimmed below the dye front before imaging the gel. I 
suspect that cleavage bands are present in all the gels but were often cut off the gel before 
visualization. Interestingly, multiple cleavage events may be occurring, as multiple 
cleavage bands are sometimes apparent and some cleavage bands disappear as additional 
cleavage events shift the bands lower in the gel where they were trimmed off and not 
visualized. Apparent KD values were calculated if enough data points were obtained for a 
full binding curve. However, as is apparent by the high deviation values, these KD values 
are skewed by the cleavage activity of CasDinG and are not accurate (Figure 6-6B). Two 
bound bands are observed for the ssDNA non-target oligo and the RNA target oligo, 





Figure 6-6. CasDinG may be a nuclease. (A) Cartoons of oligos used to test CasDinG 
binding. Same as in Figure 6-5. (B) EMSAs and binding curves for CasDinG up to 1000 
nM and oligos in (A). Data was collected in triplicate for each data point. Non-visible 
error bars are too tight to be seen behind the data point marker. Binding curves could not 
be calculated for all oligos tested. Curved arrows on gels indicate that cleavage bands 






DISCUSSION AND FUTURE DIRECTIONS 
We have shown here that the P. aeruginosa type IV-A Csf proteins combine with 
a crRNA guide to form an RNP complex which is able to bind single stranded DNA and 
RNA targets containing a sequence complementary to the spacer of the crRNA. We also 
show that the P. aeruginosa CasDinG is a potential nuclease. Altogether, the data 
presented here imply the type IV-A system provides defense through a mechanism 
mediated by Csf RNP complex binding to complementary single stranded DNA or RNA 
molecules of invasive MGEs. We hypothesize that CasDinG is recruited to invasive 
nucleic acids by the Csf RNP complex and will degrade the invasive nucleic acids to 
provide defense. To better understand the mechanisms governing the type IV-A CRISPR-
Cas system, a high-resolution structure of the Csf RNP complex and a biochemical 
characterization of DinG and its interactions with the Csf RNP complex are needed.  
 
The First Description of a Csf RNP Complex Stoichiometry 
As a type IV-A Csf RNP complex has been previously described in Aromatoleum 
aromaticum (Özcan et al., 2018), it was not surprising that the P. aeruginosa type IV-A 
Csf proteins also formed an RNP complex with a crRNA guide. We have reported here 
the first description of the stoichiometry of a IV-A Csf RNP complex as 1:2:1:1 for 
Csf1:Csf2:Csf3:Csf5. It is interesting that the Csf5 subunit is a component of the Csf 
RNP complex. The structure of a type IV-B Csf complex indicates that type IV systems 
may be evolutionarily closely related to type III CRISPR-Cas systems (Zhou et al., 2021). 
However, in type III systems the Cas6 subunit processes the crRNA then dissociates and 




contrast, the Cas6 enzyme of type I systems is a component of the RNP complex (Brouns 
et al., 2008; Hochstrasser & Doudna, 2015). The presence of the Cas6-like protein Csf5 
in the type IV-A RNP complex further supports the hypothesis that the type IV-B system 
may have acquired a type I cas6-like gene and eventually evolved to become the type IV-
A CRISPR-Cas system (Taylor et al., 2019). This hypothesis explains the dual nature of 
type IV systems, as they contain some features reminiscent of type I systems and other 
features reminiscent of type III systems. To better understand the components and 
interactions within the Csf RNP complex, a structure should be obtained. Studies are 
underway to determine a cryo-electron microscopy structure of the Csf RNP complex in 
apo form and bound to nucleic acid substrates.  
 
The Csf RNP Complex Binds Nucleic Acids Complementary to the crRNA, 
though its Preferred Substrate is Unclear 
We also report here the first evidence of crRNA guided binding of nucleic acid 
substrates. A fundamental tenant of CRISPR-Cas defense is crRNA guided binding of 
nucleic acid substrates (Barrangou et al., 2007; Garneau et al., 2010; Gasiunas et al., 
2012; Jinek et al., 2012). As the type IV-A system was recently shown to be a defense 
system (Crowley et al., 2019), we expected that the type IV-A Csf RNP complex would 
exhibit crRNA guided binding of a nucleic acid substrate. In the Crowley et al. study 
(2019), the type IV-A system provided defense against transformation by a plasmid. 
Thus, we also expected that the Csf RNP complex would specifically bind dsDNA 
containing a target (complementary to the crRNA spacer) sequence. Surprisingly, we 




sequence, but not dsDNA (Figure 6-5). We have two hypotheses that could explain this 
discrepancy.  
The first hypothesis is that the oligos used in this study do not contain an 
appropriate protospacer adjacent motif (PAM). The PAM is a 2-5 nucleotide motif in the 
target nucleic acid adjacent to the sequence complementary to the crRNA spacer (Figure 
6-5A). PAM recognition by the RNP complex is a common method for identifying self 
vs. non-self by CRISPR-Cas systems during both adaptation (the acquiring of new 
spacers in the CRISPR locus) and interference (binding of target nucleic acids for 
defense), as the PAM is present in invasive MGEs but not in the CRISPR locus (Deveau 
et al., 2008; Horvath et al., 2008; Marraffini & Sontheimer, 2010). As the crRNA spacer 
is complementary to the CRISPR sequence from which it is derived, binding the PAM 
before inducing a cleavage response is critical for avoiding autoimmunity. PAMs are 
involved in target searching and R-loop formation in CRISPR-Cas systems that target 
dsDNA (Redding et al., 2015; Sternberg et al., 2015). The RNP complex scans dsDNA 
until a PAM is identified through Cas protein interactions which disrupt the hydrogen 
bonds between the dsDNA of the PAM. The dsDNA is further unzipped as the crRNA 
binds to the complementary strand, forming the R-loop (Anders et al., 2014; Mulepati et 
al., 2014; Sternberg et al., 2014; Leenay & Beisel, 2017). Thus, if the PAM is not present, 
the RNP complex may not bind to a complementary target. This may explain why the Csf 
RNP complex is unable to bind a dsDNA oligo containing a target sequence. All the other 
oligos tested, which the Csf RNP complex did bind when a target sequence was present, 
are single stranded at the target sequence, thus negating the need for a PAM to initiate 




A systems do utilize PAM sequences (Pinilla-Redondo et al., 2019). Further studies are 
needed to investigate whether type IV-A systems require PAMs for interference and what 
the specific requirements of the PAM are. Despite unknowns regarding the need for a 
PAM, the PAM, target sequence, and other flanking sequences of the oligos used to 
perform EMSAs in this study are identical to those used by Crowley et al. (2019) to 
demonstrate that the type IV-A CRISPR-Cas system can defend against plasmids. Thus, 
we know that when a cell expressing the P. aeruginosa type IV-A CRISPR-Cas system is 
invaded by dsDNA (plasmid) complementary to the spacer of the crRNA, a defense 
response is induced, leading to the destruction of the dsDNA or death of the cell. If the 
Csf RNP complex is not directly binding the target sequence on the dsDNA, then some 
other mechanism must be at play. 
The second hypothesis that may explain why the Csf RNP complex does not bind 
dsDNA, despite being able to defend against invasive plasmids, is that the preferred 
substrate of the type IV-A Csf RNP complex is RNA, not dsDNA. Several CRISPR-Cas 
systems preferentially target RNA over DNA, mainly type III and type VI CRISPR-Cas 
systems (Elmore et al., 2016; Kazlauskiene et al., 2016; Abudayyeh et al., 2016; East-
Seletsky et al., 2016). Type III systems, specifically, have been shown to defend against 
plasmid invasion by targeting RNA transcripts (Marraffini & Sontheimer, 2008; 
Tamulaitis et al., 2014). In these systems, binding of the RNP complex to the target RNA, 
induces tightly controlled, non-specific DNase and RNase activity in various enzymes 
that leads to either destruction of the invasive MGE or death of the cell, thus preventing 
propagation of the MGE (Athukoralage et al., 2020). A similar mechanism could be used 




be bound by the Csf RNP complex, consistent with our EMSA data. When binding 
nucleic acids, the Csf RNP complex is unable to distinguish ssDNA from RNA, binding 
each with similar affinities (Figure 6-5B). It is possible that either, or both, ssDNA 
and/or RNA could be the preferred substrate for the Csf RNP complex. It should be noted 
that type III RNP complexes contain DNase activity within the Cas10 subunit that 
cleaves non-specific ssDNA and some also contain RNase activity within the Cas7-like 
subunits that cleaves the bound RNA (C. R. Hale et al., 2012; Jung et al., 2015; Staals et 
al., 2013). Although no cleavage activity was observed in the Csf RNP EMSAs we 
report, cleavage assays should be run under similar conditions to determine whether the 
Csf RNP complex exhibits any cleavage activity towards its target nucleic acid or 
spectator nucleic acids. Additionally, the type IV-A system may provide defense through 
cell death. When the type IV-A system is activated by Csf RNP complex binding, 
downstream effects result in cell death, thus protecting the bacterial community from the 
invasive nucleic acid present in the affected cell. This hypothesis should be explored 
through bacterial growth studies post infection/transformation. 
 
The Potential Cleavage Activity of CasDinG Needs to be Confirmed 
CasDinG does not contain a predicted nuclease domain (Taylor et al., 2021), so 
we were surprised to see such robust cleavage activity when attempting to perform 
EMSAs with CasDinG. Cleavage activity was observed for all oligos tested, regardless of 
sequence (Figure 6-6). The CasDinG EMSAs presented here are preliminary results and 
need to be validated. Firstly, the cleavage activity seen could be the result of a 




CasDinG nuclease active site needs to be identified, then mutated. If the mutated 
CasDinG no longer exhibits nuclease activity, then the nuclease activity can be attributed 
to CasDinG. We suspect that the CasDinG nuclease active site will exist within its arch 
domain (Taylor et al., 2021) and studies are underway to remove chunks of the arch 
domain and test for nuclease activity. CasDinG is a predicted ATP-dependent helicase 
and its ATPase activity is required for defense (Voloshin et al., 2003; Voloshin & 
Camerini-Otero, 2007; McRobbie et al., 2012; Thakur et al., 2014; Crowley et al., 2019). 
Interestingly, ATP was not added to the CasDinG EMSAs, so any CasDinG nuclease 
activity occurs independently of ATPase/helicase activity. Equilibrium dissociation 
constants (KD) could not be determined for CasDinG and the oligos tested, as binding 
was not completely visualized due to the cleavage activity. EMSAs should be repeated 
with CasDinG either in a mutated form where nuclease activity will not occur or in a 
buffer condition that allows substrate binding but will prevent nuclease activity. For 
example, if the nuclease activity is metal dependent, adding high concentrations of EDTA 
will inhibit the cleavage activity. In any of these cases where cleavage activity is 
suppressed or inhibited, binding may also be affected, and this should be taken into 
consideration when analyzing the assay. Oligonucleotide binding by CasDinG should 
also be determined in the presence of the Csf RNP complex. If CasDinG is recruited to 
invasive nucleic acids by the Csf RNP complex, CasDinG should have a higher affinity 
to oligonucleotides bound by the Csf RNP complex. If this recruitment event is 
confirmed, a structure of the Csf RNP complex bound to a substrate and CasDinG should 




We have shown conclusively that the P. aeruginosa type IV-A Csf RNP complex 
binds single stranded nucleic acid substrates in a crRNA dependent manner. Binding of 
the target nucleic acid will likely result in downstream effects that eventually lead to 
destruction of the bound target. To better understand these downstream effects, it is 
critical that we understand the activities of CasDinG and its relationship to the Csf RNP 
complex. We know that CasDinG, in addition to the Csf RNP complex, is required for 
defense to occur (Crowley et al., 2019). Additionally, all CRISPR-Cas systems encode a 
nuclease that is responsible for the ultimate destruction of targeted MGEs (Makarova et 
al., 2020). Thus, it is not without precedent that CasDinG may have nuclease activity and 
this activity needs to be confirmed before we can understand the full mechanism of type 
IV-A CRISPR-Cas defense. As the type IV-A CRISPR-Cas system can defend against 
invasive plasmids (Crowley et al., 2019), we propose that CasDinG has nuclease activity 
and CasDinG nuclease activity is required for defense. 
 
A Putative Model for Type IV-A Mediated Defense 
We hypothesize that the type IV-A CRISPR-Cas system provides defense via the 
following steps: the Csf RNP complex binds a target nucleic acid, CasDinG is recruited 
to the nucleic acid by the Csf RNP complex, and CasDinG unwinds and cleaves the 
targeted nucleic acid to prevent its propagation (Figure 6-7). As discussed above, the 
preferred substrate for the Csf RNP complex is still unclear. It may utilize a strict PAM to 
bind dsDNA and recruit CasDinG to unwind and cleave the dsDNA. Or the Csf RNP 
complex may bind an RNA target and recruit CasDinG to unwind and cleave nucleic 




thus recruiting CasDinG to a transcription bubble, where it may non-specifically degrade 
DNA and RNA substrates. Altogether, the results discussed here further our 
understanding of type IV-A defense mechanisms and make clear many questions that 
need answers in order to gain a more complete understanding of the type IV-A CRISPR-






Figure 6-7. Putative model for the defense activity of type IV-A CRISPR-Cas 
systems. Type IV-A Csf subunits form an RNP complex with a CRISPR-derived RNA 
(crRNA). The RNP complex may bind dsDNA of RNA complementary to the crRNA. 
CasDinG may be recruited by the RNP complex to the target nucleic acid, where it will 
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MATERIALS AND METHODS 
Csf RNP Complex Expression and Purification 
Several growth conditions were tested to determine the optimal expression 
parameters for the Pseudomonas aeruginosa PA83 type IV-A Csf proteins individually 
and tangentially (Table 6-2, end of methods section). To express the P. aeruginosa PA83 
type IV-A Csf RNP complex, chemically competent BL21-AI cells were transformed 
simultaneously with two plasmids encoding the csf genes and a 1X CRISPR: 
pCDFDuet_Pa_(N-His-)csf1_N-Strep-csf2_(N-His-)cas6 (secondary affinity tags were 
placed either on Csf1 or Cas6) and pACYCDuet_Pa83CR_csf3. An LB (lysogeny broth) 
starter with appropriate antibiotics was inoculated with one colony from the 
transformation and grown with shaking at 37°C overnight. 1 L of LB with appropriate 
antibiotics in a 2800 mL Fernbach culture flask was inoculated with 25 mL overnight 




0.5-0.7 was reached. The growth was then cold shocked without shaking at ~4°C for 45-
60 minutes. The growth was then induced with 1mM IPTG and 0.2% L-arabinose and 
grown with shaking at 16°C overnight. Cells were harvested by centrifugation and the 
pellet stored at -80°C. Growths were scaled up by adding additional 1L growths. 
Cell pellet was resuspended in Buffer W (100 mM Tris, pH 8.0; 150 mM NaCl; 
10 mM EDTA) with 10 µg/mL leupeptin, 2 µg/mL aprotinin, and 170 µg/mL 
phenylmethylsulfonyl fluoride (PMSF). Cells were lysed by sonication on ice at power 
3/30 for 5-10 minutes with intermittent 15 second rests. Lysate was clarified by 
centrifugation at 15000 RPM for 15 minutes at 4°C. Polyethylenimine (PEI) diluted in 
Buffer W was added to the soluble lysate at a final concentration of 0.1% PEI. Lysate 
was again clarified by centrifugation at 15000 RPM for 15 minutes at 4°C. Soluble lysate 
was combined with 4-5 mL Strep resin (IBA LifeSciences Strep-Tactin XT Superflow) 
previously equilibrated with Buffer W. Resin and lysate were incubated at 4°C overnight 
with continuous turning. Resin was settled in a column and the flow through collected. 
The resin was washed with 5 X 1 CV Buffer W. Pa IV-A RNP complex was eluted from 
the resin with 4 X 1 CV Buffer BXT (Buffer W + 50 mM biotin). Strep resin elutions 
were pooled and applied to a Ni column (constructs with a secondary affinity tag) or Q 
column (constructs with only the Strep-tag) equilibrated with Buffer W (HisTrap, crude 5 
mL, GE Healthcare). Column was washed with 5 CV Buffer W and Pa IV-A RNP 
complex was eluted with a 0-100% 5 CV gradient up to 1 M imidazole or 1 M NaCl. The 
elution peak was pooled and concentrated to ≤0.5 mL with a Spin-X UF Corning 5k 
MWCO concentrator. Concentrated Pa Csf RNP complex was further purified by size 




Cytiva). The Superose6 column was equilibrated with 1.5 CVs SEC Buffer (50 mM 
HEPES, 150 mM NaCl), protein sample applied, and purified Pa Csf RNP complex 




miRNAs were extracted from the Csf RNP complex using the PureLink RNA 
Mini Kit (Thermo Fisher Scientific). Extracted RNAs were treated with T4 PNK (NEB) 
and ethanol precipitated before being sequenced on an Illumina MiSeq (Center for 
Integrated Biosystems, Utah State University, USA). 
 
Native Mass Spectrometry 
The P. aeruginosa type IV-A Csf RNP complex was buffer exchanged into 
200 mM ammonium acetate pH 8.0 by seven consecutive dilution and concentration 
rounds on a centrifugal filter with a cut-off of 10 kDa (Sartorius) at 4°C. An aliquot of 1–
2 μl with a concentration of approximately 1 uM was loaded into an in-house prepared 
borosilicate capillary (Kwik-Fil, World Precision Instruments, Sarasota, FL) on a P97 
puller (SutterInstruments, Novato, CA). Using an Edwards Scancoat six pirani 501 
sputter coater (Edwards Laboratories, Milpitas, USA), the needles were gold coated for 
proper conductivity. Samples were analyzed in positive ion mode on a standard 
commercial Q Exactive-UHMR instrument (Thermo Fisher Scientific). Ion transfer optics 
and voltage gradients throughout the instrument were optimized to transfer ions from 




could either act as a mass filter or cause fragmentation. By applying 1.4 kV on the gold 
coated emitter ions are formed in the source. Ions are passing through a transfer tube to 
an S-lens, towards the exit lens, by applying RF on the electrodes. To further optimize the 
transfer of ions the detector optimization was set to low and the radio frequency 
amplitudes for the injection flatapole, bent flatapole, transfer multipole and higher-energy 
collisional dissociation (HCD) cell were set to 700, 940 and 900 V, respectively.  In-
source trapping (inject flatapole) was left at default setting. The setting for the ion 
transfer optics (injection flatapole, inter-flatapole lens, bent flatapole, transfer multipole 
and C-trap entrance lens), were put to 8,7,6, 4 and 5.8 V, respectively. Instead of trapping 
ions in the C-trap, ions were allowed to enter a Nitrogen filled HCD cell to allow 
sufficient collisional focusing. Increasing the collision cell pressure to approximately 2,3 
× 10−10 mbar (readout in the Orbitrap analyzer) and the use of low HCD voltage (1.0V) 
improved detection sensitivity drastically. Before measurement, the instrument was 
manually mass-calibrated by direct infusion using solutions of 25 mg/ml CsI. All spectra 
were acquired by a resolving power of 8750 (transient length of 32 ms) at m/z 200 and 
processed using the standard Xcalibur 4.4 package (ThermoFisher Scientific). 
 
Negative Stain Analysis 
For negative-stain grid preparation, 4 µl of sample (at various concentrations 
ranging from 100 – 500 nM) was incubated on glow-discharged carbon-coated Formvar 
300-mesh Cu grid for 90 seconds prior to blotting and stained twice with 20 µl 2% uranyl 
acetate (first stain immediately blotted, second stain incubated for 20 seconds prior to 




operating at 200 kV, at a nominal magnification of 75,000x. Single-particle data 
processing was performed using CryoSparc. 
 
CasDinG Expression and Purification 
To express N-Strep tagged CasDinG, 1 L of LB with appropriate antibiotics is 
inoculated with 15 mL of overnight growth and the addition of 1000X metals mix (0.1 M 
FeCl3-6H2O, 1 M CaCl2, 1 M MnCl2-4H2O, 1 M ZnSO4-7H2O, 0.2 M CoCl2-6H2O, 0.1 
M CuCl2-2H2O, 0.2 M NiCl2-6H2O, 0.1 M Na2MoO4-2H2O, 0.1 M Na2SeO3-5H2O, 0.1 
M H3BO3) and 1000X 1 M MgSO4. Cells are grown to an optical density of 0.6 at 37°C. 
When OD is reached, the cells are induced with 0.5 mM IPTG and the temperature is 
dropped to 20°C for 5 hours. The cells are then harvested by centrifugation and the cell 
pellet stored at -80°C.  
Cells are homogenized on ice with lysis buffer (100 mM Tris Base, 150 mM 
NaCl, pH 8.0). 0.5 µg/ml aprotinin, 0.5 µg/ml leupeptin, 0.7 µg/ml pepstatin A, and 170 
µg/mL PMSF are added prior to sonication. Sonication is performed on ice at settings of 
3/50 for 30 second intervals with 30 second rests for a total of 5 minutes or until the 
viscosity is close to that of water. The lysate is then centrifuged at 16000 RPM for 45 
minutes. All purification steps are performed at 4°C. The supernatant is then poured 
gently over 1 mL Strep Tactin XT SuperFlow High Capacity resin (IBA Life Sciences). 
The flow through is collected and the resin is washed with 10 CV lysis buffer. Protein is 
eluted in elution buffer (100 mM Tris Base, 150 mM NaCl, 50 mM biotin, pH 8.0. 
Fractions containing DinG are pooled and run over a desalting column with low salt 




over a HP 5mL Heparin column (GE Healthcare) using a linear gradient between low salt 
buffer and high salt buffer (100 mM Tris Base, 1 M NaCl, pH 8.0). The protein elutions 
are then run over the desalting column with 100 mM Tris Base, 500 mM NaCl, pH 8.0. 
Elutions are concentrated to greater than 1 mg/ml, mixed with an equal volume of 100 
mM Tris Base, 500 mM NaCl, 40% glycerol, pH 8.0, and flash frozen using liquid 
nitrogen for storage at -80°C. 
 
Oligonucleotide Substrate Preparation 
DNA and RNA oligonucleotides were ordered from Eurofins Genomics. 
Oligonucleotides were 5’ radiolabeled with (γ-32P)-ATP (Perkin Elmer) and T4 
polynucleotide kinase (NEB). Labeled RNAs were separated from excess ATP with a 
MicroSpin G-25 column (GE Healthcare), then gel purified on a denaturing (7M urea) 
12% polyacrylamide gel, ethanol precipitated, and recovered in water or hybridization 
buffer (20 mM HEPES pH 7.5, 75 mM NaCl, 2mM EDTA, 10% glycerol, and 0.01% 
bromophenol blue). 
dsDNA was prepared as previously described (van Erp et al., 2015) by mixing 
labeled oligonucleotides with five-fold molar excess of the complementary 
oligonucleotide in hybridization buffer, incubating at 95°C for 5 min, and gradually 
cooling to 25°C in a thermocycler. Oligonucleotide duplexes were gel purified on a non-







Electromobility Shift Assays 
Radiolabeled oligonucleotide substrates were mixed with 0-1000 nM Csf RNP or 
0-1000 nM CasDinG in hybridization buffer with 1 mM TCEP and 5 mM MgCl2. 
Reactions were incubated for 15-30 minutes at 37°C then separated on a non-denaturing 
6% polyacrylamide gel. Gels were dried, exposed to a phosphor storage screen, and 
scanned with a Typhoon (GE Healthcare) phosphorimager. Bound and unbound fractions 
were quantified using ImageQuant (GE Healthcare) software. All data were fit using 
Kaleidagraph software to the equation: 
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 𝑜𝑙𝑖𝑔𝑜 =
𝑀1 ∗  [𝑝𝑟𝑜𝑡𝑒𝑖𝑛]
𝐾𝐷 +  [𝑝𝑟𝑜𝑡𝑒𝑖𝑛]
 
Where M1 is the amplitude of the binding curve and protein refers to either Csf 
RNP complex or CasDinG. Reported data is the average of three or more replicates and 
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SUMMARY AND FUTURE DIRECTIONS 
 
INTRODUCTION 
The defense and anti-defense systems employed by prokaryotes and the mobile 
genetic elements that infect them have long been exploited to gain insights into 
prokaryotic biology and develop biotechnology to advance basic research, medicine, and 
more (Campbell, 2003; Westra et al., 2012; Doron et al., 2018; Rostøl & Marraffini, 
2019). The prokaryotic CRISPR-Cas defense systems are no different, and have spurred 
the development of several gene editing, therapeutic, and diagnostic tools (Adli, 2018; 
Pickar-Oliver & Gersbach, 2019). To provide a timely example, CRISPR-Cas systems 
have been repurposed as SARS-CoV-2 detection and diagnostic tools, as well as COVID-
19 therapeutics (Atzrodt et al., 2020; Hou et al., 2020; Nalawansha & Samarasinghe, 
2020; Nemudryi et al., 2020). Beyond their use as biotechnological tools, the study of 
CRISPR-Cas systems has broadened our knowledge of the scope of bacterial immune 
systems and allowed for the discovery of novel and intricate biological mechanisms 
(Barrangou et al., 2007; Barrangou, 2015; Doron et al., 2018). Two classes, six types, and 
over 33 subtypes of CRISPR-Cas systems have been discovered to date (Makarova et al., 
2020). Of the many diverse CRISPR-Cas types, type IV CRISR-Cas systems have been 
the least studied.  
Although originally thought to be rare and only encoded in extremophiles, type 
IV CRISPR-Cas systems are widespread and present in intensively studied disease 




Klebsiella phenumoniae (Makarova et al., 2015, 2020; Crowley et al., 2019; 
Kamruzzaman & Iredell, 2020; Newire et al., 2020). Type IV CRISPR-Cas systems are 
typified by their lack of common CRISPR-Cas elements, making them both difficult to 
study and incredibly interesting (Makarova et al., 2015). In fact, some type IV CRISPR-
Cas systems lack a CRISPR locus, thus making them CRISPR-less CRISPR-Cas systems. 
Additionally, type IV systems are almost exclusively encoded on plasmids and prophages 
(Makarova et al., 2015; Koonin & Makarova, 2017, 2019; Shmakov et al., 2018; Pinilla-
Redondo et al., 2019; Faure et al., 2019). Type IV CRISPR-Cas systems have been 
subdivided into three subtypes (IV-A, IV-B, and IV-C), each of which encodes a subtype 
specific accessory protein (CasDinG, CasCysH, and Cas10-like, respectively) (Pinilla-
Redondo et al., 2019; Makarova et al., 2020) (Figure 7-1). The minimal size, mobile 
nature, and eclectic collection of genes within type IV operons, present challenges to 
their study. However, the same reasons that make type IV systems difficult to study make 
it likely that type IV systems will reveal novel and impactful insights into prokaryotic 
biology. 
This dissertation presents some of the first structural and biochemical studies of 
type IV CRISPR-Cas systems. The studies described here have revealed the structures of 
a type IV-B Csf RNP complex and a type IV Cas6 endoribonuclease, uncovered the 
defense function of the type IV-A CRISPR-Cas system, and elucidated many 
mechanisms surrounding type IV crRNA processing and type IV-A Csf RNP complex 
binding to nucleic acid substrates. This research has answered some of the fundamental 





Figure 7-1. Operons of the type IV subtypes. Dashed lines indicate a component that is 
only sometimes present. The yellow box represents an HD nuclease domain. dinG, cysH-







presented new avenues of study, and offered questions that need answered to deepen our 
understanding of type IV CRISPR-Cas systems and their relevance in prokaryotic 
biology.   
This chapter will highlight the importance of each study reported in previous 
chapters of this dissertation and suggest future studies to further elucidate the structures, 
functions, and mechanisms of type IV CRISPR-Cas systems. As each of the type IV 
subtypes encode unique genes and have unique hypothesized functions, I will discuss 
each subtype in turn. 
 
ADVANCES IN TYPE IV-A SYSTEM STRUCTURE AND FUNCTION 
 
The Type IV Cas6/Csf5 Enzymes Process crRNAs 
Within class 1 CRISPR-Cas systems, Cas6 endoribonucleases are primarily 
responsible for processing crRNAs (CRISPR-derived RNAs) which are bound by the Cas 
RNP (ribonucleoprotein) complex and used to identify complementary, and thus invasive, 
nucleic acids (Brouns et al., 2008; Carte et al., 2008; C. Hale et al., 2008). The Cas6 
endoribonuclease encoded by the type IV-A system of Mahella australiensis was 
biochemically characterized (Taylor et al., 2019) (Chapter 3) (Figure 7-2). MaCas6 was 
determined to have endonuclease activity specific to the repeat sequence of the pre-
crRNA transcribed from a M. australiensis type IV associated CRISPR locus. The crystal 
structure of MaCas6 was determined and used to identify the active site residues (His44 
and Tyr31) required for its endoribonuclease activity. MaCas6 mutants harboring alanine 
mutations at either of the two active site residues had nearly abolished cleavage activity. 





Figure 7-2. Model of type IV-A CRISPR-Cas defense. The type IV Csf5/Cas6 
endoribonuclease processes the CRISPR transcript into crRNAs which are bound by the 
type IV-A Csf proteins to form a Csf RNP complex. The Csf RNP complex binds RNA 
complementary to the crRNA and may recruit DinG to degrade nearby nucleic acids. 





associated Cas6 enzymes (Gesner et al., 2011; Przybilski et al., 2011; Sashital et al., 
2011). This led to the hypothesis that ancestral type IV systems may have acquired a type 
I Cas6, leading to the formation of the type IV-A operon (Taylor et al., 2019). This is 
further supported by the fact that MaCas6 is most structurally similar to an orphan type I 
Cas6 enzyme. 
However, some type IV-A systems encode a Cas6-like enzyme, Csf5, that is 
different from the type IV Cas6 in several aspects (Makarova et al., 2020). Csf5 has been 
studied in the context of the type IV-A system from Aromatoleum aromaticum and the 
type IV-A system from Pseudomonas aeruginosa (Özcan et al., 2018; Crowley et al., 
2019). Importantly, although the P. aeruginosa Csf RNP complex has been shown to 
bind crRNAs (Chapter 6), crRNA processing has not been directly attributed to Csf5. 
The PaCsf5 and AaCsf5 amino acid sequences, especially at the active site residues, align 
well, indicating that PaCsf5 likely has a similar activity (Taylor et al., 2021) (Chapter 5). 
Although AaCsf5 and MaCas6 have similar structural arrangements, the AaCsf5 active 
site is composed of three arginine residues, not a histidine and tyrosine (Özcan et al., 
2018; Taylor et al., 2019, 2021).  
Type IV systems encode three different types of Cas6 enzymes: Cas6, Csf5, and 
Cas6e (Makarova et al., 2020; Taylor et al., 2021). Cas6e is the Cas6 enzyme associated 
with type I-E CRISPR-Cas systems, though the type IV Cas6e amino acid sequence is 
distinct from the Cas6e amino acid sequence (Taylor et al., 2021). Interestingly, although 
the type IV Cas6e has a histidine/tyrosine active site, the sequence is different enough 
from type IV Cas6 enzymes (like MaCas6) that the active sites do not match in a 




in type IV CRISPR-Cas systems, leads to the hypothesis that type IV systems may have 
acquired Cas6 enzymes through three separate events. Supporting this hypothesis is the 
fact that type IV-B systems sometimes encode Cas6 proteins (Pinilla-Redondo et al., 
2019; Makarova et al., 2020). Type IV-B systems encode the three Csf core proteins 
(Csf1, Csf2, Csf3), but no CRISPR. Without a CRISPR, there should not be a need to 
encode a Cas6 enzyme in the system. The presence of Cas6 in a type IV-B system may 
indicate that a common ancestor of the type IV-A and IV-B systems encoded the three 
Csf core proteins and acquired a Cas6 enzyme. Two lineages may have stemmed from 
this ancestral lineage, one becoming type IV-A systems and the other type IV-B systems. 
In this model, Cas6 may be a “vestigial” component of the type IV-B system.  
Further work on type IV systems should continue to characterize the Cas6 
enzymes from type IV-A systems, especially PaCsf5 and the uncharacterized type IV 
Cas6e. Work should also be done to determine the evolutionary history of type IV 
systems, including how, why, and when the Cas6 enzymes were acquired by type IV 
systems. Finally, the Cas6 proteins associated with type IV-B systems should be 
characterized to determine if they are functional and what their substrate is. As type IV-B 
systems have a hypothesized non-defense function and an unknown RNA component, 
IV-B associated Cas6 enzymes may have evolved to process a non-CRISPR RNA for the 
type IV-B Csf RNP complex to bind. 
 
The Type IV-A Csf Proteins Form an RNP Complex and Perform crRNA 
Guided Nucleic Acid Binding to Induce a Downstream Defense Response 
RNP effector complex formation around a crRNA is a central tenet of all 




Hale et al., 2012; Jinek et al., 2012; Zetsche et al., 2015; Yan et al., 2018). The formation 
of a Pseudomonas aeruginosa type IV-A Csf RNP complex was confirmed by SEC, 
negative stain, and native mass spectrometry (Chapter 6) (Figure 7-2). This is only the 
second description of a type IV-A Csf RNP complex, the first coming from Aromatoleum 
aromaticum (Özcan et al., 2018). However, we are the first to determine the 
stoichiometry of the Csf RNP complex and to show that it is a true Cas effector complex 
that binds nucleic acids complementary to the crRNA. Additionally, by showing that the 
P. aeruginosa type IV-A CRISPR-Cas system can prevent the transformation of invasive 
plasmids (Chapter 4) (Figure 7-2), we provided the first evidence that the type IV-A 
CRISPR-Cas system is a defense system  (Crowley et al., 2019). Interestingly both the 
putative helicase, CasDinG, and the ATPase active site of CasDinG are required to 
achieve defense. Thus, we have shown that the type IV-A CRISPR-Cas system utilizes a 
Csf RNP effector complex to bind target nucleic acids, leading to downstream effects 
involving CasDinG, which eventually provide defense against the identified nucleic acid. 
Unexpectedly, the type IV-A Csf RNP complex bound only single stranded 
oligonucleotides and did not show any preference between DNA and RNA. This could 
indicate that, to defend against an invasive plasmid, the IV-A Csf RNP complex binds 
RNA transcripts and induces downstream effects, such as plasmid cleavage or cell death, 
which eventually destroy the plasmid DNA. 
Several questions remain to better understand the structure, function, and 
mechanisms of type IV-A defense. Firstly, structures of the Csf RNP complex are needed 
to better understand how the complex assembles, how subunits interact with each other 




to obtain cryo-electron microscopy (cryo-EM) structures of the apo Csf RNP complex, 
the ssDNA bound Csf RNP complex, RNA bound Csf RNP complex, and dsDNA bound 
Csf RNP complex. These structures may also be useful in determining whether the Csf 
RNP complex recognizes a PAM on the target nucleic acid by examining the contacts the 
Csf subunits have with the target nucleic acid. Structures will also be invaluable in 
comparing the RNP complexes of other class 1 CRISPR-Cas systems to the type IV Csf 
RNP complex. Based on RNP complex stoichiometry and negative stain analysis, I 
hypothesize that the type IV Csf RNP complex has a shape unique for Cas RNP 
complexes, but has homologous subunit:subunit and subunit:crRNA interactions. 
If the Csf RNP complex can recruit CasDinG, as hypothesized, then binding 
interactions between the Csf RNP complex and CasDinG should be explored 
biochemically and structurally. 
Preliminary studies also describe the potential nuclease activity of CasDinG 
(Chapter 6). Studies are underway to confirm and characterize the cleavage activity of 
CasDinG. Determining the functional mechanisms of CasDinG and its exact role within 
the type IV-A CRISPR-Cas system will be critical to understanding how defense occurs 
after target binding by the Csf RNP complex.  
Plasmids are the only experimentally determined target of type IV-A CRISPR-
Cas defense systems. Bioinformatics studies have concluded that plasmids are the major 
target of type IV systems (Koonin & Makarova, 2019; Pinilla-Redondo et al., 2019). An 
important question of type IV systems is whether they can defend against bacteriophages. 
Some evidence suggests that phages may be targeted by type IV CRISPR-Cas systems: 




phage-encoded anti-CRISPRs proteins may block type IV systems (Shmakov et al., 2017; 
Crowley et al., 2019; Pinilla-Redondo et al., 2019; Yin et al., 2019; Nobrega et al., 2020). 
Further studies should be performed using plaque assays and other phage challenge 
assays with bacteria expressing the type IV-A CRISPR-Cas system to determine if the 
type IV-A system can defend against bacteriophage. 
 
THE COMPLETE STRUCTURE AND FUNCTION OF TYPE IV-B SYSTEMS 
ARE STILL UNKNOWN 
To date, the only published structural data on type IV-B systems is described by 
Zhou et al. (2021) (Chapter 2). No biochemical assays have been published on type IV-
B systems. The IV-B structure is a helical ribonucleoprotein complex composed of 
several Csf2 backbone subunits and several Cas11 belly subunits wound around an RNA. 
This structure provides many important insights, including showing the similarities and 
differences between Csf2 and its Cas7 homologs in other class 1 CRISPR-Cas systems 
(Taylor et al., 2021; Zhou et al., 2021) (Chapter 5). The RNA component within the Csf 
RNP complex was sequenced and determined to be a random RNA. Interestingly, the Csf 
RNP complex did not bind any available I-E crRNAs, despite the fact that many 
CRISPR-Cas systems share and commandeer crRNAs from each other (Staals et al., 
2013, 2014; Elmore et al., 2015). A major remaining question is whether the type IV-B 
Csf RNP complex binds RNAs non-specifically or if the preferred RNA substrate of the 
IV-B RNP complex was unavailable in the conditions of the study. One possible 
experiment that could determine the RNA component of the type IV-B system is to add 
an affinity tag to the csf2 gene of an organism, such as Mycobacterium sp. JS623, then 




RNA component is indeed not a crRNA, it seems unlikely that the type IV-B systems 
function could be defense. 
Many potential functions of the type IV-B CRISPR-Cas system are discussed in 
Chapter 5 (Taylor et al., 2021). However, none address how the accessory protein 
CasCysH might be involved in type IV-B function. Understanding the function of 
CasCysH will inform our ideas concerning the overall function of type IV-B systems. 
Thus, determining the structure, function, and mechanisms of CasCysH is critical. 
Finally, a future direction is to determine a more complete cryoEM structure of 
the type IV-B Csf RNP complex. The available IV-B Csf RNP complex structure is 
missing the Csf1 and Csf3 subunits, because the electron density at the ends of the 
complex was not resolved enough to allow modeling of any subunits (Zhou et al., 2021). 
I attempted to co-express the IV-B Csf proteins with an MBP-tag on either Csf1 or Csf3 
to determine a higher resolution cryoEM structure. The MBP-tag is ~40 kDa, increasing 
the size of the linked subunit. This could make the combined subunit and tag more 
“visible” in the data set. However, the bulky MBP-tag could also interfere with the 
formation of the RNP complex and alter its stoichiometry. I have made a promising start 
and future work in the Jackson lab should continue this experiment. Another potential 
route to obtaining a more complete cryoEM structure of the IV-B Csf RNP complex is to 
purify a less heterogenous sample of the complex. The Csf RNP complex we used to 
obtain a cryoEM structure was purified by affinity chromatography followed by size 
exclusion chromatography (Zhou et al., 2021). Future studies should add an additional 
step, such as anion exchange chromatography. The type IV-A Csf RNP complex was 




IV-A and IV-B Csf RNP complexes have some homologous subunits, I hypothesize that 
the IV-B Csf RNP complex would be better purified if an anion exchange column were 
added to the purification protocol after affinity chromatography. 
 
STUDY OF THE NEWLY CLASSIFIED TYPE IV-C SYSTEM WILL LIKELY 
REVEAL NEW DEFENSE OR NON-DEFENSE FUNCTIONS 
The Type IV-C subtype was very recently classified and has only been 
characterized using bioinformatics. Type IV-C systems encode the type IV signature 
gene, csf2, as well as a csf3 gene and a type IV-specific cas11 gene (Makarova et al., 
2020; Pinilla-Redondo et al., 2019) (Figure 7-1). Strikingly, type IV-C systems do not 
encode a csf1 gene. In fact, csf1 was initially characterized as the type IV signature gene 
until type IV-C and other type IV variants were discovered without csf1 (Makarova et al., 
2015). In place of a csf1 gene, Type IV-C systems encode a cas10-like gene. Cas10 is an 
enzymatic subunit of type III systems. It contains an HD nuclease domain, is a subunit of 
the type III RNP complex, and cleaves ssDNAs and, in some cases, produces cyclic 
oligoadenylates after a complementary nucleic acid is bound by the RNP complex (Jung 
et al., 2015; Osawa et al., 2015; Niewoehner et al., 2017; Kazlauskiene et al., 2017).  
Although the IV-C Cas10-like protein is related to the type III Cas10, there are 
some notable differences between the two proteins. First, the IV-C Cas10-like protein 
does not contain an active site for cyclic oligoadenylate synthesis (Pinilla-Redondo et al., 
2019). Second, the HD nuclease domain motifs of the IV-C Cas10-like protein are 
arranged most like the HD motifs of the type I Cas3 enzyme rather than those of the type 
III Cas10 enzyme (Aravind & Koonin, 1998; Makarova et al., 2020). Interestingly, I 




sequences and type I Cas3 sequences using Clustal Omega (Madeira et al., 2019), the HD 
nuclease motifs did not align (Figure 7-3). An HHPred search on the type IV-C Cas10-
like sequence from Thermococcus onnurineus returned a match for the type I-D Cas10d 
structure from Sulfolobus islandicus (PDBid: 6THH) (Manav et al., 2020; Zimmermann 
et al., 2018). An alignment of type IV-C Cas10-like sequences with type I-D Cas10d 
sequences shows high sequence similarity around an HD domain motif (Figure 7-4). 
Type I-D systems encode a Cas10 large subunit (Cas10d) instead of the Cas8 large 
subunit typically encoded by type I CRISPR-Cas systems (Makarova et al., 2015, 2020). 
Cas10d subunits cleave double stranded and single stranded DNA with an HD domain 
similar to type I Cas3 HD domains (Lin et al., 2020; Makarova et al., 2015; Manav et al., 
2020). Type I-D and type IV-C systems illustrate the crossover and evolutionary 
relationships between CRISPR-Cas systems. Although scientists impose hierarchical 
classifications upon biological systems, the systems themselves are more fluid.  
The genetic architecture of type IV-C systems indicates that they may have a 
unique function among type IV subtypes and almost certainly utilize unique mechanisms 
of action. I anticipate future work will reveal the structure and function of type IV-C RNP 
complexes. 
 
EXPANDING STUDY OF TYPE IV SYSTEMS WILL ADVANCE 
UNDERSTANDING OF TYPE IV FUNCTIONS AND MECHANISMS 
Type IV systems have only been studied in a few organisms. To fully understand 
the functions, structures, and mechanisms of type IV systems, we must study type IV 
systems in many different organisms. A broad expansion of studied type IV systems will 





Figure 7-3. Sequence alignment of IV-C Cas10 with III-A Cas10 and type I Cas3. 







Figure 7-4. Sequence alignment of IV-C Cas10 with I-D Cas10d. The HD nuclease 






importance. I have cloned several IV-A and IV-B csf genes from six organisms into 
individual and co-expression vectors. I have also performed expression tests and 
determined purification protocols for many IV-A and IV-B Csf proteins and RNP 
complexes (Table 7-1). Future work in the Jackson lab should utilize the expression 
vectors and preliminary expression and purification data I have generated to continue 
study of type IV systems. To better understand the structure and function of type IV RNP 
complexex, we should continue to elucidate the structures and functions of the type IV-B 
system from M. sp. JS623 and the type IV-A system from P. aeruginosa at a deeper level 
and focus on determining new structures and functions of Csf proteins and RNP 
complexes from organisms that have not yet been studied, including Acidithiobacillus 
ferrooxidans and Mycobacterium sp. MCS. I am especially interested in determining the 
structure and function of the RNP complex from M. australiensis. We characterized the 
pre-crRNA processing activity of Cas6 from M. australiensis but have not determined the 
structure and function of the other Csf proteins nor the RNP complex. Interestingly, the 
M. australiensis type IV-A system does not contain CasDinG and instead encodes a 
putative helicase/ATPase and a DUF4359 domain containing protein (Makarova et al., 
2020) (Figure 7-5). This exchange of CasDinG for a different helicase could change the 
function of the system, or simply allow the system to provide defense through an 
alternative mechanism. This ancillary protein exchange is commonly seen in prokaryotic 
defense systems (Gao et al., 2020; Lowey et al., 2020; Millman et al., 2020). 
Future work in the Jackson lab and others in the CRISPR field should also seek 
new organisms with type IV systems to study. In particular, determining the structure and 




Table 7-1. cas genes I cloned, expressed, and purified in the Jackson lab. 
Expression/purification trials are recorded in my lab notebooks (#1-#4) starting at the 






Figure 7-5. Operons of interesting type IV systems. (A) The M. australiensis type IV-
A operon encodes an ATPase distinct from CasDinG. (B) The R. ferrireducens type IV-A 





advance our understanding of type IV CRISPR-Cas systems, as little information is 
known about type IV-C systems. 
One major open question for type IV systems is how the CRISPR is maintained 
and whether new spacers can be acquired. Bioinformatics studies suggest that some type 
IV systems can engage in crosstalk with type I CRISPR-Cas systems, potentially co-
opting their adaptation proteins to introduce new spacers into the type IV CRISPR 
(Pinilla-Redondo et al., 2019; Bernheim et al., 2020). A few type IV systems encode 
Cas1, Cas2, and/or Cas4 proteins (Makarova et al., 2015, 2020; Pinilla-Redondo et al., 
2019; Crowley et al., 2019). For example, a type IV-A system in Rhodoferax 
ferrireducens encodes the cas1 and cas2 genes (Figure 7-5). I have cloned most of the R. 
ferrireducens type IV genes into expression vectors, including cas1 (Table 7-1). Future 
work in the Jackson lab should attempt to determine the structure and biochemistry of the 
type IV Cas1 and determine whether it has a specialized function in type IV systems. 
 
CONCLUSION 
As we better understand the structures, functions, and mechanisms of the type IV 
CRISPR-Cas systems, we will gain a more complete understanding of prokaryotic 
biology and potentially uncover novel activities that may lead to biotechnological tools 
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